NZ745376B2 - Method and compositions for cellular immunotherapy - Google Patents

Abstract

The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ T cells or combinations of CD8+ T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In certain embodiments, the chimeric receptor is encoded by a nucleic acid comprising; (a) a polynucleotide encoding an antibody or antigen-binding fragment thereof that binds to a HER2, wherein the antibody or antigen-binding fragment thereof comprises a variable light chain (VL) region comprising a CDRL1, a CDRL2, and a CDRL3 of the anti-HER2 antibody trastuzumab, and a variable heavy chain (VH) region comprising a CDRH1, a CDRH2, and a CDRH3 of the anti-HER2 antibody trastuzumab; (b) a polynucleotide encoding for a transmembrane domain; (c) a polynucleotide encoding for a polypeptide spacer located between the antibody or antigen-binding fragment thereof and the transmembrane domain, wherein the polypeptide spacer is an immunoglobulin hinge-CH2-CH3 region; and (d) a polynucleotide encoding an intracellular signaling domain that comprises a CD3ζ signaling domain and a co-stimulatory domain. Methods for preparing a host cell and pharmaceutical formulations produced by the methods, and methods of using the same, are also described. express a chimeric receptor. In certain embodiments, the chimeric receptor is encoded by a nucleic acid comprising; (a) a polynucleotide encoding an antibody or antigen-binding fragment thereof that binds to a HER2, wherein the antibody or antigen-binding fragment thereof comprises a variable light chain (VL) region comprising a CDRL1, a CDRL2, and a CDRL3 of the anti-HER2 antibody trastuzumab, and a variable heavy chain (VH) region comprising a CDRH1, a CDRH2, and a CDRH3 of the anti-HER2 antibody trastuzumab; (b) a polynucleotide encoding for a transmembrane domain; (c) a polynucleotide encoding for a polypeptide spacer located between the antibody or antigen-binding fragment thereof and the transmembrane domain, wherein the polypeptide spacer is an immunoglobulin hinge-CH2-CH3 region; and (d) a polynucleotide encoding an intracellular signaling domain that comprises a CD3ζ signaling domain and a co-stimulatory domain. Methods for preparing a host cell and pharmaceutical formulations produced by the methods, and methods of using the same, are also described.

Description

METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY This application is a divisional of New Zealand patent application 738636, which is a onal of New Zealand application 705475, which is the national phase entry in New Zealand of PCT international application (published as WO 2014//031687), and claims the benefit of priority to U.S. patent application serial no. 61/691,117 filed on 20 August 2012, the disclosure of which is incorporated herein by nce in its entirety.

Field of the Invention The present invention relates to the field of biomedicine and specifically s useful for cancer therapy. In particular, ments of the invention relate to methods and compositions for carrying out cellular immunotherapy comprising T cells modified with tumor targeting receptors.

Statement Regarding Federally Sponsored Research This invention was made with government support in the form of grants from the United States Department of Health and Human Services and from the Leukemia and Lymphoma Society. The United States government has certain rights in the invention.

Background of the Invention The adoptive transfer of human T lymphocytes that are engineered by gene transfer to s ic antigen receptors (chimeric receptors) specific for surface molecules expressed on tumor cells has the potential to effectively treat ed malignancies. ic receptors are synthetic receptors that include an extracellular ligand binding domain, most commonly a single chain variable fragment of a monoclonal antibody (scFv) linked to intracellular signaling components, most ly CD3? alone or combined with one or more costimulatory domains. Much of the research in the design of chimeric receptors has d on defining scFvs and other ligand g elements that target malignant cells without causing serious ty to essential normal tissues, and on defining the optimal composition of intracellular signaling s to activate T cell effector functions. However, it is uncertain whether the variations in chimeric receptor design that mediate superior in vitro function will translate reproducibly into improved in vivo therapeutic activity in clinical applications of chimeric receptormodified T cells.

There is a need to identify methods for determining elements of chimeric receptor design that are important for therapeutic activity and cell populations to genetically modify and adoptively transfer that provide enhanced survival and efficacy in vivo. It is an object of the present invention to go some way towards meeting this need and/or to provide the public with a useful choice.

Summary of the Invention In a first aspect the present invention provides a c acid encoding a chimeric receptor, the chimeric receptor comprising: (a) an antibody or antigen-binding nt thereof that binds to a HER2, n the antibody or antigen-binding fragment thereof comprises a le light chain (VL) domain comprising a CDRL1, a CDRL2, and a CDRL3 of the anti-HER2 antibody zumab, and a variable heavy chain (VH) domain sing a CDRH1, a CDRH2, and a CDRH3 of the anti-HER2 antibody trastuzumab; (b) a transmembrane ; (c) a polypeptide spacer located between the antibody or antigen-binding fragment thereof and the transmembrane domain, wherein the polypeptide spacer is an immunoglobulin hinge-CH2-CH3 region; and (d) an intracellular signaling domain that comprises a CD3? signaling domain and a costimulatory domain.

In a second aspect the present invention es a chimeric or encoded by the nucleic acid of the first aspect.

In a third aspect the present invention provides an expression vector, comprising the nucleic acid of the first aspect.

In a fourth aspect the present invention provides an isolated host cell, comprising the nucleic acid of the first aspect, the chimeric receptor of the second aspect or the expression vector of the third aspect.

In a fifth aspect the present invention provides a composition, sing the host cell of the fourth aspect, in a pharmaceutically acceptable excipient.

In a sixth aspect the present invention provides an in vitro method for preparing a host cell, comprising: ucing the nucleic acid of the first aspect or the expression vector of the third aspect into cells of a lymphocyte population and culturing the cells in the presence of anti-CD3 and/or anti-CD28, and at least one homeostatic cytokine.

In a seventh aspect the present invention provides a use of a pharmaceutical composition, comprising the nucleic acid of the first , the ic receptor of the second aspect, the expression vector of the third aspect, the isolated host cell of the fourth aspect, or the composition of the fifth aspect in the manufacture of a medicament for the treatment of a tumor expressing HER2.

In an eighth aspect the present invention provides a use of a population of immune cells sing the nucleic acid of the first aspect, the chimeric or of the second aspect, or the sion vector of the third aspect in the manufacture of a medicament for the treatment of a tumor expressing HER2.

In a ninth aspect the present invention provides a use of a population of CD8+ T cells comprising the nucleic acid of the first aspect, the chimeric receptor of the second aspect, or the expression vector of the third aspect in the manufacture of a medicament for the treatment of a tumor expressing HER2.

In a tenth aspect the present invention es a use of a population of CD4+ T cells comprising the nucleic acid of the first aspect, the ic receptor of the second aspect, or the expression vector of the third aspect in the manufacture of a medicament for the treatment of a tumor expressing HER2.

In an th aspect the present invention provides a use of a combination comprising a population of CD8+ T cells comprising the nucleic acid of the first aspect, the chimeric or of the second aspect, or the expression vector of the third aspect and a population of CD4+ T cells comprising the nucleic acid of the first aspect, the chimeric or of the second aspect, or the expression vector of the third aspect in the manufacture of a medicament for the treatment of a tumor expressing HER2.

Also described are methods and itions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring tumor-specific, genetically modified subsets of CD8+ or CD4+ T cells alone, or in combination. The disclosure describes chimeric receptor nucleic acids, and vectors and host cells including such nucleic acids. The nucleic acid sequence that encodes the chimeric receptor links together a number of modular components that can be excised and ed with other components in order to customize the chimeric receptor for ent T cell activation and recognition of a specific target molecule or an epitope on the target molecule.

In ments described herein, a chimeric receptor nucleic acid comprises a polynucleotide coding for a ligand binding domain, wherein the ligand is a molecule expressed on malignant or ed cells, a cleotide coding for a polypeptide spacer wherein the polypeptide spacer is about 200 amino acids or less, a cleotide coding for a transmembrane domain; and a polynucleotide coding for intracellular signaling domains. In embodiments, the polypeptide spacer comprises a modified IgG4 hinge region containing an amino acid sequence X1PPX2P that may be linked to other amino acid sequences including but not limited to the CH2 and CH3 or CH3 only sequences of the Ig Fc. It has been surprisingly found that the length of the spacer region that is presumed not to have ing capability affects the in vivo efficacy of the T cells modified to express the chimeric receptor and needs to be customized for individual target molecules for optimal tumor or target cell recognition.

Another aspect of the disclosure describes an isolated chimeric receptor nucleic acid comprising: a polynucleotide coding for a ligand binding domain, wherein the ligand is a tumor specific antigen, viral n, or any other molecule expressed on a target cell population that is suitable to mediate ition and elimination by a lymphocyte; a polynucleotide coding for a polypeptide spacer wherein the polypeptide spacer is of a ized length that is specific for each targeted ligand, wherein the spacer provides for enhanced T cell proliferation and/ or cytokine tion as compared to a reference chimeric receptor; a polynucleotide coding for a transmembrane domain; and a polynucleotide coding for one or more intracellular signaling domains. In embodiments, a long spacer is employed if the epitope on the target ligand is in a ne proximal position and a short spacer is employed if the epitope on the target ligand is in a membrane distal position. The disclosure includes expression vectors and host cells comprising the isolated chimeric receptor as described .

Another aspect of the disclosure bes a chimeric receptor polypeptide comprising a ligand binding , wherein the ligand is a tumor specific antigen, viral antigen or any other molecule that is expressed on a target cell population and can be ed to mediate recognition and elimination by lymphocytes; a polypeptide spacer wherein the polypeptide spacer is about 10-229 amino acids; a transmembrane domain; and one or more ellular signaling domains. In embodiments, the polypeptide spacer comprises a modified IgG hinge region containing the amino acid ce X1PPX2P.

In another , the present disclosure describes compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring tumor-specific, subset specific genetically modified CD4+ T cells, wherein the CD4+ T cells confer and/or augment the ability of CD8+ T cells to sustain anti-tumor reactivity and increase and/or maximize tumor-specific proliferation. In embodiments, the CD4+ cells are genetically modified to express a chimeric receptor nucleic acid and/or chimeric receptor polypeptide as described .

In another aspect, described are compositions to confer and/or augment immune responses ed by cellular immunotherapy, such as by adoptively transferring tumor-specific, subset ic genetically modified CD8+ T cells. In embodiments, the CD8+ cells express a ic receptor nucleic acid and/or chimeric receptor polypeptide as described herein.

Also described is an adoptive cellular immunotherapy composition having a genetically modified CD8+ cytotoxic T lymphocyte cell preparation to confer and/or augment immune responses, wherein the cytotoxic T lymphocyte cell preparation comprises CD8+ T cells that express a chimeric receptor comprising a ligand binding domain for a ligand associated with the disease or disorder, a customized spacer region, a transmembrane domain; and an intracellular signaling domain of a T cell or other receptors, such as a ulatory , and/or a genetically modified helper T cyte cell preparation, wherein the helper T lymphocyte cell preparation has CD4+ T cells that express a chimeric receptor comprising an antibody le domain specific for the ligand associated with the disease or disorder, a customized spacer region, a transmembrane ; and one or more intracellular signaling domains.

Also described is a method of performing cellular immunotherapy in a subject having a disease or disorder by administering to the subject a genetically modified cytotoxic T lymphocyte cell ation that provides a cellular immune response, wherein the cytotoxic T lymphocyte cell ation comprises CD8+ T cells that have a chimeric receptor sing a polynucleotide coding for a ligand binding domain, wherein the ligand is a tumor specific antigen, viral antigen, or any other molecule sed on a target cell population that is suitable to mediate recognition and elimination by a lymphocyte; a polynucleotide coding for a polypeptide spacer wherein the polypeptide spacer is of a customized length that is specific for each targeted ligand, wherein the spacer provides for enhanced T cell proliferation and/or cytokine tion as compared to a reference chimeric receptor; a polynucleotide coding for a transmembrane domain; and a polynucleotide coding for one or more ellular signaling domains. In embodiment, the ligand binding domain is an extracellular antibody variable domain specific for a ligand associated with the disease or disorder. An ment includes a cally modified helper T lymphocyte cell preparation that wherein the helper T lymphocyte cell preparation comprises CD4+ T cells that have a ic receptor comprising an a polynucleotide coding for a ligand binding domain, wherein the ligand is a tumor specific antigen, viral antigen, or any other molecule expressed on a target cell population that is le to mediate recognition and elimination by a cyte; a polynucleotide coding for a polypeptide spacer wherein the polypeptide spacer is of a customized length that is specific for each ed ligand, wherein the spacer provides for enhanced T cell eration and/or cytokine production as compared to a reference chimeric receptor; a polynucleotide coding for a transmembrane domain; and a polynucleotide coding for one or more intracellular signaling domains. In embodiments, the genetically modified CD8+ and genetically modified CD4+ cell population are coadministered. In embodiments, the T cells are autologous or allogeneic T cells.

Various modifications of the above method are possible. For e, the ic receptor that is expressed by the CD4+ T cell and the CD8+ T cell can be the same or different.

Also described is a method of manufacturing an adoptive immunotherapy composition by obtaining a chimeric receptor modified specific CD8+ cytotoxic T lymphocyte cell preparation that elicits a cellular immune response and expresses an antigen-reactive ic receptor, wherein the modified cytotoxic T lymphocyte cell preparation comprises CD8+ T cells that have a chimeric receptor comprising a ligand binding domain, wherein the ligand is a tumor specific antigen, viral antigen, or any other molecule sed on a target cell population that is suitable to mediate recognition and elimination by a lymphocyte; a polypeptide spacer wherein the ptide spacer is of a customized length that is specific for each targeted ligand, n the spacer provides for ed T cell proliferation and/or cytokine production as compared to a nce chimeric receptor; a transmembrane domain; and one or more intracellular signaling domains.; and/or obtaining a ed naïve or memory CD4+ T helper cell wherein the modified helper T lymphocyte cell preparation comprises CD4+ cells that have a chimeric receptor sing a ligand binding domain, wherein the ligand is a tumor specific antigen, viral antigen, or any other molecule expressed on a target cell population that is suitable to mediate recognition and elimination by a lymphocyte; a polypeptide spacer wherein the polypeptide spacer is of a customized length that is specific for each targeted ligand, wherein the spacer provides for enhanced T cell proliferation and/or cytokine production as compared to a reference chimeric receptor; a embrane domain; and one or more intracellular signaling domains.

These and other embodiments of the invention are described further in the accompanying specification, drawings and claims.

Brief Description of the Drawings Figure 1 Library of spacer ces. We constructed a plasmid library that contain codon optimized DNA sequences that encode ellular components including of the IgG4 hinge alone, IgG4 hinge linked to CH2 and CH3 domains, or IgG4 hinge linked to the CH3 domain. Any scFV sequence (VH and VL) can be cloned 5’ to the sequences encoding this library of variable spacer domains. The spacer domains are in turn linked to CD28 transmembrane and intracellular signaling domains and to CD3 zeta. A T2A sequence in the vector separates the chimeric receptor from a able marker encoding a truncated human mal growth factor receptor (tEGFR).

Figure 2: In vitro cytotoxicity, cytokine production, and proliferation of T-cells ed to express 2A2 ROR1 chimeric receptors with modified spacer length. (A) Phenotype of purified CD8+ TCM-derived cell lines modified with each of the 2A2 ROR1 ic receptors with long, ediate and short spacer domain. Staining with anti-F(ab) antibody that binds to an epitope in the 2A2 scFV shows surface expression of ROR1 ic receptors with full length or truncated spacer. (B) Cytolytic activity of T-cells expressing the various 2A2 ROR1 chimeric receptors with long (?), intermediate (?) and short spacer (?), or a tEGFR control lentiviral vector against ROR1+ (x) and control target cells. The bar diagram summarizes cytotoxicity data from 3 independent experiments (E:T = 30:1) ized to cytolytic activity by 2A2 ROR1 chimeric receptor ‘long’ = 1, and analyzed by Student’s t-test. (C) CFSE dye dilution was used to measure proliferation of 2A2 ROR1 chimeric receptor and tEGFR control T-cells, 72 hours after stimulation with Raji/ROR1 (left panel) and primary CLL cells (right panel) without addition of exogenous cytokines. For is, triplicate wells were pooled and the proliferation of live (PI-), CD8+ T-cells analyzed. Numbers above each histogram te the number of cell divisions the proliferating subset underwent, and the fraction of T-cells in each gate that underwent /1 cell divisions is ed next to each plot. (D) Multiplex cytokine assay of supernatants obtained after 24 hours from triplicate co-cultures of 5x104 T-cells expressing the various 2A2 ROR1 chimeric ors with Raji/ROR1 and y CLL cells. Multiplex cytokine data from 3 independent experiments were normalized (cytokine release by 2A2 ROR1 chimeric receptor ‘long’ = 1) and analyzed by Student’s t-test (right bar diagram).

Figure 3. R11 chimeric receptor requires a long spacer for recognition of ROR1+ tumor cells. The ces encoding the scFV from the R11 monoclonal antibody that is specific for an epitope in the membrane proximal Kringle domain of the orphan tyrosine kinase receptor ROR1 were cloned upstream of IgG4 hinge only (short), IgG4 hinge/CH3 (intermediate), and IgG4 hinge/CH2/CH3 ces in our chimeric receptor library containing the 4-1BB ulatory domains and prepared as iral vectors. A). Human CD8+ T cells were transduced and the transduction efficiency with each of the short, intermediate and long chimeric receptors was determined by ng for the tEGFR marker. B). Transduced T cells expressing the short (top), intermediate (middle), and long (bottom) were assayed for lysis of K562 leukemia cells alone or transfected to express ROR1. Only the T cells expressing the long spacer chimeric receptor efficiently killed ROR1+ K562 cells. C).

Transduced T cells expressing the short (top), intermediate (middle), and long (bottom) were labeled with CFSE, stimulated with K562 cells expressing ROR1 or CD19 (control) and assayed for cell proliferation over 72 hours. The T cells expressing the long spacer chimeric or proliferated ically to the ROR1+ K562 cells. D). Transduced T cells expressing the short (top), intermediate (middle), and long m) were stimulated with Raji lymphoma cells and K562 cells that expressed ROR1 or CD19 (control) and assayed for the secretion of interferon gamma into the supernatant over 24 hours. The T cells expressing the long spacer chimeric receptor proliferated and produced the highest levels of interferon gamma in response to ROR1 positive target cells.

Figure 4: Design of ROR1 chimeric receptors with modified spacer length and derived from the 2A2 and R12 scFV with different affinity. (A) Design of lentiviral transgene inserts encoding a panel of ROR1 chimeric receptors containing the 2A2 scFV, an c d spacer of ‘Hinge-CH2-CH3’ (long spacer, 229 AA), ‘Hinge-CH3’ (intermediate, 119 AA), or ‘Hinge’ only (short, 12 AA), and a signaling module with CD3? and CD28. Each chimeric receptor te contains a ted EGFR marker encoded downstream of a T2A element. (B) Lentiviral transgene inserts encoding ROR1-specific chimeric receptors derived from the R12 and 2A2 scFV with short IgG4-Fc ‘Hinge’ spacer (12 AA), and a signaling module containing CD28 or 4-1BB and CD3? respectively (total: 4 constructs).

Figure 5: umor reactivity of T-cells modified with ROR1 chimeric receptors derived from mAb R12 with higher ty than 2A2. (A) tEGFR expression on purified polyclonal CD8+ TCM-derived T-cell lines modified with each of the R12 and 2A2 ROR1 chimeric ors with short IgG4-Fc ‘Hinge’ spacer, and CD28 or 4-1BB ulatory domain. (B) Cytotoxicity against ROR1+ and l target cells by T-cells expressing R12(28-?; 4-1BB-?) and 2A2 ROR1 chimeric receptors (28-?; 4-1BB?) or a tEGFR control vector (x). (C) Multiplex cytokine assay of supernatants obtained after 24 hours from co-cultures of 5x104 T- cells expressing the various ROR1 chimeric receptors with Raji/ROR1 tumor cells.

The middle/right bar diagrams show normalized multiplex data from 3 independent experiments (cytokine release by ROR1 chimeric or 2A2 = 1) analyzed by Student’s t-test. (D) Proliferation of ROR1 chimeric or T-cells and tEGFR control T-cells 72 hours after stimulation with Raji/ROR1 cells and without addition of exogenous cytokines was assessed by CFSE dye dilution. Numbers above each histogram indicate the number of cell divisions the proliferating subset underwent, and the on of T-cells in each gate that underwent =4/3/2/1 cell divisions is provided above each plot.

Figure 6: Analysis of ne production and proliferation of CD4+ T- cells lines modified with a ROR1 chimeric or derived from mAb R12 with higher affinity than 2A2. (A-B) The 2A2 and R12 ROR1 chimeric receptors had the short spacer and a CD28 costimulatory domain. (A) Multiplex cytokine analysis from supernatants obtained 24 hours after stimulation of 5x104 CD4+ T- cells expressing the 2A2 and R12 ROR1 chimeric receptor with Raji/ROR1 tumor cells. (B) Proliferation of CD4+ R12 and 2A2 ROR1 chimeric receptor s and tEGFR control T-cells 72 hours after stimulation with Raji/ROR1 cells and without addition of exogenous cytokines was assessed by CFSE dye dilution. Numbers above each histogram indicate the number of cell divisions the proliferating subset underwent, and the fraction of T-cells in each gate that underwent =5/4/3/2/1 cell divisions is provided above the histograms.

Figure 7: ition of primary CLL by T-cells modified with 2A2 and R12 ROR1 chimeric receptors with optimal short spacer and 4-1BB costimulatory domain or with a CD19-specific chimeric receptor. (A) Expression of ROR1/CD19 on primary CLL, and CD80/86 on primary CLL and Raji/ROR1 tumor cells (black dot plots) that can engage CD28 on chimeric receptor T-cells (white histograms). Staining with matched isotype control mAbs is shown as grey dot plots/histograms. (B) Cytolytic activity of T-cells expressing the 2A2(?) and R12 ROR1 ic receptor (¦), a CD19-specific chimeric receptor (?) and s modified with a tEGFR control vector (x) against y CLL (left diagram) and normal B cells (right diagram) analyzed by chromium release assay.

Cytotoxicity data against primary CLL from 4 independent experiments (E:T = :1) were normalized (cytolytic activity by ROR1 ic receptor 2A2 = 1) and analyzed by Student’s t-test (bar m). (C) Multiplex cytokine analysis after a 24-hour stimulation of 5x104 chimeric receptor s with primary CLL cells.

Cytokine release of unstimulated chimeric receptor T-cells was below 3.6 pg/ml (detection limit) (left bar m). ELISA for IFN-? production by 5x104 2A2 and R12 ROR1 chimeric receptor T-cells after a 24-hour co-culture with primary CLL.

O.D. of 1 corresponds to approximately 250 pg/ml (right bar diagram). (D) Proliferation of CD8+ T-cells modified with the 2A2 ROR1, R12 ROR1 and a CD19 chimeric receptor, 72 hours after stimulation with primary CLL cells. Numbers above each ram indicate the number of cell divisions, and the fraction of T- cells in each gate that underwent =3/2/1 cell divisions is provided next to each plot.

Figure 8: The function of ROR1-chimeric receptor and CD19-chimeric receptor modified CD8+ T-cells against primary CLL is augmented by chimeric receptor-modified CD4+ helper T-cells. (A) ELISA for IL-2 production from cate co-cultures of 5x104 CD8+ and CD4+ T-cells sing the R12 ROR1 and CD19-chimeric receptor respectively, incubated with y CLL for 24-hours.

O.D. of 1 ponds to approx. 800 pg/ml. (B) Proliferation of chimeric receptormodified CD8+ T-cells in se to primary CLL is ed by addition of chimeric receptor-modified CD4+ T-cells. CFSE-labeled CD8+ T-cells expressing the 2A2 ROR1, R12 ROR1 and CD19-chimeric receptor respectively, were co- cultured with tumor cells and with 2A2 ROR1, R12 ROR1 and CD19-chimeric receptor transduced or control untranduced CD4+ T-cells (CD8+:CD4+ = 1:1).

Proliferation of the CD8+ subset was analyzed 72 hours after stimulation. Numbers above each histogram indicate the number of cell divisions, and the on of T- cells in each gate that underwent =3/2/1 cell divisions is provided above each plot.

Figure 9: In vivo anti-tumor efficacy of 2A2 ROR1, R12 ROR1 and CD19 chimeric or T-cells. Cohorts of mice were ated with 0.5x106 JeKo-1/ffluc MCL via tail vein injection, and 5x106 2A2 ROR1, R12 ROR1 or CD19 chimeric receptor T-cells, or T-cells expressing a tEGFR control vector were administered 7 days after tumor inoculation. All chimeric receptor constructs had the short IgG4 ‘Hinge-only’ spacer and a 4-1BB costimulatory domain. (A, B) Serial bioluminescence g of tumor in cohorts of mice treated with T-cells expressing the 2A2 ROR1 chimeric receptor (?), the high affinity R12 ROR1 chimeric receptor (¦), a pecific chimeric receptor (?), with T-cells transduced with tEGFR alone (?), and untreated mice. Bioluminescence imaging showed tumor manifestations in the bone marrow and thorax and thus, signal intensity was measured in regions of interest that encompassed the entire body and thorax of each individual mouse. (C) -Meier is of survival in individual treatment and control groups. Statistical analyses were performed using the log-rank test. The data shown in A-C are representative of results obtained in 2 independent experiments.

(D) Proliferation of 2A2 ROR1, R12 ROR1 and CD19 chimeric receptor T-cells in vivo. Tumor bearing NSG/JeKo-1 mice received a single dose of 5x106 CFSE- labeled 2A2 ROR1, R12 ROR1 or CD19 chimeric receptor T-cells on day 7 after tumor inoculation, and 72 h later peripheral blood, bone marrow and spleen were collected from each individual mouse. The frequency and proliferation of live (PI-), CD45+ CD8+ tEGFR+ T-cells was analyzed. The frequency of 2A2 ROR1, R12 ROR1 and CD19 chimeric receptor T-cells respectively is provided on the left of each ram as percentage of live cells, and the on of s that underwent =4/3/2/1 cell ons is provided above each plot.

Figure 10 Expression of ROR1 and NKG2D ligands on epithelial cancer cell lines. (A) Expression of ROR1 on the triple negative breast cancer cell lines MDA-MB-231 and 468, and the renal cell cancer lines FARP, TREP and RWL (black histograms). Staining with d isotype control antibody is shown as grey histograms. (B) Expression of 6 and the NKG2D ligands MICA/B on MDAMB-231 and Raji/ROR1 tumor cells, and NKG2D (CD314) on 2A2 and R12 ROR1- chimeric receptor T-cells. Staining with matched isotype l mAbs is shown as grey dot plots/histograms.

Figure 11: ROR1-chimeric receptor modified T-cells recognize ROR1+ lial tumor cells in vitro. (A) Chromium release assay to evaluate the cytolytic activity of R12 ROR1-chimeric receptor modified T-cells (short spacer/4- 1BB ulatory domain, closed symbols) and tEGFR control T-cells (open symbols) against ROR1+ breast cancer and renal cell cancer lines. (A-D) The 2A2 and R12 ROR1-chimeric receptors had the optimal short spacer and a 4-1BB costimulatory domain. (B) lex cytokine analysis after stimulation of T-cells expressing the 2A2 and R12 ROR1-chimeric receptor with -231 and Raji/ROR1 tumor cells. (C) Proliferation of CD8+ T-cells ed with the 2A2 and R12 ROR1-chimeric receptor 72 hours after stimulation with -231 tumor cells. For analysis, triplicate wells were pooled and the proliferation of live (PI-), CD8+ T-cells analyzed. Numbers above each histogram indicate the number of cell divisions the proliferating subset ent, and the fraction of T-cells in each gate that underwent =4/3/2/1 cell divisions is provided next to each ram. (D) ELISA for IL-2 production by R12 ROR1-chimeric receptor T-cells after a 24-hour co-culture with MDA-MB-231 in plain medium, and after addition of an antibody cocktail blocking of the NKG2D pathway [anti-NKG2D (clone 1D11), anti-MICA/B (clone 6D4) and anti-ULBP] or matched isotype control mAbs. O.D. of 0.6 corresponds to approximately 1900 pg/ml.

Figure 12. Effect of extracellular spacer length on recognition and triggering of tumor cell lysis by CD8+ human T cells that express a HER2- specific chimeric receptor. A.) Depiction of Herceptin Fab epitope location on tumor cell membrane proximal epitope on human HER2, B.) Structural s of Herceptin scFv CAR spacer length variants as –T2A- linked polypeptides with the carboxyl EGFRt marker embrane protein, C.) Western blot detection of short, medium, and long spacer Herceptin-CAR variant expression in human CD8+ CTL’s, D.) Flow cytometric detection of EGFRt by uced human CD8+ CTL’s transduced with Herceptin CAR variants then immunomagnetically purified by Herceptin-biotin, anti-biotin microbeads, E.) Distinct tic function by T cells transduced to express the Herceptin CAR variants (short – S; medium – M; and long – L) against HER2+ Med411FH and D283 human medulloblastoma cell lines (D341 is a HER2- control medulloblastoma cell line, inset flow plots are tumor target lines stained with anti-HER2 specific mAb). Green=full IgG4 (Long Spacer,?), Blue=IgG4hinge:CH3(Medium Spacer;?), Red=IgG4hinge only (Short ;¦).

Figure 13: CD19-chimeric receptor vectors and generation of CD19- chimeric receptor T cells.

(A) Design of lentiviral transgene inserts encoding a panel of CD19-specific ic receptors that differ in extracellular spacer length and intracellular co- ation. Each chimeric receptor encoded the CD19-specific single chain variable fragment derived from the FMC63 mAb in a VL-VH orientation, an erived spacer domain of Hinge-CH2-CH3 (long spacer, 229 AA) or Hinge only (short spacer, 12 AA), and a signaling module containing CD3? with CD28 or 4-1BB alone or in tandem. Each chimeric receptor cassette contains a truncated EGFR marker encoded downstream of a cleavable 2A element. (B, C) Polyclonal T cell lines modified with each of the CD19-chimeric receptor constructs were prepared from ed CD8+ CD45RO+ CD62L+ central memory T cells (TCM) of normal donors.

Following lentiviral transduction, transgene-positive T cells in each cell line were ed using the tEGFR marker and expanded for in vitro and in vivo experiments.

(D) MFI after staining for the tEGFR marker shows equivalent transgene expression in T cells modified with each of the CD19-chimeric receptors.

Figure 14: In vitro cytotoxicity, cytokine production, and proliferation of T cells modified with ct CD19-chimeric receptors. (A) Cytolytic activity of T cells expressing the various CD19-chimeric receptors t CD19+ and control target cells. (B) Multiplex cytokine assay of supernatants obtained after 24 hours from triplicate co-cultures of T cells expressing the various CD19-chimeric receptors and K562 cells transfected with CD19, and CD19+ Raji cells. (C) ison of cytokine production by T cells expressing the various CD19- chimeric receptors. Multiplex cytokine data from 6 independent experiments were normalized (cytokine release by CD19-chimeric or ‘short/CD28’ CTL = 1) and analyzed by Student’s t-test. (D) CFSE dye dilution was used to measure proliferation of CD19-chimeric receptor T cells 72 hours after stimulation with D19 (upper panel) and CD19+ Raji tumor cells (lower panel) without addition of exogenous cytokines. For analysis, triplicate wells were pooled and the proliferation of live (PI-), CD8+ T cells analyzed. Numbers above each histogram indicate the number of cell divisions the proliferating subset underwent, and the on of T cells in each gate that underwent =4/3/2/1 cell divisions is provided in the upper left of each plot. (E) PI staining was performed at the end of a 72-hour coculture of T cells expressing the various himeric receptors with Raji tumor cells. The percentage of PI+ cells within in chimeric receptor T cell line (CD3+) is provided in each ram.

Figure 15: CD19-chimeric receptor T cells with a short extracellular spacer domain eradicate Raji tumors in ID mice. (A) Cohorts of mice were inoculated with Raji-ffluc via tail vein injection, and T cells transduced with CD19-chimeric receptors containing long and short spacer domains or with tEGFR alone were administered 2 and 9 days after tumor inoculation by tail vein injection.

Tumor progression and distribution was ted by serial bioluminescence imaging after ion of luciferin substrate. (B) Serial bioluminescence imaging of tumor in cohorts of mice either treated with T cells expressing himeric receptors with short spacer (‘short/CD28’ and ‘short/4-1BB’) and long spacer (‘long/CD28’ and ‘long/4-1BB’) domains, with T cells transduced with the tEGFR control vector, or ted. Each diagram representing cohorts of mice treated with CD19-chimeric receptor or tEGFR transduced T cells also shows the mean of tumor progression in ted mice for comparison (red triangles). (C) Kaplan-Meier analyses of survival of untreated mice and mice treated with T cells expressing CD19-chimeric receptors with short spacer (‘short/CD28’ and ‘short/4-1BB’), long spacer (‘long/CD28’ and ‘long/4-1BB’) domains, and with control tEGFR.

Statistical analyses were performed using the nk test. The data shown in B and C are representative of results ed in 3 independent experiments.

Figure 16: CD19-chimeric receptor T cells with a short spacer (short/4- 1BB) eradicate established Raji tumors in NSG mice in a dose-dependent manner. (A) Mice were inoculated with Raji-ffluc via tail vein ion and tumor engraftment confirmed by bioluminescence imaging on day 6. On day 7, mice received a single i.v. injection of various doses of T cells transduced with the CD19- chimeric receptor ‘short/4-1BB’ or with the tEGFR-control lentivirus. (B, C) Dose dependent anti-tumor efficacy of T cells expressing the CD19-chimeric receptor ‘short/4-1BB’. A l cohort of mice received a single high dose of T cells modified with tEGFR alone. (D) Persistence of CD19-chimeric receptor T cells following adoptive transfer into NSG/Raji mice. Flow cytometric analysis of peripheral blood (eye ) in the cohort of mice treated with 2.5x106 CD19- ic receptor /4-1BB’ T cells. The frequency of CD8+ tEGFR+ T cells is shown as percentage of live peripheral blood cells.

Figure 17: T cells expressing CD19-chimeric receptors with a short spacer and either CD28 or 4-1BB are more effective against established lymphoma than those expressing CD19-chimeric receptors with a long spacer.

(A) NSG mice were inoculated with Raji-ffluc on day 0, and d on day 7 with one dose of 2.5x106 CD19 chimeric receptor T cells sing short or long spacer and either CD28 or 4-1BB costimulatory domain. (B) Kaplan-Meier analyses of survival of mice in each of the treatment groups. Statistical analyses were med using the nk test. (C) Bioluminescence imaging of cohorts of mice treated with T cells expressing himeric receptors with short spacers (‘short/CD28’ and ‘short/4-1BB’), and long spacers (‘long/CD28 and ‘long/4-1BB’). The mean tumor burden observed in untreated mice at each time point is shown in each diagram for comparison (triangles). (D) In vivo persistence of T cells expressing himeric receptor with short spacer domain is enhanced compared to T cells expressing himeric receptors with long spacer domain. The frequency of CD8+ tEGFR+ T cells in the peripheral blood obtained at day 3 and 10 after transfer was ined by flow cytometry and is shown as percentage of live (PI-) peripheral blood cells. tical analyses were performed by Student’s t-test. The data shown in B-D are representative for results obtained in 3 independent experiments.

Figure 18: Increasing chimeric receptor T cell dose or augmenting costimulatory signaling does not improve the anti-tumor efficacy of CD19- chimeric receptors with a long spacer domain against established lymphoma.

(A) Cytolytic activity of T cells expressing ‘long/CD28’, ‘long/4-1BB’ and ‘long/CD28_4-1BB’ CD19 chimeric receptors against CD19+ and control target cells. (B) Multiplex cytokine assay of supernatant obtained after 24 hours from triplicate co-cultures of K562/CD19 and Raji tumor cells with T cells expressing the various CD19-chimeric receptors. (C) Evaluation of proliferation of CD19-chimeric receptor T cells 72 hours after stimulation with CD19+ tumor cells (K562/CD19 – left panel; Raji – right panel) by CFSE dye dilution. For analysis, triplicate wells were pooled and the proliferation of live (PI-) CD8+ T cells analyzed. Numbers above each histogram indicate the number of cell divisions the proliferating subset underwent, and the fraction of T cells in each gate that underwent =4/3/2/1 cell divisions is provided in the upper left of each plot. (D) -Meier analyses of survival of mice treated with T cells expressing CD19-chimeric receptors with short (‘short/CD28’) and long spacer domain (‘long/CD28’ and ‘long/CD28_4-1BB’), or T cells modified with a tEGFR-encoding control lentiviral vector. Statistical analyses were performed using the log-rank test. (E) Bioluminescence imaging of cohorts of mice treated with T cells expressing CD19-chimeric receptors with short spacer (‘short/CD28’), and long spacers (‘long/CD28 and ‘long/CD28_4-1BB’).

Diagrams show mean tumor progression in untreated mice for comparison (red triangles). (F) In vivo persistence of T cells expressing the various CD19-chimeric receptors. The frequency of CD8+ tEGFR+ T cells in the eral blood obtained at day 3 and 10 after transfer was determined by flow try and is shown as percentage of live (PI-) peripheral blood cells. tical analyses were performed by Student’s t-test.

Figure 19: CD19-chimeric receptor T cells with a long spacer domain are ted by tumor in vivo but fail to increase in cell number. (A) Expression of CD69 and CD25 on T cells modified with each CD19-chimeric receptor prior to transfer into NSG/Raji mice. (B) Cohorts of mice were inoculated with Raji-ffluc tumor cells and 7 days later received CFSE-labeled CD19-chimeric receptor transduced or control T cells. Bone marrow and spleens were ted from subgroups of mice 24 and 72 hours after T cell administration. (C, D) Multiparameter flow cytometric analysis of bone marrow mononuclear cells obtained 24 hours (C) and 72 hours (D) after T cell transfer. Dot plots show anti CD3 and anti CD45 staining after gating on PI- cells to detect viable human T cells.

The CD3- CD45+ gate ns Raji tumor cells. Expression of CD25 and CD69 on live (PI-) CD3+ CD45+ T cells is shown in the histograms. (E) Frequency of CD3+ CD45+ T cells in spleens obtained 24 and 72 hours after T cell transfer. Dot plots are gated on live PI- cytes and the percentage of CD3+ CD45+ T cells is shown in each plot. (F) PI staining of bone marrow and splenocytes hours after T cell transfer into ji mice. The numbers in the histograms indicate the percentage of PI+ cells within the CD3+ population. (G) Bioluminescence g of cohorts of mice treated with T cells expressing CD19-chimeric receptors with short spacer (‘short/CD28’ and ‘short/4-1BB’), long spacers /CD28 and ‘long/4-1BB’), or control T cells.

Figure 20: T cells expressing CD19 chimeric receptors with 4-1BB and CD3zeta and a modified IgG4-Fc hinge exhibit or in vitro and in vivo function compared to T cells expressing CD19 chimeric receptors with 4-1BB and CD3zeta and a CD8 alpha hinge.A. Cytolytic ty of CD19 chimeric or modified T-cells with IgG4 Fc hinge, CD8 alpha hinge and control T cells against Cr51-labeled K562 cells transfected with CD19, Raji lymphoma cells that express CD19, and K562 control T cells.

Lysis is shown at different E/T ratios in a 4 hour Cr51 release assay. B. Interferon gamma production by 5x104 T cells expressing a CD19 chimeric receptor with an IgG4 Fc hinge or CD8 alpha hinge after a 24-hour coculture with Raji tumor cells. O.D. of 1 corresponds to ~500 pg/ml of interferon gamma. C. CFSE dye dilution assay to measure proliferation of T cells expressing a CD19 chimeric receptor with an IgG4 Fc hinge or CD8 alpha hinge and T cells that s tEGFR alone (control) after 72 hours coculture with CD19 positive Raji lymphoma cells. Numbers above each histogram te the number of cell divisions the proliferating cell subset underwent. The fraction of T cells in each gate that underwent >3/2/1 cell divisions is provided next to the plot. D. In vivo antitumor activity of T cells expressing a CD19 ic receptor with an IgG4 Fc hinge (group 1) or CD8 alpha hinge (group 2) and T cells that express tEGFR alone (group 3) in NSG mice inoculated with Raji tumor cells expressing firefly luciferase (ffluc). Mice were imaged 17 days after tumor inoculation and 10 days after T cell inoculation. The data shows greater tumor burden in mice treated with control tEGFR T cells (group 3) or with CD19 ic receptor CD8 alpha hinge T cells (group 2) compared with mice treated with CD19 ic receptor IgG4 Fc hinge T cells (group 1).

Detailed Description Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains.

"About" as used herein when referring to a measurable value is meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±l%, and still more preferably ±0.1 % from the specified value. ation", as used herein, refers to the state of a T cell that has been sufficiently stimulated to induce detectable cellular proliferation, cytokine production or expression of cell surface markers such as CD69 and CD25, or detectable effector functions. ation Induced cell death" as used herein refers to a state of a T cell that is activated but is not able to proliferate for more than 2 generations and exhibits markers of sis.

"Antigen" or "Ag" as used herein refers to a molecule that provokes an immune se. This immune response may involve either antibody production, or the tion of specific immunologically-competent cells, or both. It is readily apparent that an antigen can be generated synthesized, produced recombinantly or can be derived from a biological sample. Such a biological sample can include, but is not limited to a tissue sample, a tumor sample, a cell or a biological fluid.

"Anti-tumor effect" as used herein, refers to a biological effect, which can be manifested by a decrease in tumor volume, a decrease in the number of tumor cells, a decrease in the number of metastases, an increase in life expectancy, or a se of various physiological symptoms associated with the cancerous condition. An "anti-tumor effect" can also be manifested by a decrease in recurrence or an increase in the time before recurrence. ric receptor" as used herein refers to a synthetically designed receptor comprising a ligand binding domain of an antibody or other protein ce that binds to a molecule associated with the e or disorder and is linked via a spacer domain to one ore more intracellular signaling domains of a T cell or other receptors, such as a costimulatory .

"Co-stimulatory domain," as the term is used herein refers to a signaling moiety that provides to T cells a signal which, in addition to the primary signal provided by for instance the CD3 zeta chain of the TCR/CD3 complex, mediates a T cell response, including, but not d to, activation, proliferation, differentiation, cytokine secretion, and the like. A co-stimulatory domain can include all or a portion of, but is not d to, CD27, CD28, 4-1BB, OX40, CD30, CD40, , ICOS, lymphocyte function-associated antigen-l (LFA-l), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that ically binds with CD83. In embodiments, the costimulatory domain is an intracellular signaling domain that interacts with other intracellular mediators to e a cell response ing activation, proliferation, differentiation and cytokine secretion, and the like.

"Coding for" are used herein refers to the property of ic sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other macromolecules such as a defined sequence of amino acids. Thus, a gene codes for a n if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system. A "nucleic acid sequence coding for a polypeptide" includes all nucleotide sequences that are degenerate versions of each other and that code for the same amino acid sequence. oxic T cyte "(CTL) as used herein refers to a T lymphocyte that expresses CD8 on the surface thereof (i.e., a CD8+ T cell). In some embodiments such cells are preferably "memory" T cells (TM cells) that are antigenexperienced.

"Central memory" T cell (or "TCM") as used herein refers to an antigen experienced CTL that expresses CD62L or CCR-7 and CD45RO on the surface thereof, and does not express or has decreased expression of CD45RA as compared to naive cells. In embodiments, central memory cells are positive for expression of CD62L, CCR7, CD28, CD127, CD45RO, and CD95, and have decreased sion of CD54RA as compared to naïve cells.

"Effector memory" T cell (or "TEM") as used herein refers to an n experienced T cell that does not express or has decreased expression of CD62L on the surface thereof as compared to central memory cells, and does not express or has decreased expression of CD45RA as compared to naïve cell. In embodiments, effector memory cells are negative for expression of CD62L andCCR7, compared to naïve cells or central memory cells, and have variable expression of CD28 and "Naïve " T cells as used herein refers to a non n experienced T lymphocyte that expresses CD62L and CD45RA, and does not express CD45RO- as compared to central or effector memory cells. In some embodiments, naïve CD8+ T lymphocytes are characterized by the expression of phenotypic markers of naïve T cells including CD62L, CCR7, CD28, CD127, and CD45RA.

"Effector " "TE" T cells as used herein refers to a antigen experienced cytotoxic T lymphocyte cells that do not express or have decreased expression of CD62L, CCR7, CD28, and are positive for granzyme B and perforin as compared to central memory or naïve T cells.

"Enriched" and ted" as used herein to describe amounts of cell types in a mixture refers to the subjecting of the mixture of the cells to a process or step which results in an increase in the number of the "enriched" type and a decrease in the number of the ted" cells. Thus, depending upon the source of the original population of cells subjected to the enriching s, a mixture or ition may contain about 60, 70, 80, 90, 95, or 99 percent or more (in number or count) of the "enriched" cells and about 40, 30, 20, 10, 5 or 1 percent or less (in number or count) of the "depleted" cells.

"Epitope" as used herein refers to a part of an antigen or molecule that is recognized by the immune system including antibodies, T cells, and/ or B cells.

Epitopes usually have at least 7 amino acids and can be linear or conformational.

"Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide or c acid that has been identified and separated and/or recovered from a component of its natural environment. Preferably, the ed polypeptide or nucleic acid is free of association with all components with which it is naturally associated. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or eutic uses for the polypeptide or nucleic acid, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.

"Intracellular ing " as used herein refers to all or a portion of one or more domains of a molecule (here the chimeric receptor molecule) that provides for activation of a lymphocyte. Intracellular domains of such molecules e a signal by interacting with cellular mediators to result in proliferation, differentiation, activation and other effector functions. In embodiments, such molecules include all or ns of CD28, CD3, 4-1BB, and combinations thereof.

"Ligand" as used herein refers to a substance that binds specifically to another substance to form a complex. e of ligands include epitopes on antigens, molecules that bind to receptors, substrates, inhibitors, es, and activators. "Ligand binding domain" as used herein refers to substance or portion of a nce that binds to a ligand. Examples of ligand binding domains include antigen binding portions of dies, extracellular domains of receptors, and active sites of enzymes. bly linked" as used herein refers to functional linkage between a regulatory sequence and a heterologous nucleic acid sequence resulting in expression of the latter. For example, a first nucleic acid sequence is operably linked with a second nucleic acid ce when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For ce, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding ce. Generally, ly linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Percent (%) amino acid sequence identity" with respect to the chimeric receptor polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference ce for each of the ligand binding domain, spacer, transmembrane domain, and/or the cyte activating domain, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum t sequence identity, and not considering any vative substitutions as part of the sequence identity. Alignment for purposes of determining t amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For example, % amino acid sequence identity values generated using the WU-BLAST-2 computer program [Altschul et al., Methods in Enzymology, 266:460-480 (1996)] uses several search parameters, most of which are set to the t values. Those that are not set to default values (i.e., the adjustable parameters) are set with the following values: p , overlap fraction=0.125, word old (T)=11 and scoring matrix=BLOSUM62. A % amino acid sequence identity value is determined by ng (a) the number of matching identical amino acid residues between the each or all of the polypeptide amino acid sequence of the reference chimeric receptor sequence provided in Table 2 and the comparison amino acid sequence of interest as determined by WUBLAST-2 by (b) the total number of amino acid residues of the ptide of interest.

"Chimeric receptor variant polynucleotide" or "chimeric receptor variant nucleic acid ce" as used herein refers to a polypeptide-encoding nucleic acid molecule as defined below having at least about 80% nucleic acid sequence identity with the polynucleotide acid ce shown in Table 1 or a specifically derived nt thereof, such as polynucleotide coding for an antigen g domain, a polynucleotide encoding a spacer domain, a polynucleotide coding for a transmembrane domain and/ or a polynucleotide coding for a lymphocyte atory domain. Ordinarily, a chimeric receptor t of polynucleotide or fragment thereof will have at least about 80% nucleic acid sequence identity, more preferably at least about 81% nucleic acid sequence identity, more preferably at least about 82% nucleic acid sequence identity, more preferably at least about 83% nucleic acid sequence identity, more ably at least about 84% nucleic acid sequence identity, more preferably at least about 85% nucleic acid sequence identity, more preferably at least about 86% nucleic acid sequence identity, more preferably at least about 87% nucleic acid sequence identity, more preferably at least about 88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid sequence identity, more preferably at least about 90% nucleic acid ce identity, more preferably at least about 91% c acid sequence identity, more preferably at least about 92% nucleic acid sequence ty, more preferably at least about 93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid sequence identity, more preferably at least about 95% nucleic acid sequence ty, more preferably at least about 96% nucleic acid sequence identity, more ably at least about 97% nucleic acid sequence identity, more preferably at least about 98% nucleic acid sequence identity and yet more preferably at least about 99% nucleic acid sequence identity with the nucleic acid sequence as shown in Table or a d fragment thereof. Variants do not encompass the native nucleotide sequence.

In this regard, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of chimeric or variant polynucleotides having at least about 80% nucleic acid sequence identity to the nucleotide sequence of Table 1 will encode a polypeptide having an amino acid sequence which is identical to the amino acid sequence of Table 2.

"Substantially purified" refers to a molecule that is essentially free of other molecule types or a cell that is essentially free of other cell types. A ntially purified cell also refers to a cell, which has been separated from other cell types with which it is normally associated in its naturally occurring state. In some instances, a population of substantially purified cells refers to a homogenous tion of cells.

"Not substantially found" when used in reference the presence of a tumor antigen or other molecules on normal cells refers to the tage of a normal cell type that has the antigen or molecule, and / or the density of the antigen on the cells.

In embodiments, not substantially found means that the n or molecule is found on less than 50% of normal cell type and/or at a 50% less density as compared to the amount of cells or antigen found on a tumor cell or other diseased cell.

"T cells" or "T lymphocytes" as used herein may be from any mammalian, preferably primate, species, including monkeys, dogs, and humans. In some embodiments the T cells are allogeneic (from the same species but different donor) as the recipient subject; in some embodiments the T cells are autologous (the donor and the recipient are the same); in some embodiments the T cells arc syngeneic (the donor and the recipients are ent but are identical twins).

Modes of the Disclosure Described herein are chimeric or nucleic acids, and s and host cells including such nucleic acids. The chimeric receptor nucleic acid comprises a number of modular components that can be excised and replaced with other components in order to customize the chimeric receptor for a specific target molecule. The disclosure describes that one of the r components is the spacer component. It has been surprisingly found that the length of the spacer region that is presumed not to have signaling capability affects the in vivo efficacy of the T cells modified to express the ic receptor and needs to be customized for individual target molecules for enhanced therapeutic ty.

In one aspect, s and nucleic acid constructs are described to design a chimeric receptor that has improved tumor recognition, increased T cell proliferation and/or cytokine production in response to the ligand as compared to a nce chimeric receptor. In embodiments, a library of nucleic acids is described, wherein each nucleic acid codes for a spacer region that differs from the others in sequence and length. Each of the nucleic acids can then be used to form a chimeric receptor nucleic acid construct that can be tested in vivo (in an animal model) and/or in vitro so that a spacer can be selected that provides for improved tumor recognition, increased T cell eration and/or cytokine production in response to the ligand.

In embodiments, a chimeric receptor nucleic acid comprises a polynucleotide coding for a ligand binding domain, wherein the ligand is a tumor or viral specific antigen or molecule, a polynucleotide coding for a ized polypeptide spacer, wherein the spacer provides for enhanced T cell proliferation; a polynucleotide coding for a transmembrane domain; and a cleotide coding for one or more intracellular signaling domains. In embodiments, a long spacer is employed if the epitope of the target molecule is ne proximal on the target cell and a short spacer is employed if the epitope of the target molecule is membrane distal on the target cell.

The design of a chimeric receptor can be customized depending on the type of tumor or virus, the target antigen or le present on the tumor, the affinity of the antibody for the target molecule, the flexibility needed for the antigen binding domain, and/or the intracellular signaling domain. In ments, a number of chimeric receptor constructs are tested in vitro and in in vivo models to determine the ability of T cells ed with the receptor to kill tumor cells in deficient mice and to proliferate and persist after adoptive transfer. In ments, a chimeric receptor is selected that provides for lity of at least 30% of the cells to proliferate through at least two generations in vitro and/or within 72 hours after introduction in vivo. In embodiments, a chimeric receptor is not selected that results in r than 50% of the cells undergoing activation induced cell death (AICD) within 72 hours in vivo in immunodeficient mice, and fails to eradicate tumor cells.

Depending on whether the target molecule is present on a subject’s tumor cells, the chimeric receptor es a ligand binding domain that specifically binds to that target molecule. In embodiments, a subject’s tumor cells are characterized for cell surface tumor molecules. The target molecule may be selected based on a ination of its presence on a particular subject’s tumor cells. In embodiments, a target molecule is selected that is a cell surface le found predominantly on tumor cells and not found on normal tissues to any substantial degree. In embodiments, an antibody is selected to bind to an epitope on the targeted cell surface molecule. In some cases, the epitope is characterized with respect to its proximity to the cell membrane. An epitope is terized as proximal to the membrane when it is predicted or known by structural analysis to reside closer to the target cell membrane than alternative epitopes that are predicted or known by ural analysis to reside a greater distance from the target cell membrane. In embodiments, the affinity of the antibody from which the scFV is constructed is compared by binding assays, and antibodies with different affinities are examined in chimeric receptor formats sed in T cells to ine which affinity confers optimal tumor recognition, based on superior xicity of target cells, and/or T cell cytokine tion and proliferation.

In addition, the spacer region of the chimeric receptor may be varied to optimize T cell ition of the ligand on the target cell. In embodiments, when an antibody binds to an epitope on the target cell that is very proximal to the membrane, a spacer is selected that is longer than about 15 amino acids. For example, in embodiments, if the epitope or portion thereof on the target antigen is in the first 100 amino acids of the linear sequence of the extracellular domain adjacent to the transmembrane domain, a long spacer region may be selected. In ments, when an antibody binds to an epitope on the target cell that is distal to the membrane, a spacer is selected that is about 119 or 15 amino acids or less. For example, in embodiments, when the epitope or portion thereof is found in the 150 amino acids of the linear sequence of the extracellular domain from the terminus, a short or mediate spacer may be utilized. In embodiments, a spacer comprises an amino acid sequence X1PPX2P.

A variety of combinations of primary and costimulatory intracellular signaling domain may be employed to enhance the in vivo efficacy of the ic receptor. In embodiments, different constructs of the chimeric receptor can be tested in an in vivo animal model to determine efficacy for tumor killing. In embodiments, a ulatory intracellular ing domain is selected from the group consisting of CD28 and modified versions thereof, 4-1BB and modified versions thereof and combinations thereof. Other costimulatory domains, such as OX40 may be incorporated.

CD8+ central memory T cells have an intrinsic mming that allows them to t for extended periods after administration, which makes them a preferred subset of CD8+ T cells for immunotherapy. In ments, CD19 specific chimeric receptor modified cytotoxic T cells prepared from sort purified CD8+ central memory T cells are administered in the presence or absence of CD4+ CD19 specific chimeric receptor -modified T cells. In embodiments, tumor-specific CD4+ T cells exert anti-tumor reactivity and provide help to specific CD8+ T cells in vitro and in vivo. In a specific embodiment, tumor-specific CD4+ T cells or CD4+ T cells selected from the naïve or the central memory subsets are utilized alone or in combination with CD8+ TCM.

Nucleic Acids, Vectors, and polypeptides Also described is a chimeric receptor nucleic acid useful for transforming or transducing lymphocytes for use in adoptive immunotherapy. In embodiments, the nucleic acid contains a number of modular components that provide for easy substitution of elements of the nucleic acid. While not meant to limit the scope of the sure, it is believed that the chimeric receptor for each tumor n is desirably customized in terms of components in order to provide for in vivo efficacy and efficient expression in mammalian cells. For example, in a ic embodiment, for efficacy of a chimeric receptor comprising a scFV that binds to a ROR1 epitope located in the ne distal Ig/Frizzled domain, a spacer that is about 15 amino acids or less is ed. In another specific embodiment, for efficacy of a chimeric receptor comprising a scFV that binds to a ROR1 epitope located in the membrane proximal Kringle domain, a spacer that is longer than 15 amino acids is employed.

In another embodiment, for efficacy of a chimeric receptor comprising a scFV that binds to CD19, a spacer that is 15 amino acids or less is employed.

In embodiments, an isolated chimeric receptor nucleic acid comprises a polynucleotide coding for a ligand g domain, wherein the target molecule is a tumor ic antigen, a polynucleotide coding for a polypeptide spacer n the ptide spacer is about 229 amino acids or less; a polynucleotide coding for a transmembrane domain; and a polynucleotide coding for an intracellular signaling domain. In embodiments, an expression vector comprises a chimeric nucleic acid as described herein. Polypeptides encoded by all of or a n of the chimeric receptor c acids are also included herein.

Ligand binding domain In embodiments, the chimeric receptor nucleic acid comprises a polynucleotide coding for a ligand binding domain. In embodiments, the ligand binding domain specifically binds to a tumor or viral specific antigen. In embodiments, the ligand binding domain is an antibody or fragment thereof. A nucleic acid sequence coding for an antibody or antibody fragment can readily be determined. In a specific embodiment, the polynucleotide codes for a single chain Fv that specifically binds CD19. In other specific embodiments, the polynucleotide codes for a single chain Fv that specifically binds ROR1. The sequences of these antibodies are known to or can readily be determined by those of skill in the art.

Tumor ns are proteins that are produced by tumor cells that elicit an immune response. The selection of the ligand binding domain described herein will depend on the type of cancer to be treated, and may target tumor antigens or other tumor cell surface molecules. A tumor sample from a subject may be characterized for the presence of certain kers or cell surface markers. For example, breast cancer cells from a subject may be positive or negative for each of u, Estrogen receptor, and/or the Progesterone receptor. A tumor antigen or cell surface molecule is selected that is found on the individual subject’s tumor cells. Tumor antigens and cell surface molecules are well known in the art and include, for example, carcinoembryonic n (CEA), prostate specific antigen, PSMA, Her2/neu, estrogen receptor, progesterone receptor, B2, CD19, CD20, CD22, CD23, CD123, CS-1, ROR1, mesothelin, c-Met, GD-2, and MAGE A3 TCR. In embodiments a target molecule is a cell surface molecule that is found on tumor cells and is not substantially found on normal tissues, or restricted in its sion to non-vital normal tissues.

Other target molecules include but are not limited to antigens derived from ious pathogens such as HIV (human immunodeficiency virus), HBV (hepatitis B virus), HPV (human oma virus) and Hepatitis C virus.

In one ment, the target molecule on the tumor comprises one or more epitopes associated with a malignant tumor. ant tumors s a number of proteins that can serve as target antigens for T cell receptor or chimeric receptor mediated recognition. Other target molecules belong to the group of cell transformation-related molecules such as the oncogene HER-2/Neu/ErbB2. In embodiments, the tumor antigen is selectively expressed or overexpressed on the tumor cells as compared to control cells of the same tissue type. In other embodiments, the tumor antigen is a cell surface polypeptide.

Once a tumor cell surface molecule that might be targeted with a chimeric or is fied, an epitope of the target molecule is selected and terized.

In embodiments, an epitope is selected that is proximal to the tumor cell membrane.

In other embodiments, an epitope is selected that is distal to the tumor cell membrane. An e is characterized as proximal to the membrane when it is predicted or known by structural is to reside closer to the target cell membrane than alternative epitopes that are predicted or known by structural analysis to reside a greater distance from the target cell membrane. dies that specifically bind a tumor cell surface molecule can be prepared using methods of obtaining monoclonal antibodies, methods of phage display, methods to generate human or zed antibodies, or methods using a enic animal or plant engineered to produce human antibodies. Phage display libraries of partially or fully synthetic antibodies are available and can be screened for an antibody or fragment thereof that can bind to the target molecule. Phage display libraries of human dies are also available. In ments, dies specifically bind to a tumor cell surface molecule and do not cross react with nonspecific components such as bovine serum albumin or other ted antigens.

Once identified, the amino acid sequence or polynucleotide sequence coding for the antibody can be isolated and/or determined.

Antibodies or antigen binding fragments include all or a portion of polyclonal antibodies, a monoclonal antibody, a human dy, a humanized antibody, a synthetic antibody, a chimeric antibody, a bispecific antibody, a minibody, and a linear antibody. Antibody fragments" comprise a portion of an intact antibody, preferably the n binding or variable region of the intact antibody and can readily be prepared. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

In embodiments, a number of different antibodies that bind to a particular tumor cell surface molecules can be isolated and characterized. In embodiments, the antibodies are terized based on epitope specificity of the targeted molecule. In addition, in some cases, antibodies that bind to the same epitope can be selected based on the affinity of the antibody for that epitope. In ments, an antibody has an affinity of at least 1 mM, and preferably <50 nM. In embodiments, an antibody is selected that has a higher affinity for the epitope as compared to other antibodies. For example, an antibody is selected that has at least a 2 fold, at least a 5 fold, at least a 10 fold, at least a 20 fold, at least a 30 fold, at least a 40 fold, or at least a 50 fold greater affinity than a nce dy that binds to the same epitope.

In embodiments, target molecules are selected from the group consisting of CD19, CD20, CD22, CD23, CD123, CS-1, ROR1, mesothelin, Her2, c-Met, PSMA, GD-2, MAGE A3 TCR and combinations thereof.

In specific embodiments, the target antigen is CD19. A number of antibodies specific for CD19 are known to those of skill in the art and can be readily characterized for sequence, epitope binding, and affinity. In a specific embodiment, the chimeric receptor construct es a scFV sequence from FMC63 antibody. In other embodiments, the scFV is a human or humanized ScFv comprising a variable light chain comprising a CDRL1 sequence of RASQDISKYLN, CDRL2 sequence of SRLHSGV, and a CDRL3 sequence of GNTLPYTFG. In other embodiments, the scFV is a human or zed ScFv comprising a variable heavy chain comprising CDRH1 sequence of DYGVS , CDRH2 sequence of VIWGSETTYYNSALKS, and a CDRH3 ce of YAMDYWG. The sure also contemplates variable regions that have at least 90% amino acid ce identity to that of the scFv for FMC63 and that have at least the same affinity for CD19. In embodiments, the chimeric or has a short or intermediate spacer of 119 amino acids or less, or 12 amino acids or less. In a specific embodiment, the spacer is 12 amino acid or less and has a sequence of SEQ ID NO:4.

In embodiments, CDR regions are found within antibody regions as numbered by Kabat as follows: for the light chain; CDRL1 amino acids 24- 34;CDRL2 amino acids 50-56; CDRL3 at amino acids 89-97; for the heavy chain at CDRH1 at amino acids 31-35; CDRH2 at amino acids 50-65; and for CDRH3 at amino acids 95-102. CDR regions in antibodies can be y determined.

In specific embodiments, the target antigen is ROR1. A number of antibodies specific for ROR1 are known to those of skill in the art and can be readily characterized for sequence, epitope binding, and affinity. In a specific embodiment, the chimeric receptor construct includes a scFV sequence from R12 antibody. In other embodiments, the scFV is a human or humanized ScFv comprising a variable light chain sing a CDRL1 sequence of ASGFDFSAYYM, CDRL2 sequence of TIYPSSG, and a CDRL3 sequence of ADRATYFCA. In other embodiments, the scFV is a human or humanized ScFv comprising a variable heavy chain comprising CDRH1 sequence of DTIDWY, CDRH2 sequence of VQSDGSYTKRPGVPDR, and a CDRH3 sequence of FG. The disclosure also contemplates variable regions that have at least 90% amino acid sequence identity to that of the scFv for R12 and that have at least the same affinity for ROR1. In embodiments, the chimeric or has a short or intermediate spacer of 119 amino acids or less, or 12 amino acids or less. In a ic embodiment, the spacer is 12 amino acid or less and has a sequence of SEQ ID NO:4.

In specific embodiments, the target antigen is ROR1. A number of antibodies specific for ROR1 are known to those of skill in the art and can be readily characterized for sequence, epitope binding, and affinity. In a specific embodiment, the chimeric receptor uct includes a scFV sequence from R11 antibody. In other embodiments, the scFV is a human or zed ScFv comprising a variable light chain comprising a CDRL1 sequence of SGSDINDYPIS, CDRL2 sequence of INSGGST, and a CDRL3 sequence of YFCARGYS. In other embodiments, the scFV is a human or humanized ScFv comprising a le heavy chain comprising CDRH1 sequence of SNLAW, CDRH2 sequence of SGVPSRFSGS, and a CDRH3 sequence of NVSYRTSF. The disclosure also contemplates variable regions that have at least 90% amino acid sequence identity to that of the scFv for R11 and that have at least the same affinity for ROR1. In embodiments, the ic receptor has a long spacer of 229 amino acids or less. In a specific embodiment, the spacer is 229 amino acids and has a sequence of SEQ ID NO:50.

In specific embodiments, the target antigen is Her2. A number of antibodies specific for Her2 are known to those of skill in the art and can be readily characterized for ce, e binding, and affinity. In a ic ment, the chimeric receptor construct includes a scFV sequence from tin antibody.

In other embodiments, the scFV is a human or humanized ScFv comprising a variable light chain comprising a CDRL1 sequence, CDRL2 sequence and a CDRL3 sequence of the Herceptin antibody. In other embodiments, the scFV is a human or humanized ScFv comprising a variable heavy chain comprising CDRH1 sequence, CDRH2, and a CDRH3 sequence of Herceptin. The CDR sequences can readily be determined from the amino acid sequence of Herceptin. The disclosure also contemplates variable regions that have at least 90% amino acid sequence identity to that of the scFv for Herceptin and that have at least the same affinity for Her2. In embodiments, the chimeric receptor has a long spacer of 229 amino acids or less. In a specific embodiment, the spacer is 229 amino acids and has a sequence of SEQ ID NO:50.

In embodiments, a polynucleotide coding for a ligand binding domain is operably linked to a polynucleotide coding for a spacer region. In embodiments, the polynucleotide coding for a ligand g domain may also have one or more restriction enzyme sites at the 5’ and/or 3’ ends of the coding sequence in order to provide for easy excision and replacement of the polynucleotide with another polynucleotide coding for a ligand binding domain coding for a different antigen or that has different binding characteristics. For example, a restriction site, NheI, is encoded upstream of the leader sequence; and a 3’ RsrII located within the hinge region allows subcloning of any desirable scFv into a chimeric receptor vector. In embodiments, the polynucleotide is codon optimized for expression in mammalian cells.

In ments, the polynucleotide coding for a ligand g domain is ly linked to a signal peptide. In embodiments the signal peptide is a signal peptide for granulocyte colony stimulating factor. Polynucleotides coding for other signal peptides such as CD8 alpha can be utilized.

In embodiments, the cleotide coding for a ligand binding domain is operably linked to a promoter. A er is ed that provides for sion of the chimeric antigen receptor in a mammalian cell. In a specific embodiment the promoter is the elongation growth factor promoter (EF-1). Another example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. However, other constitutive promoter sequences may also be used, including, but not limited to the simian virus 40 (SV 40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HlV) long terminal repeat (LTR) promoter, MuMoLV promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, as well as human gene promoters such as, but not d to, the actin promoter, the myosin promoter, the hemoglobin promoter, and the ne kinase promoter. Inducible promoters are also contemplated. Examples of inducible promoters include, but are not limited to a metallothionine promoter, a glucocorticoid promoter, a terone promoter, and a tetracycline promoter.

A specific embodiment of a polynucleotide coding for a ligand binding domain is shown in Table 1 as the scFv from an antibody that specifically binds CD19, such as FMC63. A polynucleotide encoding for a flexible linker including the amino acids GSTSGSGKPGSGEGSTKG (SEQ ID NO:36)separates the VH and VL chains in the scFV. The amino acid sequence of the scFv including the linker is shown in Table 2.(SEQ ID NO:11) Other CD19-targeting dies such as SJ25C1 and HD37 are known. (SJ25C1: Bejcek et al. Cancer Res 2005, PMID 1; HD37: Pezutto et al. JI 1987, PMID 2437199).

Spacer In embodiments, the chimeric receptor nucleic acid comprises a polynucleotide coding for a spacer region. It has been surprisingly found that the length of the spacer region that is ed not to have signaling lity s the in vivo efficacy of the T cells modified to s the chimeric receptor and needs to be customized for individual target molecules for optimal tumor or target cell recognition. In embodiments, the chimeric receptor nucleic acid comprises a polynucleotide coding for a customizable spacer region selected from a y of polynucleotides coding for spacer s. In embodiments, a spacer length is selected based upon the location of the epitope, affinity of the antibody for the epitope, and/or the ability of the T cells expressing the chimeric receptor to proliferate in vitro and/or in vivo in response to antigen recognition.

Typically a spacer region is found between the ligand binding domain and the transmembrane domain of the chimeric receptor. In embodiments, a spacer region provides for flexibility of the ligand binding domain, allows for high expression levels in lymphocytes. A CD19-specific chimeric receptor having a spacer domain of about 229 amino acids had less antitumor activity than a CD19- specific chimeric receptor with a short spacer region comprised of the modified IgG4 hinge only. Other chimeric receptors, such as those constructed from the R12 or 2A2 scFvs also require a short spacer for optimal triggering of T cell effector functions, while a chimeric receptor constructed with the R11 ROR1 scFv requires a long spacer domain of about 229 amino acids for tumor recognition.

In embodiments, a spacer region has at least about 10 to 229 amino acids, about 10 to 200 amino acids, about 10 to 175 amino acids, about 10 to 150 amino acids, about 10 to 125 amino acids, about 10 to 100 amino acids, about 10 to 75 amino acids, about 10 to 50 amino acids, about 10 to 40 amino acids, about 10 to 30 amino acids, about 10 to 20 amino acids, or about 10 to 15 amino acids, and including any integer between the nts of any of the listed ranges. In embodiments, a spacer region has about 12 amino acids or less, about 119 amino acids or less, or about 229 amino acids or less.

In some embodiments, the spacer region is d from a hinge region of an immunoglobulin like molecule. In embodiments, a spacer region ses all or a portion of the hinge region from a human IgG1, human IgG2, a human IgG3, or a human IgG4, and may n one or more amino acid substitutions. Exemplary sequences of the hinge regions are provided in Table 8. In ments, a portion of the hinge region includes the upper hinge amino acids found between the variable heavy chain and the core, and the core hinge amino acids including a polyproline region. Typically, the upper hinge region has about 3 to 10 amino acids. In some cases, the spacer region comprises an amino acid sequence of X1PPX2P(SEQ ID NO:1). In embodiments, X1 is a cysteine, e, or arginine and X2 is a cysteine or a threonine.

In embodiments, hinge region ces can be modified in one or more amino acids in order to avoid undesirable structural interactions such as dimerization. In a specific embodiment, the spacer region comprises a portion of a modified human hinge region from IgG4, for example, as shown in Table 2 or Table 8(SEQ ID NO:21). A representative of a polynucleotide coding for a portion of a modified IgG4 hinge region is provided in Table 1. (SEQ ID NO:4)In embodiments, a hinge region can have at least about 90%, 92%, 95%, or 100% sequence identity with a hinge region amino acid sequence identified in Table 2 or Table 8. In a specific embodiment, a portion of a human hinge region from IgG4 has an amino acid substitution in the core amino acids from CPSP to CPPC.

In some embodiments, all or a portion of the hinge region is combined with one or more domains of a nt region of an immunoglobulin. For example, a portion of a hinge region can be combined with all or a portion of a CH2 or CH3 domain or variant thereof. In embodiments, the spacer region does not include the 47-48 amino acid hinge region sequence from CD8apha or the spacer region consisting of an extracellular portion of the CD28 molecule.

In ments, a short spacer region has about 12 amino acids or less and comprises all or a portion of a IgG4 hinge region sequence or variant thereof, an intermediate spacer region has about 119 amino acids or less and comprises all or a portion of a IgG4 hinge region ce and a CH3 region or variant f, and a long spacer has about 229 amino acids or less and comprises all or a portion of a IgG4 hinge region sequence , a CH2 region, and a CH3 region or variant thereof.

A polynucleotide coding for a spacer region can be readily prepared by synthetic or recombinant methods from the amino acid sequence. In embodiments, a cleotide coding for a spacer region is operably linked to a polynucleotide coding for a transmembrane region. In embodiments, the polynucleotide coding for the spacer region may also have one or more restriction enzyme sites at the 5’ and/or 3’ ends of the coding sequence in order to provide for easy excision and replacement of the polynucleotide with another polynucleotide coding for a different spacer region. In embodiments, the polynucleotide coding for the spacer region is codon optimized for expression in mammalian cells.

In embodiments, a library of polynucleotides, each coding for ent spacer region is described. In an embodiment, the spacer region is selected from the group consisting of a hinge region sequence from IgG1, IgG2, IgG3, or IgG4 or portion thereof, a hinge region sequence from IgG1, IgG2, IgG3, or IgG4 in combination with all or a portion of a CH2 region or variant thereof, a hinge region ce from IgG1, IgG2, IgG3, or IgG4 in ation with all or a portion of a CH3 region or variant thereof, and a hinge region sequence from IgG1, IgG2, IgG3, or IgG4 in ation with all or a portion of a CH2 region or variant thereof, and a CH3 region or variant f. In embodiments, a short spacer region is a modified IgG4 hinge sequence(SEQ ID NO:4) having 12 amino acids or less, an intermediate sequence is a IgG4 hinge sequence with a CH3 sequence having 119 amino acids or less(SEQ ID NO:49); or a IgG4 hinge ce with a CH2 and CH3 region having 229 amino acids or less (SEQ ID NO:50) In embodiments, a method of selecting a spacer region for a ic receptor is described herein. Surprisingly some chimeric receptor constructs, although effective to activate T cells and direct their killing of tumor cells in vitro, were not effective in vivo. In addition, the side effect profile of the chimeric receptor modified T cells can be such as to result in more cells undergoing tion induced cell death or causing an se in in vivo cytokines. In embodiments, a method comprises providing a plurality of chimeric receptor nucleic acids, wherein the chimeric receptor nucleic acids differ only in the spacer region; introducing each of the chimeric receptor nucleic acids into a separate T lymphocyte population; expanding each separate lymphocyte population in vitro, and introducing each lymphocyte population into an animal bearing a tumor to determine the anti-tumor efficacy of each of the chimeric receptors when expressed in T cells, and selecting a ic receptor that provides anti-tumor efficacy as compared to each of the other separate lymphocyte populations modified with each of the other chimeric receptors.

Animal models of different tumors are known. Anti-tumor efficacy can be measured by identifying a decrease in tumor volume, by determining animal death, persistence of the genetically modified T cells in vivo, activation of genetically modified T cells (for e, by detecting an increase in expression of CD25 and/CD69), and/or eration of genetically modified T cells in vivo. In an embodiment, a chimeric or is selected that provides for the best anti-tumor efficacy in vivo as determined by one or more of these parameters. Lack of antitumor efficacy can be ined by lack of persistence of the genetically modified lymphocytes in vivo, animal death, an increase in apoptosis as measured by an se in induction of e -3, and/or a decrease in proliferation of genetically modified cytes.

In other embodiments, a method for selecting a spacer ses selecting an epitope of a target molecule and characterizing the on of the epitope with respect to the cell membrane, selecting a spacer region that is long or short depending on the location of the epitope with respect to the cell membrane, selecting an antibody or fragment thereof that has an affinity for the epitope that is higher or lower as compared to a reference antibody, and determining whether the chimeric receptor uct provides for enhanced T cell proliferation or cytokine production in vitro and/or in vivo.

In some embodiments, if the target epitope or portion thereof is located proximal to the membrane it is located in the first 100 amino acids of the linear sequence of the extracellular domain adjacent to the transmembrane domain. If the epitope is located proximal to the membrane, a long spacer (e.g. 229 amino acids or less and greater than 119 amino acids) is selected. In some embodiments, if the target epitope is located distal to the ne, it is located in the first 150 amino acids of the linear sequence of the extracellular domain terminus. If the epitope is located distal to the membrane, an ediate or short spacer is selected (e.g. 119 amino acids or less or 12-15 amino acids or less). Alternatively, whether the e is proximal or distal to the membrane can be determined by ng of the three dimensional structure or based on analysis of the crystal structure, In some embodiments, a chimeric receptor is selected that provides for at least 30% of the cells proliferating h two generations in vitro and/or in vivo.

In other embodiments a chimeric receptor is not selected if it results in at least 50% of the cells undergoing activation induced cell death in 72 hours. In embodiments, a short spacer (e.g. 15 amino acids or less) is ed if the epitope is distal to the membrane. In embodiments, a long spacer (e.g. 229 amino acid or less and greater than 119 amino acids) is selected if the epitope is proximal to the ne.

In embodiments, providing a plurality of chimeric receptor nucleic acids, wherein the chimeric receptor nucleic acids differ only in the spacer region comprises providing a chimeric receptor construct comprising a polynucleotide coding for a ligand g domain, wherein the ligand is a tumor specific antigen, viral antigen, or any other molecule expressed on a target cell population that is le to mediate recognition and elimination by a lymphocyte; a polynucleotide coding for a first polypeptide spacer having a defined restriction site at the 5’ and 3’ end of the coding sequence for the first polypeptide spacer; a cleotide coding for a embrane domain; and a polynucleotide coding for one or more intracellular signaling domains.

In embodiments, a method further comprises providing one or more polynucleotides, each encoding a different spacer region. In embodiments, the different spacer regions are selected from the group consisting of a hinge region sequence from IgG1, IgG2, IgG3, or IgG4 or variant thereof or portion f, a hinge region sequence from IgG1, IgG2, IgG3, or IgG4 in combination with all or a portion of a CH2 region or t f, a hinge region sequence from IgG1, IgG2, IgG3, or IgG4 in combination with all or a portion of a CH3 region or t thereof, and a hinge region sequence from IgG1, IgG2, IgG3, or IgG4 in ation with all or a portion of a CH2 region or variant thereof and a CH3 region or variant thereof. In embodiments, CH2 or CH3 s may be modified by one or more deletions or amino acid tutions in order to provide for expression in lymphocytes and/or in order to minimize interactions with other molecules. In embodiments, a portion of a hinge region comprises at least the upper amino acids and the core sequence. In embodiments, a hinge region comprises the sequence X1PPX2P.

In embodiments, a method further comprises replacing the polynucleotide coding for the spacer region with a polynucleotide ng a different spacer region to form a chimeric receptor nucleic acid with a different spacer region. The method can be repeated to form any number of chimeric receptor nucleic acids, each differing in the spacer region. In embodiments, the chimeric receptor nucleic acids differ from one another only in the spacer region.

Transmembrane domain In embodiments, the chimeric receptor nucleic acid comprises a polynucleotide coding for a transmembrane domain. The transmembrane domain es for anchoring of the chimeric or in the membrane.

In an embodiment, the transmembrane domain that naturally is associated with one of the domains in the chimeric receptor is used. In some cases, the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface ne proteins to minimize interactions with other members of the receptor x.

The transmembrane domain may be derived either from a natural or a synthetic source. When the source is natural, the domain may be derived from any membrane-bound or transmembrane protein. embrane regions comprise at least the transmembrane region(s) of) the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3, CD45, CD4, CD8, CD9, CD16, CD22; CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154. In a specific embodiment, the transmembrane domain comprises the amino acid sequence of the CD28 transmembrane domain as shown in Table 2. A representative polynucleotide sequence coding for the CD28 transmembrane domain is shown in Table 1(SEQ ID NO:5).

A transmembrane domain may be synthetic or a variant of a naturally occurring transmembrane domain. In ments, synthetic or variant embrane domains comprise predominantly hydrophobic residues such as leucine and valine. In embodiments, a transmembrane domain can have at least about 80%, 85%, 90%, 95%, or 100% amino acid sequence ty with a transmembrane domain as shown in Table 2 or Table 6. Variant transmembrane domains preferably have a hydrophobic score of at least 50 as calculated by Kyte Doolittle.

A polynucleotide coding for a transmembrane domain can be readily prepared by synthetic or recombinant methods. In embodiments, a polynucleotide coding for a transmembrane domain is operably linked to a polynucleotide coding for a ellular signaling region. In ments, the polynucleotide coding for a transmembrane domain may also have one or more restriction enzyme sites at the 5’ and/or 3’ ends of the coding sequence in order to provide for easy excision and replacement of the polynucleotide coding for a transmembrane domain with another polynucleotide coding for a different transmembrane domain. In embodiments, the polynucleotide coding for a transmembrane domain is codon optimized for expression in mammalian cells.

Intracellular signaling domain In embodiments, the ic receptor nucleic acid ses a polynucleotide coding for an intracellular signaling domain. The intracellular signaling domain provides for activation of one on of the transduced cell expressing the chimeric receptor upon binding to the ligand expressed on tumor cells. In embodiments, the intracellular ing domain contains one or more intracellular signaling domains. In embodiments, the intracellular signaling domain is a portion of and/or a variant of an intracellular signaling domain that provides for activation of at least one function of the transduced cell.

Examples of intracellular signaling s for use in a chimeric receptor of the disclosure include the cytoplasmic sequences of the CD3 zeta chain, and/or co- receptors that act in concert to initiate signal transduction following chimeric receptor engagement, as well as any derivative or variant of these sequences and any synthetic sequence that has the same functional capability. T cell tion can be said to be mediated by two distinct s of cytoplasmic signaling sequence: those that initiate antigen-dependent primary activation and provide a T cell receptor like signal (primary cytoplasmic signaling sequences) and those that act in an antigenindependent manner to provide a secondary or co-stimulatory signal (secondary cytoplasmic ing sequences). y cytoplasmic ing sequences that act in a stimulatory manner may contain signaling motifs which are known as receptor tyrosine-based activation motifs or ITAMs. Examples of ITAM containing primary cytoplasmic signaling sequences include those derived from CD3 zeta, FcR gamma, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, and CD66d. In embodiments, the y signaling intracellular domain can have at least about 80%, 85%, 90%, or 95% sequence identity to a having a ce provided in Table 2. In embodiments variants, of CD3 zeta retain at least one, two, three or all ITAM regions as shown in Table 7.

In a preferred embodiment, the intracellular signaling domain of the chimeric receptor can be designed to comprise the CD3-zeta signaling domain by itself or combined with any other d cytoplasmic domain(s). For e, the intracellular signaling domain of the chimeric or can comprise a CD3zeta chain and a costimulatory signaling region.

The costimulatory signaling region refers to a portion of the chimeric receptor comprising the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule other than an antigen or or their s that is required for a response of lymphocytes to an antigen. Examples of such molecules include CD27, CD28, 4-1BB (CD 137), OX40, CD30, CD40, lymphocyte function-associated antigen-1 (LFA-l), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that specifically binds with CD83. In embodiments, the costimulatory signaling domain can have at least about 80%, 85%, 90%, or 95% amino acid sequence identity to the intracellular domain of CD28 as shown in Table or to 4-1BB having a ce provided in Table 2. In an embodiment, a variant of the CD28 intracellular domain comprises an amino acid substitution at positions 186-187, wherein LL is substituted with GG.

The intracellular signaling sequences of the chimeric receptor may be linked to each other in a random or specified order. Optionally, a short oligo- or polypeptide , preferably between 2 and 10 amino acids in length may form the linkage. In one ment, the intracellular signaling domains comprises all or a portion of the signaling domain of CD3-zeta or variant f and all or a portion of the signaling domain of CD28 or a variant thereof. In another embodiment, the intracellular signaling domain comprises all or a portion of the signaling domain of CD3-zeta or variant thereof and all or a portion of the signaling domain of 4-lBB or variant thereof. In yet another embodiment, the intracellular signaling domain comprises all or a portion of the signaling domain of CD3-zeta or t thereof, all or a portion of the signaling domain of CD28 or variant f, and all or a portion of the signaling domain of 4-lBB or variant thereof. In a specific embodiment, the amino acid sequence of the intracellular signaling domain comprising a variant of CD3zeta and a portion of the 4-1BB intracellular signaling domain is provided in Table 2. A entative nucleic acid sequence is ed in Table 1(SEQ ID NO:6; SEQ ID NO:7).

In an embodiment, a polynucleotide coding for an intracellular signaling domain comprises a 4-1BB intracellular domain linked to a portion of a CD3zeta domain. In other embodiments, a 4-1BB intracellular domain and a CD28 intracellular domain are linked to a portion of a CD3 zeta domain.

A polynucleotide coding for an intracellular signaling domain can be readily prepared by synthetic or recombinant methods from the amino acid sequence. In embodiments, the polynucleotide coding for an intracellular signaling domain may also have one or more ction enzyme sites at the 5’ and/or 3’ ends of the coding sequence in order to provide for easy excision and replacement of the polynucleotide coding for an intracellular ing domain with another polynucleotide coding for a different intracellular signaling . In embodiments, the polynucleotide coding for an intracellular signaling domain is codon optimized for expression in mammalian cells.

Marker sequences In ments, the chimeric receptor nucleic acid optionally further ses a polynucleotide ce coding for a marker sequence. A marker sequence can provide for selection of transduced cells, and identification of transduced cells. In embodiments, the marker sequence is operably linked to a polynucleotide sequence coding for a linker sequence. In embodiments, the linker sequence is a cleavable linker sequence.

A number of different marker sequences can be employed. Typically a marker sequence has a functional teristic that allows for selection of transduced cells and/or detection of transduced cells. In ments, the marker sequence is compatible with transduction of human lymphocytes.

The positive selectable marker may be a gene, which upon being introduced into the host cell, expresses a dominant phenotype permitting ve selection of cells carrying the gene. Genes of this type are known in the art, and include, inter alia, hygromycin-B phosphotransferase gene (hph) which confers resistance to ycin B, the amino glycoside phosphotransferase gene (neo or aph) from Tn5 which codes for resistance to the antibiotic G418, the dihydrofolate reductase (DHFR) gene, the ine deaminase gene (ADA), and the multi-drug resistance (MDR) gene.

In an embodiment, a chimeric receptor nucleic acid further comprises a polynucleotide coding for a marker sequence. In an embodiment, the marker sequence is a truncated epidermal growth factor receptor as shown in Table 2. An exemplary polynucleotide for the truncated mal growth factor receptor is shown in Table 1. (SEQ ID n embodiments, the polynucleotide coding for the marker sequence is operably linked to a polynucleotide coding for a linker sequence.

In a specific embodiment, the linker sequence is a cleavable linker sequence T2A as shown in Table 2. An exemplary polynucleotide sequence coding for the T2A linker is provided in Table 1.(SEQ ID NO:8) A polynucleotide coding for marker sequence can be readily prepared by synthetic or recombinant methods from the amino acid sequence. In embodiments a polynucleotide coding for a marker sequence is operably linked to a polynucleotide coding for an ellular signaling domain. In embodiments, the polynucleotide coding for a marker sequence may also have one or more restriction enzyme sites at the 5’ and/or 3’ ends of the coding sequence in order to provide for easy excision and replacement of the polynucleotide coding for a marker sequence with another polynucleotide coding for a different marker sequence. In embodiments, the polynucleotide coding for a marker sequence is codon zed for expression in mammalian cells.

Vectors, Cells and Methods of transducing cells Selection and Sorting of T lymphocyte tions The compositions described herein provide for CD4+ and/or CD8+ T lymphocytes. T lymphocytes can be collected in accordance with known techniques and enriched or depleted by known techniques such as affinity binding to dies such as flow cytometry and/or immunomagnetic selection. After enrichment and/or depletion steps, in vitro expansion of the desired T cytes can be carried out in accordance with known techniques (including but not limited to those bed in US Patent No. 6,040,177 to Riddell et al.), or variations thereof that will be apparent to those skilled in the art. In embodiments, the T cells are autologous T cells obtained from the patient.

For example, the desired T cell population or subpopulation may be expanded by adding an initial T lymphocyte population to a culture medium in vitro, and then adding to the culture medium feeder cells, such as non-dividing peripheral blood mononuclear cells (PBMC), (e.g., such that the resulting population of cells contains at least about 5, 10, 20, or 40 or more PBMC feeder cells for each T lymphocyte in the initial population to be expanded); and incubating the culture (e.g. for a time sufficient to expand the numbers of T cells). The non-dividing feeder cells can se gamma-irradiated PBMC feeder cells. In some embodiments, the PBMC are irradiated with gamma rays in the range of about 3000 to 3600 rads to prevent cell division. The order of addition of the T cells and feeder cells to the culture media can be reversed if d. The culture can typically be ted under conditions of temperature and the like that are suitable for the growth of T lymphocytes. For the growth of human T lymphocytes, for example, the temperature will generally be at least about 25 s Celsius, preferably at least about 30 degrees, more preferably about 37 degrees.

The T lymphocytes expanded e CD8+ cytotoxic T lymphocytes (CTL) and CD4+ helper T cytes that may be specific for an antigen present on a human tumor or a pathogen.

Optionally, the ion method may further comprise the step of adding viding EBV-transformed lymphoblastoid cells (LCL) as feeder cells. LCL can be irradiated with gamma rays in the range of about 6000 to 10,000 rads. The LCL feeder cells may be provided in any suitable amount, such as a ratio of LCL feeder cells to initial T lymphocytes of at least about 10:1.

Optionally, the expansion method may further comprise the step of adding anti-CD3 and/or anti CD28 antibody to the culture medium (e.g., at a concentration of at least about 0.5 ng/ml). Optionally, the expansion method may further comprise the step of adding IL-2 and/or IL-15 to the culture medium (e.g., wherein the concentration of IL-2 is at least about 10 units/m1).

After isolation of T lymphocytes both cytotoxic and helper T lymphocytes can be sorted into naïve, memory, and effector T cell subpopulations either before or after expansion.

CD8+ cells can be obtained by using standard methods. In some ments, CD8+ cells are r sorted into naïve, central memory, and effector memory cells by identifying cell surface antigens that are associated with each of those types of CD8+ cells. In embodiments, memory T cells are present in both CD62L+ and CD62L- subsets of CD8+ peripheral blood lymphocytes. PBMC are sorted into CD62L-CD8+ and CD62L+CD8+ fractions after staining with anti-CD8 and anti-CD62L antibodies. In some embodiments, the expression of phenotypic markers of central memory TCM include CD45RO, CD62L, CCR7, CD28, CD3, and CD127 and are negative or low for granzyme B. In some embodiments, central memory T cells are CD45RO+, CD62L+, CD8+ T cells. In some embodiments, effector TE are negative for CD62L, CCR7, CD28, and CD127, and positive for granzyme B and perforin. In some embodiments, naïve CD8+ T lymphocytes are characterized by the sion of phenotypic markers of naïve T cells including CD62L, CCR7, CD28, CD3, CD127, and . r a cell or cell population is positive for a particular cell surface marker can be determined by flow cytometry using ng with a specific antibody for the surface marker and an isotype matched control antibody. A cell population negative for a marker refers to the absence of significant staining of the cell population with the specific antibody above the isotype control, positive refers to uniform staining of the cell population above the isotype control. In some embodiments, a decrease in expression of one or markers refers to loss of 1 log10 in the mean fluorescence intensity and/or decrease of percentage of cells that exhibit the marker of at least about 20% of the cells, 25% of-the cells, 30% of the cells, 35% of the cells, 40% of the cells, 45% of the cells, 50% of the cells, 55% of the cells, 60% of the cells, 65% of the cells, 70% of the cells, 75% of the cells, 80% of the cells, 85% of the cells, 90% of the cell, 95% of the cells, and 100% of the cells and any % between 20 and 100% when compared to a reference cell population. In some embodiments, a cell tion positive for one or markers refers to a percentage of cells that exhibit the marker of at least about 50% of the cells, 55% of the cells, 60% of the cells, 65% of the cells, 70% of the cells, 75% of the cells, 80% of the cells, 85% of the cells, 90% of the cell, 95% of the cells, and 100% of the cells and any % between 50 and 100% when compared to a reference cell population.

CD4+ T helper cells are sorted into naïve, central memory, and effector cells by identifying cell populations that have cell surface antigens. CD4+ lymphocytes can be obtained by standard methods. In some embodiments, naïve CD4+ T lymphocytes are -, CD45RA+, CD62L+, CD4+ T cells. In some embodiments, l memory CD4+ cells are CD62L+ and CD45RO+. In some embodiments, effector CD4+ cells are CD62L- and CD45RO-.

In embodiments, populations of CD4+ and CD8+ that are antigen specific can be obtained by stimulating naïve or antigen ic T lymphocytes with antigen.

For example, antigen-specific T cell lines or clones can be generated to Cytomegalovirus antigens by isolating T cells from infected subjects and stimulating the cells in vitro with the same antigen. Naïve T cells may also be used. Any number of antigens from tumor cells may be utilized as targets to elicit T cell responses. In some embodiments, the adoptive cellular immunotherapy compositions are useful in the treatment of a e or disorder including a solid tumor, hematologic malignancy, breast cancer or ma.

Modification of T lymphocyte populations In some embodiments it may be d to introduce onal genes into the T cells to be used in immunotherapy in accordance with the present sure.

For example, the uced gene or genes may improve the efficacy of therapy by promoting the ity and/or function of transferred T cells; or they may e a genetic marker to permit selection and/or tion of in vivo survival or migration; or they may incorporate functions that improve the safety of immunotherapy, for example, by making the cell susceptible to negative selection in vivo as described by Lupton S. D. et al., Mol. and Cell Biol., 11:6 (1991); and l et al., Human Gene Therapy 3:319-338 (1992); see also the publications of PCT/US91/08442 and PCT/US94/05601 by Lupton et al. bing the use of bifunctional selectable fusion genes derived from fusing a dominant positive able marker with a negative able marker. This can be carried out in accordance with known techniques (see, e.g., US Patent No. 6,040,177 to Riddell et al. at s 14-17) or variations thereof that will be apparent to those skilled in the art based upon the t disclosure.

In embodiments, T cells are modified with chimeric receptors as described herein. In some embodiments, the T cells are obtained from the subject to be treated, in other embodiments, the lymphocytes are ed from allogeneic human donors, preferably healthy human donors.

In some ments, chimeric receptors comprise a ligand binding domain that specifically binds to a tumor cell e molecule, a polypeptide spacer region, a transmembrane domain and an intracellular signaling domain as described herein.

In embodiments, the ligand binding domain is a single-chain antibody fragment (scFv) that is derived from the variable heavy (VH) and variable light (VL) chains of a monoclonal antibody (mAb). Costimulatory signals can also be provided through the chimeric receptor by fusing the costimulatory domain of CD28 and/or 4-1BB to the CD3? chain. Chimeric receptors are specific for cell surface molecules independent from HLA, thus overcoming the limitations of TCR-recognition including HLA-restriction and low levels of HLA-expression on tumor cells.

Chimeric receptors can be constructed with a specificity for any cell surface marker by utilizing antigen binding fragments or antibody variable domains of, for example, antibody molecules. The antigen binding molecules can be linked to one or more cell signaling modules. In embodiments, cell signaling modules include CD3 transmembrane domain, CD3 intracellular signaling domains, and CD28 transmembrane domains. In embodiments, the intracellular signaling domain comprises a CD28 transmembrane and signaling domain linked to a CD3 zeta intracellular domain. In some embodiments, a chimeric receptor can also include a uction marker such as tEGFR.

In ments, the same or a different chimeric receptor can be introduced into each of population of CD4+ and CD8+ T lymphocytes. In ments, the chimeric or in each of these populations has a ligand binding domain that specifically binds to the same ligand on the tumor or infected cell. The cellular signaling modules can differ. In embodiments, the intracellular signaling domain of the CD8+ cytotoxic T cells is the same as the ellular signaling domain of the CD4+ helper T cells. In other embodiments, the intracellular ing domain of the CD8+ cytotoxic T cells is different than the intracellular signaling domain of the CD4+ helper T cells.

In embodiments each of the CD4 or CD8 T lymphocytes can be sorted in to naïve, central memory, effector memory or effector cells prior to transduction as described herein. In alternative ments, each of the CD4 or CD8 T cytes can be sorted in to naïve, central memory, or memory, or effector cells after transduction.

Various transduction techniques have been developed which utilize recombinant infectious virus particles for gene delivery. This represents a currently preferred approach to the transduction of T lymphocytes described herein. The viral vectors which have been used in this way include virus vectors d from simian virus 40, adenoviruses, adeno-associated virus (AAV), lentiviral s, and retroviruses. Thus, gene transfer and expression methods are numerous but essentially function to uce and express c material in mammalian cells.

Several of the above techniques have been used to transduce hematopoietic or lymphoid cells, including calcium phosphate transfection, protoplast fusion, electroporation, and infection with recombinant adenovirus, adeno-associated virus and retrovirus vectors. Primary T lymphocytes have been successfully transduced by electroporation and by retroviral or lentiviral infection.

Retroviral and lentiviral vectors provide a highly efficient method for gene transfer into eukaryotic cells. Moreover, retroviral or lentiviral ation takes place in a controlled fashion and results in the stable integration of one or a few copies of the new genetic information per cell.

It is contemplated that overexpression of a stimulatory factor (for example, a lymphokine or a cytokine) may be toxic to the treated individual. ore, it is within the scope of the present disclosure to include gene segments that cause the T cells described herein to be susceptible to negative ion in vivo. By ''negative selection" is meant that the infused cell can be eliminated as a result of a change in the in vivo condition of the individual. The negative selectable phenotype may result from the insertion of a gene that confers sensitivity to an administered agent, for e, a compound. Negative able genes are known in the art, and include, inter alia the ing: the Herpes simplex virus type I thymidine kinase (HSV-I TK) gene, which confers ganciclovir sensitivity; the cellular hypoxanthine phosphribosyltransferase (HPRT) gene, the cellular adenine phosphoribosyltransferase (APRT) gene, and bacterial cytosine deaminase, In some embodiments it may be useful to include in the T cells a positive marker that enables the selection of cells of the negative selectable phenotype in vitro. The positive selectable marker may be a gene that upon being introduced into the host cell expresses a dominant phenotype permitting positive selection of cells carrying the gene. Genes of this type are known in the art, and include, inter alia, hygromycin-B phosphotransferase gene (hph) which confers resistance to ycin B, the amino glycoside phosphotransferase gene (neo or aph) from Tn5 which codes for resistance to the antibiotic G418, the dihydrofolate ase (DHFR) gene, the adenosine deaminase gene (ADA), and the multi-drug ance (MDR) gene.

A variety of methods can be employed for transducing T lymphocytes, as is well known in the art. In embodiments, transduction is carried out using lentiviral In embodiments, CD4+ and CD8+ cells each can tely be ed with an expression vector encoding a chimeric receptor to form defined populations. In embodiments, these cells are then further sorted into subpopulations of naïve, central memory and effector cells as described above by sorting for cell surface antigens unique to each of those cell populations. In addition, CD4+ or CD8+ cell populations may be selected by their cytokine profile or proliferative activities. For example, CD4+ T lymphocytes that have enhanced production of cytokines such as IL-2, IL-4, IL-10, TNFa, and IFN? as compared to sham transduced cells or transduced CD8+ cells when stimulated with antigen can be selected. In other embodiments, naïve or central memory CD4+ T cells that have ed production of IL-2 and/or TNFa are selected. Likewise, CD8+ cells that have enhanced IFN? production are selected as compared to sham transduced CD8+ cells.

In embodiments, CD4+ and lls that proliferate in response to antigen or tumor s are selected. For example, CD4+ cells that proliferate vigorously when stimulated with antigen or tumor targets as compared to sham transduced cells, or CD8+ transduced cells are selected. In some ments, CD4+ and CD8+ cells are selected that are cytotoxic for antigen bearing cells. In embodiments, CD4+ are expected to be weakly cytotoxic as compared to CD8+ cells.

In a preferred embodiment, uced lymphocytes, such as CD8+ l memory cells, are selected that provide for tumor cell killing in vivo using an animal model established for the particular type of . Such animal models are known to those of skill in the art and exclude human beings. As described herein, not all chimeric or constructs transduced into lymphocytes confer the ability to kill tumor cells in vivo despite the ability to become activated and kill tumor cells in vitro. In particular, for some target molecules T cells having chimeric receptor constructs with a long spacer region were less effective at killing tumor cells in vivo as compared to T cells having a chimeric receptor with short spacer region. For other target molecules, T cells having chimeric receptor constructs with a short spacer region were less effective at killing tumor cells in vivo as compared to T cells having chimeric receptors with a long spacer region.

In yet other embodiments, transduced chimeric receptor expressing T cells are selected that can persist in vivo using an animal model ished for the particular type of cancer. In embodiments, transduced chimeric receptor CD8+ central memory cells with a short spacer region have been shown to persist in vivo after introduction into the animal for about 3 day or more, 10 days or more, 20 days or more, 30 days or more, 40 days or more, or 50 days or more.

The disclosure contemplates that ations of CD4+ and CD8+ T cells will be utilized in the compositions. In one embodiment, combinations of chimeric receptor transduced CD4+ cells can be combined with chimeric receptor transduced CD8+ cells of the same ligand specificity or combined with CD8+ T cells that are ic for a distinct tumor . In other embodiments, chimeric receptor transduced CD8+ cells are combined with chimeric receptor transduced CD4+ cells specific for a different ligand expressed on the tumor. In yet another ment, chimeric receptor modified CD4+ and CD8+ cells are combined. In embodiments CD8+ and CD4+ cells can be combined in different ratios for example, a 1:1 ratio of CD8+ and CD4+, a ratio of 10:1 of CD8+ to CD4+, or a ratio of 100:1 of CD8+ to CD4+. In embodiments, the combined population is tested for cell proliferation in vitro and/or in vivo, and the ratio of cells that provides for eration of cells is selected.

As bed herein, the disclosure contemplates that CD4+ and CD8+ cells can be further separated into subpopulations, such as naïve, central memory, and effector memory cell populations. As described herein, in some embodiments, naïve CD4+ cells are CD45RO-, CD45RA+, CD62L+, CD4+ positive T cells. In some ments, central memory CD4+ cells are CD62L positive and CD45RO positive. In some embodiments, effector CD4+ cells are CD62L negative and CD45RO positive. Each of these populations may be independently ed with a chimeric receptor.

As described herein, in embodiments, memory T cells are present in both CD62L+ and CD62L- subsets of CD8+ peripheral blood cytes. PBMC are sorted into CD62L-CD8+ and CD62L+CD8+ fractions after staining with anti-CD8 and anti-CD62L antibodies. In some embodiments, the expression of phenotypic markers of central memory T cells (TCM) include CD62L, CCR7, CD28, CD3, and CD127 and are negative or low for granzyme B. In some embodiments, central memory T cells are +, CD62L+, CD8+ T cells. In some embodiments, effector T cells (TE) are negative for CD62L, CCR7, CD28, and CD127, and positive for granzyme B and perforin. In some embodiments, naïve CD8+ T lymphocytes are characterized by CD8+, CD62L+, CD45RO+, CCR7+, CD28+ CD127+, and CD45RO+. Each of these populations may be independently ed with a chimeric receptor .

After transduction and/or selection for chimeric receptor bearing cells, the cell populations are preferably expanded in vitro until a sufficient number of cells are obtained to provide for at least one infusion into a human subject, lly around 104 cells/kg to 109 kg In embodiments, the transduced cells are cultured in the ce of antigen bearing cells, anti CD3, anti CD28, and IL 2, IL-7, IL 15, IL-21 and combinations thereof.

Each of the subpopulations of CD4+ and CD8+ cells can be combined with one another. In a specific embodiment, modified naïve or central memory CD4+ cells are combined with modified central memory CD8+ T cells to provide a synergistic cytotoxic effect on antigen bearing cells, such as tumor cells.

Compositions Also described is an adoptive ar immunotherapy composition comprising a genetically modified T lymphocyte cell preparation as bed herein.

In embodiments, the T lymphocyte cell preparation comprises CD4 + T cells that have a chimeric or comprising an extracellular antibody variable domain specific for a ligand associated with the disease or disorder, a izable spacer region, a transmembrane domain, and an intracellular signaling domain of a T cell receptor or other receptors as described herein. In other embodiments, an adoptive cellular immunotherapy composition further comprises a chimeric receptor modified tumor-specific CD8+ cytotoxic T lymphocyte cell preparation that provides a cellular immune response, wherein the cytotoxic T lymphocyte cell preparation comprises CD8+ T cells that have a chimeric or comprising an ellular single chain antibody specific for a ligand associated with the disease or disorder, a customizable spacer region, a transmembrane domain, and an ellular signaling domain of a T cell receptor as described herein. In embodiments, the chimeric receptor ed T cell population of the disclosure can persist in vivo for at least about 3 days or longer.

In some ments, an adoptive cellular immunotherapy composition comprises a chimeric receptor modified tumor-specific CD8+ cytotoxic T lymphocyte cell preparation that provides a cellular immune response, wherein the cytotoxic T lymphocyte cell preparation comprises CD8+ T cells that have a chimeric receptor comprising an extracellular single chain dy specific for a ligand associated with the disease or disorder, a customizable spacer region, a embrane domain, and an intracellular ing domain of a T cell receptor, in combination with an antigen-reactive chimeric or modified naïve CD4+ T helper cell derived from CD45RO- CD62L+ CD4+ T cells, and a pharmaceutically able carrier.

In other embodiments, an adoptive cellular immunotherapy composition comprises an n specific CD8+ cytotoxic T lymphocyte cell preparation that provides a cellular immune response derived from the patient combined with an antigen-reactive chimeric receptor modified naïve CD4+ T helper cell that ts the CD8+ immune response, wherein the helper T lymphocyte cell preparation comprises CD4 + T cells that have a chimeric receptor comprising an extracellular antibody variable domain specific for the antigen associated with the disease or disorder, a customizable spacer region, a transmembrane domain, and an intracellular signaling domain of a T cell receptor.

In a further embodiment, an adoptive ar immunotherapy composition ses an antigen-reactive chimeric or modified naïve CD4+ T helper cell that augments the CD8+ immune response, wherein the helper T lymphocyte cell preparation comprises CD4 + T cells that have a chimeric receptor comprising an extracellular antibody variable domain specific for a ligand ated with a disease or disorder, a customizable spacer region, a transmembrane domain, and an intracellular signaling domain of a T cell receptor.

In ments, the CD4+ T helper lymphocyte cell is selected from the group consisting of naïve CD4+ T cells, central memory CD4+ T cells, effector memory CD4+ T cells, or bulk CD4+ T cells. In some embodiments, CD4+ helper cyte cell is a naïve CD4+ T cell, wherein the naïve CD4+ T cell comprises a CD45RO-, CD45RA+, CD62L+ CD4+ T cell. In embodiments, the CD8+ T cytotoxic lymphocyte cell is selected from the group consisting of naïve CD8+ T cells, central memory CD8+ T cells, or memory CD8+ T cells or bulk CD8+ T cells. In some embodiments, the CD8+ cytotoxic T lymphocyte cell is a central memory T cell wherein the central memory T cell comprises a CD45RO+, CD62L+, CD8+ T cell. In yet other embodiments, the CD8+ xic T lymphocyte cell is a central memory T cell and the CD4+ helper T lymphocyte cell is a naïve or central memory CD4+ T cell.

Methods Also described are s of making ve immunotherapy compositions and uses or methods of using these compositions for performing cellular immunotherapy in a t having a disease or disorder. In embodiments, the chimeric receptor modified T cells as described herein are able to persist in vivo for at least 3 days, or at least 10 days. In embodiments, the chimeric receptor modified T cells as described herein can proliferate in vivo through at least 2, or at least 3 generations as determined by CFSE dye dilution. Proliferation and persistence of the chimeric receptor modified T cells can be determined by using an animal model of the disease or disorder and administering the cells and determining persistence and/ or proliferative capacity of the transferred cells. In other embodiments, proliferation and activation can be tested in vitro by going through multiple cycles of activation with antigen g cells.

In embodiments, a method of manufacturing the compositions comprises obtaining a modified naïve CD4+ T helper cell, n the modified helper T cyte cell preparation comprises CD4+ T cells that have a chimeric receptor comprising a ligand binding domain ic for a tumor cell surface molecule, a customized spacer domain, a embrane domain, and an intracellular signaling domain as bed herein.

In another embodiment, a method further comprises obtaining a modified CD8+ xic T cell, wherein the modified cytotoxic T lymphocyte cell preparation comprises CD8+ cells that have a chimeric or comprising a ligand binding domain specific for a tumor cell surface molecule, a customized spacer domain, a transmembrane domain, and an intracellular signaling domain as bed herein.

In another embodiment, a method comprises obtaining a ed CD8+ cytotoxic T cell, wherein the modified cytotoxic T cyte cell preparation comprises CD8+ T cells that have a chimeric receptor comprising a ligand binding domain ic for a tumor cell surface molecule, a customized spacer domain, a transmembrane domain, and an intracellular signaling domain as described herein, and further comprising combining the modified CD8+ cytotoxic T cells with a CD4+ helper cell cyte cell preparation.

The preparation of the CD4+ and CD8+ cells that are modified with a chimeric receptor has been described above as well as in the examples. Antigen specific T lymphocytes can be obtained from a patient having the disease or disorder or can be ed by in vitro stimulation of T lymphocytes in the presence of antigen. Subpopulations of CD4+ and CD8+ T lymphocytes that are not selected for antigen specificity can also be isolated as described herein and combined in the s of manufacturing. In embodiments, the combination of cell populations can be ted for uniformity of cell surface makers, the ability to erate through at least two generations, to have a uniform cell differentiation status. Quality control can be med by coculturing an cell line expressing the target ligand with chimeric receptor modified T cells to determine if the chimeric receptor ed T cells recognize the cell line using cytotoxicity, proliferation, or cytokine production assays that are known in the field. Cell differentiation status and cell surface markers on the chimeric receptor modified T cells can be determined by flow cytometry. In embodiments, the markers and cell differentiation status on the CD8+ cells include CD3, CD8, CD62L, CD28, CD27, CD69, CD25, PD-1, CTLA-4, CD45RO, and . In embodiments, the markers and the cell differentiation status on the CD4+ cells include CD3, CD4, CD62L, CD28, CD27, CD69, CD25, PD-1, CTLA-4 CD45RO, and CD45RA.

In embodiments, a method of selecting a spacer region for a chimeric receptor is described herein. Surprisingly some chimeric receptor constructs, although effective to activate T cells in vitro, were not effective in vivo. In embodiments, a method comprises providing a plurality of chimeric receptor nucleic acids, wherein the chimeric receptor nucleic acids differ only in the spacer region; ucing each of the chimeric receptor nucleic acids into a separate T lymphocyte population; expanding each separate lymphocyte population in vitro, and introducing each lymphocyte tion into an animal bearing a tumor to determine the anti-tumor efficacy of each of the chimeric receptor modified T cells, and selecting a chimeric receptor that provides anti-tumor efficacy as compared to each of the other separate cyte populations modified with each of the other chimeric receptor ed T cells.

Animal models of different tumors are known. Anti-tumor efficacy can be measured by identifying a decrease in tumor , by determining animal death, persistence of the genetically modified T cells in vivo, activation of genetically modified T cells (for example, by detecting an increase in expression of CD25 69), and/or proliferation of genetically modified T cells in vivo. In an embodiment, a chimeric receptor is selected that provides for the best anti-tumor efficacy in vivo as determined by one or more of these parameters. Lack of antitumor cy can be determined by lack of tence of the genetically modified lymphocytes in vivo, animal death, an increase in sis as measured by an increase in induction of caspase -3, and/or a decrease in proliferation of genetically modified lymphocytes.

In embodiments, providing a plurality of chimeric receptor nucleic acids, wherein the chimeric receptor nucleic acids differ only in the spacer region comprises providing a chimeric or construct comprising a polynucleotide coding for a ligand binding domain, wherein the ligand is a tumor specific antigen, viral antigen, or any other molecule expressed on a target cell population that is le to mediate ition and elimination by a lymphocyte; a polynucleotide coding for a first polypeptide spacer having a defined restriction site at the 5’ and 3’ end of the coding sequence for the first polypeptide spacer; a polynucleotide coding for a transmembrane domain; and a polynucleotide coding for an intracellular signaling domain.

Also described are methods of ming cellular immunotherapy in a subject having a e or disorder sing: administering a composition of lymphocytes expressing a chimeric receptor as described herein. In other embodiments, a method ses administering to the subject a genetically modified cytotoxic T lymphocyte cell preparation that provides a cellular immune response, wherein the cytotoxic T lymphocyte cell ation comprises CD8 + T cells that have a chimeric receptor comprising a ligand binding domain specific for a tumor cell surface molecule, a customized spacer domain, a transmembrane domain, and an intracellular signaling domain as bed herein, and a genetically modified helper T lymphocyte cell preparation that elicits direct tumor ition and augments the genetically modified cytotoxic T lymphocyte cell preparations ability to mediate a cellular immune response, wherein the helper T lymphocyte cell ation ses CD4+ T cells that have a chimeric receptor comprising a ligand binding domain specific for a tumor cell surface molecule, a customized spacer domain, a transmembrane domain, and an ellular signaling domain as described herein.

While not limiting the scope of the disclosure, it is believed by selecting the chimeric receptor modified T cell population that can persist and erate in vivo prior to administration may result in the ability to use a lower dose of T cells and provide more uniform therapeutic activity. In embodiments, the dose of T cells can be reduced at least 10%, 20%, or 30% or greater. Reduction in the dose of T cells may be cial to reduce the risk or tumor lysis syndrome and cytokine storm.

In another embodiment, a method of performing cellular immunotherapy in subject having a disease or disorder comprises: administering to the subject a cally modified helper T lymphocyte cell preparation, wherein the modified helper T lymphocyte cell preparation comprises CD4+ T cells that have a chimeric receptor comprising a ligand g domain specific for a tumor cell surface molecule, a ized spacer domain, a transmembrane domain, and an intracellular signaling domain as described herein. In an embodiments, the method further comprises administering to the subject a genetically modified cytotoxic T lymphocyte cell preparation, wherein the modified cytotoxic T lymphocyte cell preparation ses CD8+ cells that have a chimeric receptor comprising a ligand binding domain specific for a tumor cell surface molecule, a customized spacer domain, a transmembrane , and an intracellular signaling domain as described herein.

Another embodiment describes a method of performing cellular immunotherapy in a subject having a disease or disorder sing: ing a biological sample of the subject for the presence of a target molecule associated with the disease or disorder and administering the adoptive immunotherapy compositions described , wherein the chimeric or specifically binds to the target molecule.

In some embodiments, the CD4+ T helper lymphocyte cell is ed prior to introduction of the chimeric receptor from the group consisting of naïve CD4+ T cells, central memory CD4+ T cells, effector memory CD4+ T cells or bulk CD4+ T cells. In a specific embodiment, CD4+ helper lymphocyte cell is a naïve CD4+ T cell, wherein the naïve CD4+ T cell comprises a CD45RO-, CD45RA+, CD62L+ CD4+ T cell. In yet other embodiments, the CD8+ T cytotoxic lymphocyte cell is selected prior to introduction of the chimeric receptor from the group ting of naïve CD8+ T cells, central memory CD8+ T cells, or memory CD8+ T cells or bulk CD8+ T cells. In a specific embodiment, the CD8+ cytotoxic T lymphocyte cell is a central memory T cell wherein the central memory T cell comprises a CD45RO+, CD62L+, CD8+ T cell. In a specific embodiment, the CD8+ cytotoxic T lymphocyte cell is a central memory T cell and the CD4+ helper T lymphocyte cell is a naïve CD4+ T cell.

In embodiments, the CD8+ T cell and the CD4+ T cell are both genetically ed with a ic receptor comprising an antibody heavy chain domain that specifically binds a tumor-specific cell surface molecule. In other embodiments, the intracellular signaling domain of the CD8 cytotoxic T cells is the same as the intracellular signaling domain of the CD4 helper T cells. In yet other embodiments, the intracellular signaling domain of the CD8 cytotoxic T cells is different than the intracellular signaling domain of the CD4 helper T cells.

Subjects that can be treated by the methods described herein are, in general, human and other primate subjects, such as monkeys and apes for veterinary medicine purposes. The subjects can be male or female and can be any suitable age, ing infant, juvenile, adolescent, adult, and geriatric subjects.

The methods are useful in the treatment of, for example, hematologic malignancy, melanoma, breast cancer, and other epithelial malignancies or solid tumors. In some ments, the molecule associated with the disease or disorder is ed from the group consisting of orphan tyrosine kinase or ROR1, Her2, CD19, CD20, CD22, mesothelin, CEA, and tis B surface antigen.

Subjects that can be treated include subjects afflicted with cancer, ing but not limited to colon, lung, liver, breast, renal, prostate, ovarian, skin (including melanoma), bone, and brain cancer, etc. In some embodiments the tumor ated antigens or molecules are known, such as melanoma, breast cancer, squamous cell carcinoma, colon cancer, leukemia, myeloma, and prostate cancer. In other embodiments the tumor associated molecules can be targeted with genetically modified T cells expressing an engineered chimeric or. es include but are not limited to B cell lymphoma, breast cancer, prostate cancer, and leukemia.

Cells prepared as described above can be utilized in methods and compositions for adoptive immunotherapy in accordance with known techniques, or variations thereof that will be apparent to those skilled in the art based on the instant disclosure.

In some embodiments, the cells are formulated by first harvesting them from their culture , and then washing and concentrating the cells in a medium and container system suitable for administration (a aceutically acceptable" carrier) in a treatment-effective amount. Suitable infusion medium can be any isotonic medium ation, typically normal saline, Normosol R t) or Plasma-Lyte A (Baxter), but also 5% dextrose in water or Ringer's lactate can be utilized. The infusion medium can be supplemented with human serum albumin, fetal bovine serum or other human serum components.

A treatment ive amount of cells in the composition is at least 2 cell subsets (for example, 1 CD8+ l memory T cell subset and 1 CD4+ helper T cell subset) or is more typically greater than 102 cells, and up to 106, up to and including 108 or 109 cells and can be more than 1010 cells. The number of cells will depend upon the ultimate use for which the composition is intended as will the type of cells ed therein. For example, if cells that are specific for a particular antigen are desired, then the population will contain greater than 70%, generally greater than 80%, 85% and 90-95% of such cells. For uses described herein, the cells are generally in a volume of a liter or less, can be 500 mls or less, even 250 mls or 100 mls or less. Hence the density of the desired cells is typically r than 104 cells/m1 and generally is r than 107 cells/ml, generally 108 cells/ml or greater.

The clinically relevant number of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed 106, 107, 108, 108, 109, 1010 or 1011 cells.

In some embodiments, the lymphocytes described herein may be used to confer immunity to individuals. By "immunity" is meant a lessening of one or more physical symptoms associated with a response to infection by a pathogen, or to a tumor, to which the lymphocyte response is directed. The amount of cells administered is y in the range present in normal individuals with immunity to the pathogen. Thus, the cells are usually administered by on, with each infusion in a range of from 2 cells, up to at least 106 to 3x1010 cells, preferably in the range of at least 107 to 109 cells. The T cells may be administered by a single infusion, or by multiple ons over a range of time. However, since different duals are expected to vary in responsiveness, the type and amount of cells infused, as well as the number of infusions and the time range over which multiple infusions are given are determined by the attending physician, and can be determined by e examination. The generation of sufficient levels of T lymphocytes (including cytotoxic T lymphocytes and/or helper T lymphocytes) is readily achievable using the rapid expansion method described herein, as exemplified herein. See, e.g., US Patent No. 6,040,177 to Riddell et al. at column 17.

In embodiments, the composition as described herein are administered intravenously, intraperitoneally, intratumorly, into the bone marrow, into the lymph node, and /or into cerebrospinal fluid. In embodiments, the ic receptor ered compositions are delivered to the site of the tumor. Alternatively, the compositions as described herein can be combined with a compound that targets the cells to the tumor or the immune system tments and avoid sites such as the lung.

In embodiments, the compositions as described herein are administered with chemotherapeutic agents and/or immunosuppressants. In an embodiment, a patient is first treated with a chemotherapeutic agent that inhibits or destroys other immune cells ed by the compositions described . In some cases, chemotherapy may be avoided entirely.

The present invention is illustrated further in the examples set forth below.

EXPERIMENTAL Example I. Customizing spacer domain length and scFv affinity for optimal recognition of ROR1 with chimeric receptor modified T cells We constructed chimeric receptors specific for the ROR1 le that is expressed on a large number of human malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, and breast, lung prostate, pancreas and ovarian cancer. The ROR1 chimeric receptors were designed from ROR1 specific scFVs with different affinities and containing extracellular IgG4-Fc spacer domains of different lengths. The ability of T-cells expressing each ROR-1 specific chimeric receptor to recognize ROR1+ hematopoietic and epithelial tumors in vitro, and to eliminate human mantle cell lymphoma engrafted into deficient mice was analyzed. als and s Human subjects Peripheral blood clear cells (PBMC) were obtained from healthy donors and patients after written informed consent on research ols approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center (FHCRC).

Cell lines The K562, Raji, JeKo-1, MDA-MB-231, MDA-MB-468, and 293T cell lines were obtained from the American Type Culture Collection. Dr. Edus H. Warren (FHCRC) kindly provided the renal cell cancer lines FARP, TREP and RWL.

K562/ROR1 and OR1 were generated by iral uction with the full- length ROR1-gene. To derive JeKo-1/ffluc, native JeKo-1 cells were transduced with a lentiviral vector encoding the firefly luciferase (ffluc)-gene upstream of a T2A sequence and eGFP. The transduced JeKo-1 cells were sorted for eGFP expression, and expanded for in vivo experiments.

Immunophenotyping PBMC and cell lines were stained with the following conjugated mAbs: CD3, CD4, CD5, CD8, CD19, CD28, CD45RO, CD62L, CD314 (NKG2D), MICA/B and matched isotype controls (BD ences). Propidium iodide (PI) staining was performed for live/dead cell discrimination. Cell surface expression of ROR1 was analyzed using a polyclonal goat anti-human-ROR1 antibody (R&D Systems).

Surface expression of 2A2 ROR1chimeric receptor was ed using a polyclonal goat anti-mouse-IgG antibody (Fab-specific) (Jackson ImmunoResearch).

Flow analyses were done on a nto®, sort-purifications on a FACSAriaII® (Becton Dickinson) and data analyzed using FlowJo® software (Treestar).

Vector construction and preparation of chimeric receptor encoding lentivirus ROR1-specific and CD19-specific chimeric ors were constructed using VL and VH chain segments of the 2A2, R12, and R11 mAbs (ROR1) and FMC63 mAb (CD19). ble region sequences for R11 and R12 are provided in Yang et al, Plos One 6(6):e21018, June 15, 2011) Each scFV was linked by a (G4S)3(SEQ ID NO:12) peptide to a spacer domain derived from IgG4-Fc (Uniprot se: ,SEQ ID NO:13) comprising either ‘Hinge-CH2-CH3’ (229 AA, SEQ ID NO:), ‘Hinge-CH3’ (119 AA,SEQ ID NO:) or ‘Hinge’ only (12 AA,SEQ. ID NO:4) sequences (Figure 1). All spacers contained a S?P substitution within the ‘Hinge’ domain located at position 108 of the native IgG4-Fc n, and were linked to the 27 AA embrane domain of human CD28 (Uniprot: P10747, SEQ ID NO:14) and to a signaling module comprising either (i) the 41 AA cytoplasmic domain of human CD28 with an LL?GG substitution located at positions 186-187 of the native CD28 protein (SEQ ID NO:14)or (ii) the 42 AA cytoplasmic domain of human 4-1BB (Uniprot: Q07011, SEQ ID NO:15), each of which was linked to the 112 AA asmic domain of isoform 3 of human CD3? (Uniprot: P20963, SEQ ID NO;16). The construct encoded a T2A ribosomal skip element (SEQ ID NO:8))and a tEGFR sequence (SEQ ID NO:9) downstream of the chimeric receptor.

Codon-optimized nucleotide sequences encoding each transgene were synthesized (Life Technologies) and cloned into the epHIV7 lentiviral vector ROR1-chimeric receptor, CD19-chimeric receptor or tEGFR-encoding lentiviruses were ed in 293T cells using the packaging vectors pCHGP-2, pCMV-Rev2 and pCMV-G, and Calphos® transfection reagent (Clontech).

Generation of T-cell lines expressing ROR1 and CD19-chimeric receptors CD8+ + CD62L+ central memory T-cells (TCM) or bulk CD4+ T- cells were sorted from PBMC of normal donors, activated with anti-CD3/CD28 beads (Life Technologies), and transduced on day 3 after activation by centrifugation at 800 g for 45 min at 32ºC with lentiviral supernatant (MOI = 3) supplemented with 1 µg/mL polybrene (Millipore). T-cells were expanded in RPMI with 10% human serum, 2 mM L-glutamine and 1% penicillin-streptomycin (CTL ), supplemented with recombinant human IL-2 to a final concentration of 50 U/mL. The tEGFR+ subset of each T-cell line was enriched by immunomagnetic ion with biotin-conjugated anti-EGFR mAb (ImClone Systems) and streptavidin-beads (Miltenyi). ROR1-chimeric receptor and tEGFR control T-cells were expanded using a rapid expansion protocol (Riddell SR, Greenberg PD,The use of anti-CD3 and anti-CD28 onal antibodies to clone and expand human antigen-specific T cells J Immunol Methods. 1990;128(2):189-201. Epub 1990/04/17.), and CD19-chimeric receptor modified T-cells were expanded by stimulation with irradiated (8,000 rad) B-LCL at a T-cell:LCL ratio of 1:7. T-cells were cultured in CTL medium with 50 U/mL IL-2. xicity, cytokine secretion and proliferation assays Target cells were labeled with 51Cr nElmer), washed and incubated in triplicate at 1-2x103 cells/well with effector chimeric receptor ed T-cells at various effector to target (E:T) ratios. atants were harvested for ?-counting after a 4-hour incubation and specific lysis calculated using the rd formula.

For analysis of cytokine ion, 5x104 T-cells were plated in triplicate with target cells at an E:T ratio of 1:1 (primary CLL), 2:1 (Raji/ROR1; JeKo-1), 4:1 (K562/ROR1, K562/CD19 and K562) or 10:1 (MDA-MB-231), and IFN-?, TNF-a and IL-2 measured by ELISA or lex cytokine immunoassay (Luminex) in supernatant removed after 24-h tion. In experiments ng NKG2D signaling, anti-NKG2D (clone 1D11), anti-MICA/B (clone 6D4, all from BD) and LBP (kindly provided by Dr. Veronika Groh, FHCRC) were used at saturating concentrations. For analysis of proliferation, T-cells were labeled with 0.2 µM carboxyfluorescein succinimidyl ester (CFSE, Invitrogen), washed and plated in triplicate with stimulator cells in medium without exogenous cytokines. After 72-h incubation, cells were labeled with anti-CD8 mAb and PI, and analyzed by flow cytometry to assess cell division of live CD8+ T-cells.

Experiments in ID/?c-/- (NSG) mice The Institutional Animal Chimeric receptor and Use Committee approved all mouse experiments. Six- to 8-week old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from the Jackson Laboratory or bred in-house. Mice were injected with 0.5x106 JeKo-1/ffluc tumor cells via tail vein and received a subsequent tail vein injection of chimeric or-modified or control T-cells.

For bioluminescence imaging of tumor growth, mice received intraperitoneal injections of luciferin substrate (Caliper Life Sciences) resuspended in PBS (15 µg/g body weight). Mice were anesthetized with isoflurane and imaged using an n IVIS Imaging System (Caliper) 10, 12 and 14 minutes after the injection of luciferin in small binning mode at an acquisition time of 1 s to 1 min to obtain unsaturated images. Luciferase activity was analyzed using Living Image Software (Caliper) and the photon flux analyzed within regions of interest that assed the entire body or the thorax of each individual mouse.

Statistical analyses Statistical analyses were performed using Prism Software (GraphPad®).

Student’s t-test was performed as a two-sided paired test with a ence interval of 95% and results with a e of p<0.05 were considered significant. Statistical analysis of survival were done by log-rank testing and results with a p-value of p<0.05 ered significant.

Results Truncating the spacer domain of the 2A2 ROR1-chimeric receptor confers or recognition of ROR1+ tumors We usly reported the design of a ROR1-specific ic receptor using the 2A2 scFV, which binds to an epitope in the NH2-terminal, ne distal Ig-like/Frizzled portion of ROR1-1. The initial 2A2 ROR1-chimeric receptor had a long 229 AA spacer that included the ‘Hinge-CH2-CH3’ region of IgG4-Fc, and incorporated CD28 costimulatory and CD3? signaling domains (Hudecek M et al. Blood, 2010). This chimeric receptor conferred specific recognition of ROR1+ tumors, but we hypothesized that because of the membrane distal location of the ROR1 epitope, truncating the spacer domain might enhance tumor recognition and T-cell signaling. Therefore, we constructed 2 additional chimeric receptors in which the IgG4-Fc spacer domain was sequentially deleted to derive ‘Hinge-CH3’ (119 AA, ediate), and ‘Hinge-only’ (12 AA, short) variants. Each of the new receptors contained the identical 2A2 scFV, and CD28 and CD3? signaling modules.

The transgene cassette included a truncated EGFR (tEGFR) to serve as a transduction, selection and in vivo tracking marker for chimeric receptor-modified T-cells.

We transduced purified CD8+ TCM with the 2A2 ROR1-chimeric ors containing full length or truncated IgG4-Fc spacers, and with a tEGFR control vector. The mean transduction efficiency was 15% (range 9-22%), and transgenepositive T-cells were enriched to m purity (>90%) on day 10 by selection for tEGFR expression, and expanded (Figure 2A). Surface expression of each of the chimeric receptors was confirmed by staining with F(ab)-specific antibodies (Figure 2A).

Analysis of the in vitro function of CD8+ T-cells modified to express each of the 2A2 ROR1-chimeric receptors demonstrated that each receptor conferred ic lysis of JeKo-1 MCL and primary CLL cells that naturally express ROR1, and of K562 cells that had been uced with ROR1, but did not confer recognition of control ROR1- targets e 2B). T-cells expressing the short ‘Hinge-only’ 2A2 ROR1-chimeric receptor had maximum cytolytic activity, and a hierarchy (short>intermediate>>long) of tumor lysis was clearly evident t all ROR1+ tumor targets (Figure 2B), illustrating the importance of spacer domain length on the recognition of ROR1+ tumor cells.

Anti-tumor efficacy of adoptive T-cell y correlates with proliferation and survival of erred T-cells, which could be altered by signaling through the chimeric receptor. We used CFSE dilution assays to analyze proliferation of T-cells modified with each of the 2A2 ROR1-chimeric receptors after engagement of Raji/ROR1 or CLL, and found that the short spacer construct promoted the greatest T-cell proliferation following stimulation (Figure 2C). To ensure that the enhanced proliferation was not associated with greater activation induced cell death (AICD), we also analyzed the tion of 2A2 ROR 1 chimeric receptor modified T-cells that d with propidium iodide (PI) after stimulation with Raji/ROR1 and JeKo- 1 tumor cells. We detected a much lower frequency of PI+ CD8+ T-cells in the T-cell line modified with the short (Raji/ROR1: 17.2%/JeKo-1: 20.2%) compared to the intermediate (41.6%/42.4%) and long (44.5%/48.5%) spacers.

Quantitative analysis of ne production in response to stimulation with Raji/ROR1 and primary CLL cells showed production of IFN-?, TNF-a and IL-2 by T-cells expressing each of the 2A2 ROR1 chimeric receptors. As ed in cytotoxicity assays, the short spacer construct was superior in mediating ne ion after tumor recognition (Figure 2D). Thus, this analysis shows that truncating the extracellular IgG4-Fc spacer domain of the 2A2 ROR1-chimeric receptor leads to a significant increase in cytotoxicity, proliferation and in vitro effector functions after tumor recognition.

The R11 scFv that is specific for a membrane proximal epitope in the ROR1 Kringle domain requires a long extracellular spacer domain.

We transduced purified CD8+ T cells with ROR1-chimeric receptors containing the R11 scFv that is specific for the Kringle domain of ROR1 and containing full length or truncated IgG4-Fc s (CH3 and hinge only). The transduction ency with each of the short (IgG4 hinge only), intermediate (IgG4 hinge/CH3), and long (IgG4 hinge/CH2/CH3) vectors was able %) as measured by EGFR expression. (Figure 3A). T cells transduced with each of the vectors were assayed for cytolysis (Figure 3 B), proliferation e 3C), and cytokine tion (Figure 3D) in response to leukemia or lymphoma cells that did or did not express ROR1. As shown, only T cells transduced with the R11 chimeric receptor containing a long spacer sequence were able to efficiently recognize ROR1+ tumors and mediate effector functions.

ROR1 chimeric receptors derived from a mAb R12 with higher affinity than 2A2 mediate superior anti-tumor reactivity We next examined whether increasing the affinity of the scFV used to construct the ROR1 chimeric receptor might influence tumor recognition and T-cell function. We generated ROR1-specific chimeric receptors from the mAb R12 that like 2A2, binds to an epitope in the NH2-terminal Ig/Frizzled domain of ROR1 but with ld higher monovalent binding affinity.

R12 ROR1 chimeric receptors were ucted with both long and short IgG4-Fc spacers to determine whether the optimal spacer design for this higher ty scFV differed from that for a lower affinity scFV. We found that similar to 2A2, the short spacer R12 ROR1 chimeric or red ed tic activity, cytokine secretion and proliferation (data not shown), suggesting that the shorter spacer length provides superior spatial engagement of the T-cell and ROR1+ target cell for T-cell activation.

We then designed R12 and 2A2 ROR1 chimeric receptors that contained an optimal (short) extracellular spacer, and either a CD28 or 4-1BB costimulatory domain in tandem with CD3? (4 constructs) for ison (Figure 4A.B). These ROR1-chimeric receptor ucts were expressed in purified CD8+ TCM of healthy donors, and we confirmed equivalent transgene expression by tEGFR staining (Figure 5A). T-cells modified with each of the 2A2 and R12 ROR1-chimeric receptors specifically lysed K562/ROR1 and Raji/ROR1 tumor cells with approximately equivalent efficiency (Figure 5B). r, analysis of cytokine production showed that the high affinity R12 ROR1 chimeric ors that contained CD28 or 4-1BB conferred significantly higher IFN-?, TNF-a and IL-2 production compared to the corresponding 2A2 constructs (Figure 5C). We found that T-cells expressing chimeric ors with a CD28 costimulatory domain produced more IFN-?, TNF-a and IL-2 compared to those with 4-1BB.

Experiments to analyze the proliferation of ROR1 chimeric receptor T-cells showed a higher percentage of proliferating T-cells and a higher number of cell divisions in T-cells expressing the high affinity R12 ROR1 chimeric receptors with CD28 and 4-1BB domain compared to T-cells expressing the respective 2A2 counterparts (Figure 4D). There was more vigorous proliferation in T-cells that expressed chimeric receptors with a CD28 domain, consistent with higher IL-2 production induced by these receptors. There was a lower frequency of AICD as ed by PI staining in T-cell lines modified with R12 compared to 2A2 ROR1- chimeric receptors after stimulation with Raji/ROR1 and JeKo-1 tumor cells respectively (R12: 5.6%/6.9% vs. 2A2: 65%). T-cell lines that expressed chimeric receptors with a CD28 domain also had lower AICD compared to 4-1BB in response to Raji/ROR1 and JeKo-1 tumor cells respectively (R12: 16.4%/18.4% vs. 2A2 38.1%/39.6%).

To determine if the enhanced function observed with R12 ROR1 chimeric receptors in CD8+ T-cells extended to CD4+ T-cells, we transduced bulk CD4+ T- cells with the 2A2 and R12 ROR1 chimeric ors containing the short spacer and CD28 costimulatory domain. In response to Raji/ROR1+ tumor cells, CD4+ T- cells that expressed the high affinity R12 scFV produced higher levels of IFN-?, TNF-a, IL-2, IL-4, and IL-10, and underwent greater proliferation than CD4+ s that expressed 2A2 (Figure 5A,B). Both cytokine production and proliferation was superior in CD4+ compared to CD8+ T-cells ed with the same ROR1 chimeric receptors. In summary, our data demonstrate that tailoring both the length of the non-signaling ellular chimeric receptor spacer domain and scFV ty are independent parameters that affect the on of ROR1-chimeric receptor T-cells.

D8+ T-cells modified with a high affinity ROR1 chimeric receptor have comparable activity to a CD19 chimeric receptor against primary CLL in vitro ROR1 and CD19 are both uniformly sed on all primary CLL (Figure 6A), however the absolute number of olecules per tumor cell is estimated to be 10-fold lower than that of CD19, which has been successfully targeted in clinical trials with CD19 chimeric or T-cells. We compared recognition of primary CLL by CD8+ T-cells expressing the optimized R12 and 2A2 ROR1 chimeric receptors, and a CD19 chimeric receptor derived from the FMC63 scFV.

We used purified CD8+ TCM for chimeric receptor-modification to provide a m cell product and each chimeric receptor contained a short c ‘Hingeonly ’ spacer and 4-1BB costimulatory domain. We confirmed our CD19 chimeric receptor (IgG4 Hinge) was at least as and more effective in recognizing CD19+ tumors as a CD19 ic receptor with CD8a Hinge spacer and 4-1BB costimulatory domain that is being used in ongoing clinical trials. (Figure 20). T cells expressing CD19 chimeric receptors with 4-1BB and a and a modified IgG4-Fc hinge exhibit superior in vitro and in vivo function compared to T cells expressing CD19 chimeric receptors with 4-1BB and CD3zeta and a CD8 alpha hinge. In Figure 20D, in vivo antitumor activity of T cells expressing a CD19 chimeric receptor with an IgG4 Fc hinge (group 1) or CD8 alpha hinge (group 2) and T cells that express tEGFR alone (group 3) in NSG mice inoculated with Raji tumor cells expressing firefly luciferase (ffluc) were compared. Mice were imaged 17 days after tumor inoculation and 10 days after T cell inoculation. The data shows greater tumor burden in mice treated with control tEGFR T cells (group 3) or with CD19 chimeric receptor CD8 alpha hinge T cells (group 2) compared with mice treated with CD19 chimeric or IgG4 Fc hinge T cells (group 1).

The cytolytic activity of R12 ROR1 chimeric receptor T-cells against y tumor cells from multiple CLL patients (n=4) was higher ed to T- cells modified with the lower affinity 2A2 ROR1 chimeric receptor, and equivalent to the lysis observed with CD19 chimeric receptor T-cells (Figure 6B). Multiplex cytokine analysis showed nearly equivalent production of IFN-? and TNF-a, but less IL-2 production by CD8+ T-cells expressing the R12 ROR1 compared with those expressing the CD19-chimeric receptor after co-culture with primary CLL (Figure 6C). 2A2 ROR1 chimeric receptor T-cells produced lower amounts of all cytokines than R12 ROR1 chimeric receptor s as noted previously. Cytokine production by all of the chimeric receptor-transduced s after stimulation with CLL was substantially less than with Raji/ROR1, which unlike CLL expresses both CD80 and CD86 that can engage CD28 expressed on ic receptor T-cells (Figure 6A, C).

We observed less proliferation of T-cells expressing the R12 and 2A2 ROR1 chimeric receptor ed to the CD19 ic or after stimulation with CLL R12>2A2) (Figure 6D). We hypothesized that proliferation of CD8+ ROR1 chimeric receptor T-cells in response to CLL may be augmented in the ce of chimeric receptor-modified CD4+ T-cells because of their higher secretion of IL-2 compared to CD8+ TCM (Figure 4A; Figure 8A). To test this possibility, we performed in vitro co-culture experiments where CD4+ and CD8 TCM were separately modified with the R12 ROR1, 2A2 ROR1 and CD19 chimeric receptors respectively, ed for chimeric receptor expression, and combined at a 1:1 ratio to ensure equivalent proportions of CD8+ and CD4+ T-cells modified with each of the vectors. These cells were CFSE-labeled and stimulated with y CLL. We observed a dramatic increase in proliferation of CD8+ R12 ROR1 chimeric receptor T-cells after addition of ic receptor-transduced, but not untransduced CD4+ T-cells (Figure 8B). Notably, when provided with CD4-help, we observed equivalent proliferation of R12 ROR1 and CD19 chimeric receptor CD8+ T-cells in response to CLL, whereas proliferation of CD8+ s expressing the lower affinity 2A2 ROR1 chimeric receptor ed less. Collectively, our data show that the high affinity R12 ROR1 chimeric or confers superior reactivity compared to 2A2 against primary CLL cells in vitro.

ROR1-chimeric receptor T-cells e in vivo anti-tumor activity in a mouse model of systemic mantle cell lymphoma It remained uncertain whether the superior in vitro ty of T-cells ed with the higher affinity R12 ic receptor would translate into improved anti-tumor activity in vivo, and how targeting ROR1 would compare to targeting CD19. To address these questions, we ated cohorts of immunodeficient NSG mice with the human MCL line JeKo-1/ffluc by tail vein injection, and seven days later when tumor was disseminated, treated the mice with a single intravenous dose of R12 ROR1, 2A2 ROR1 or CD19 chimeric receptor CD8+ T-cells. Control mice were treated with tEGFR T-cells or untreated. All chimeric receptors had the optimal short spacer and the 4-1BB ulatory domain.

Untreated NSG/JeKo-1 mice developed a rapidly progressive systemic lymphoma necessitating euthanasia approximately 4 weeks after tumor inoculation (Figure 9A- C).

We observed tumor regression and improved survival in all mice treated with R12 ROR1, 2A2 ROR1 and CD19 chimeric receptor T-cells. Mice treated with R12 ROR1 chimeric or T-cells had a superior anti-tumor response and al compared to mice treated with 2A2 ROR1 chimeric receptor T-cells (p<0.01), and comparable anti-tumor activity to mice treated with CD19 chimeric receptor T-cells (Figure 9A-C).

We analyzed the frequency of chimeric receptor T-cells in the peripheral blood ing adoptive transfer and detected higher numbers of tEGFR+ T-cells in mice treated with the R12 ROR1 ic receptor compared to the 2A2 ROR1 chimeric receptor, suggesting more vigorous proliferation in vivo improved tumor control. To confirm this, we administered CFSE-labeled CD19 ic receptor, R12 and 2A2 ROR1 chimeric receptor T-cells to cohorts of NSG mice bearing JeKo-1/ffluc, and analyzed T-cell proliferation in the peripheral blood, bone marrow and spleen 72 hours after er. A higher percentage of the R12 and CD19 chimeric receptor T-cells proliferated and ent a greater number of cell divisions compared to 2A2 ROR1 chimeric receptor T-cells (Figure 9D). The JeKo- 1 tumor eventually recurred in all mice treated with ROR1 or CD19 chimeric receptor s (Figure 9A-C). Tumor recurrence was not a result of the selection of ROR1 or CD19 loss variants, as recurrent tumors were positive for both molecules.

For comparison, we analyzed anti-tumor efficacy of CD19 chimeric receptor T-cells in NSG mice engrafted with Raji tumors and observed complete tumor eradication, indicating the recurrence of JeKo-1 reflects difficulty eradicating this tumor (data not shown). In summary, this data is the first to show that ROR1 chimeric receptor T-cells have anti-tumor efficacy in vivo, and t that for B- cell malignancies, an optimized ROR1 chimeric receptor such as R12 may be effective and spare normal CD19+ s that lack ROR1 expression.

T-cells expressing the R12 ROR1 chimeric receptor have superior reactivity compared to 2A2 against ROR1+ epithelial tumor cells ROR1 has been ed on many epithelial , although it is unknown whether ROR1 expression is sufficient for recognition by ROR1 ic receptor T-cells. Using flow cytometry, we confirmed ROR1 expression on breast cancer lines MDA-MB-231 and 468, and on the renal cell carcinoma lines FARP, TREP, and RWL (Figure 10A). We then analyzed tumor recognition by CD8+ T-cells transduced with the R12 ROR1 chimeric receptors with the optimal short spacer and 4-1BB domain, and observed efficient recognition of MDA-MB-231, MDA-MB- 468, FARP, TREP and RWL (Figure 11A). We ed cytokine secretion and eration of s modified with the R12 and 2A2 ROR1-chimeric receptors after co-culture with MDA-MB-231, and observed greater cytokine production and proliferation with the R12 ROR1 chimeric receptor (Figure 11 B, C). r to what we observed with ROR1+ B cell malignancies, the superior tion of R12 ROR1 chimeric receptor T cells after stimulation with MDA-MB-231 was not associated with increased AICD (R12: 9.8% vs. 2A2: .

Discussion ROR1 has attracted interest as a potential target for cancer immunotherapy due to its expression on the surface of many B-lymphoid and epithelial cancers, including subsets of lung, colorectal and renal cell cancer. We previously showed that CLL and MCL were specifically recognized by T-cells modified to express a ROR1-specific chimeric receptor (Hudecek M, et al. Blood. 2010;116(22):4532-41.

Epub 2010/08/13). The design and function of ROR1-chimeric receptors has been improved through modification of the extracellular spacer domain and deriving the chimeric receptor from a scFV of higher affinity, and demonstrate that T-cells ed with designed ROR1 chimeric receptors have in vivo activity t ROR1+ B-cell lymphoma and in vitro activity against a wide range of epithelial tumors.

We ed the function of T-cells modified with ROR1 chimeric receptors d from the 2A2 mAb that contained either the original long IgG4-Fc ‘Hinge-CH2-CH3’ spacer that we have shown enables high level cell surface expression, or truncated intermediate ‘Hinge-CH3’ and short -only’ spacer variants. We preserved the 12 AA Hinge domain in our short spacer construct based on prior data that a flexible spacer was required for separating the scFV from the T- cell membrane and allowing antigen recognition on tumor cells ( Fitzer-Attas CJ, et al.,Harnessing Syk family tyrosine kinases as signaling domains for ic single chain of the variable domain receptors: optimal design for T cell activation. J l. 1998;160(1):145-54. Epub 1998/04/29.) Our studies with the 2A2 ROR1 chimeric receptor show that T-cell cytokine secretion and proliferation after tumor cell recognition are superior with the intermediate and short spacer ucts compared to the long spacer construct.

Staining with anti-F(ab) Abs showed equivalent chimeric receptor expression of all three receptors, demonstrating the improved T-cell function with the short spacer chimeric receptor was not due to ences in chimeric receptor density. This data supports the principle that the design of extracellular s should be tailored for each target molecule and epitope.

The affinity of the scFV selected for designing a chimeric receptor is an additional ter that could affect T-cell recognition. We generated and characterized a panel of ROR1-specific mAbs of different ties and selected the R12 mAb, which recognizes an epitope in the Ig-like/Frizzled region as 2A2. R12 has a higher affinity for ROR1-protein due to a much slower dissociation. The R12 chimeric or, like the 2A2 chimeric receptor conferred optimal T-cell recognition and function when designed with a short ellular spacer. A direct comparison of proliferation and cytokine production after tumor engagement by T- cells modified with the 2A2 and R12 chimeric ors demonstrated that the R12 chimeric receptor derived from the higher affinity mAb was superior. We were ned that the slower dissociation of R12 from ROR1 could g T-cell activation and confer an increased susceptibility to AICD. However, we detected a lower rate of AICD in T-cells modified with the R12 ROR1-chimeric receptor compared to 2A2, demonstrating that the increased affinity of R12 had no detrimental effect on T-cell al in our preclinical models.

ROR1 has a potential advantage over CD19 as a target for CLL and MCL since it is not expressed on normal mature naïve and memory B-cells. r, there is a lower number of ROR1 molecules on B-cell tumors compared with CD19 and it is uncertain if an optimized ROR1 chimeric receptor would be as effective as a CD19 chimeric receptor similar in design to those being used in the clinic.

Unfortunately, B-cell tumor xenograft models used previously in NSG mice to evaluate the function of CD19 ic receptor T-cells including Raji, Daudi and Nalm-6, are not d from CLL or MCL and do not constitutively express ROR1.

Thus, to compare targeting CD19 and ROR1 in vivo, we used the JeKo-1 MCL cell line, which naturally expresses both CD19 and ROR1 and engrafts in NSG mice. To make our model clinically nt, we inoculated JeKo-1 lymphoma cells intravenously to generate systemic tumors, and treated mice with T-cell products of uniform consistency once tumors were established. We found that T-cells expressing the high affinity R12 chimeric receptor conferred equivalent anti-tumor activity in vivo as CD19 chimeric receptor T-cells. tent with our in vitro analysis, the R12 ROR1 chimeric receptor also mediated superior ty in vivo compared to the optimal 2A2 ROR1-chimeric receptor. These results should be interpreted cautiously since murine tumor models may not predict the efficacy of adoptive therapy in clinical settings. r, the results suggest that ROR1 warrants eration as an alternative to CD19, or to provide an additional target to minimize the potential for CD19 loss variants to emerge.

ROR1 appears to play a decisive role in survival of some epithelial tumors.

Thus, an advantage of targeting ROR1 is that a single chimeric receptor may be useful to treat patients with a large number of hematopoietic and matopoietic tumors.

Our data shows for the first time that T-cells that express a designed ROR1 chimeric receptor efficiently recognize epithelial cancers in vitro. Cytokine secretion and T-cell proliferation induced by ROR1+ breast cancer cells were higher than that induced by ia cells, despite the absence of the CD80/86 ulatory ligand.

The studies ed here demonstrate that the design of the extracellular spacer domain and chimeric receptor affinity are parameters that can be modulated to enhance the recognition of ROR1+ hematologic and epithelial tumors in vitro and in vivo by ROR1-chimeric receptor modified T-cells. The development of ROR1- chimeric ors with ed tumor reactivity provides the opportunity for clinical applications in a variety of human cancers.

Example 2 Effect of extracellular spacer domain length on triggering of tumor cell lysis with a Her2-specific chimeric receptor that recognizes an epitope located proximal to the tumor cell membrane.

The effect of CAR spacer length on recognition and ring of tumor cell recognition by CD8+ human T lymphocytes that expressed a HER2-specific chimeric receptor was examined using similar methods to those described above for ROR1. HER2-specific chimeric receptors were constructed using VL and VH chain segments of a HER2-specific mAb that recognized a membrane proximal epitope on HER2 (Figure 12A), and the scFVs were linked to IgG4 hinge/CH2/CH3, IgG4 hinge/CH3, and IgG4 hinge only extracellular spacer domains and to the CD28 transmembrane domain, 4-1BB and CD3 zeta signaling domains (Figure 12B).

Primary CD8+ T cells were uced with each of the HER2 chimeric receptors and ed for expression of the EGFR transducton marker (Figure 12D).

Expression of the HER2 chimeric receptors and the size of each receptor was confirmed by Western Blot (Figure 12C). The T cells were then expanded with anti CD3 mAb and feeder cells and examined for their ability to recognize HER2+ tumor cells. As observed with the R11 ROR 1 ic ic receptor, the HER2 chimeric receptor that contained a long ellular spacer domain conferred or T cell recognition of HER2+ tumor cells (Figure 12E).

Discussion This example of the effect of ellular spacer length on chimeric receptor modified T cell recognition of tumor cells used a chimeric receptor comprising a scFv built from the VH+L sequences of the Herceptin chimeric mAb. Studies by Cho et al (Nature 421:756, 2003) localized to epitope location of Herceptin to a ne proximal location on the HER2 (ERRB2) extracellular domain (Figure 12A). Based on our understanding of the structure of human IgG4 hinge:Fc variants (Figure 12B), we hypothesize that a membrane proximal location of the targeting epitope on an extracellular tumor cell antigen would best ized by effector T cells that express a chimeric receptor encoding a long spacer. Our data trating a nt of cytolytic activity from near back ground ty by T cells expressing a short spacer Herceptin chimeric or, to intermediate activity by T cells expressing a medium length spacer chimeric receptor, and maximal lysis by T cells that expressed the long spacer chimeric receptor. Thus, the extracellular spacer has definitive effects on tumor recognition by T cells, and this data provides further support for the need to tailor chimeric receptor design based on epitope location of tumor expressed target les.

Example 3 – Customizing spacer length and sequence for optimal recognition and in vivo efficacy of CD19 with chimeric receptor modified T cells.

Materials and Methods Human subjects Blood samples were obtained from healthy donors who provided written informed consent to participate in research ols ed by the Institutional Review Board of the Fred nson Cancer Research Center (FHCRC). Peripheral blood mononuclear cells (PBMC) were isolated by centrifugation over Ficoll- Hypaque (Sigma, is, MO), and cryopreserved in RPMI, 20% human serum and 10% dimethyl sulfoxide.

Cell lines The K562, Raji, JeKo-1, and 293T cell lines were obtained from the American Type Culture Collection (Manassas, VA) and cultured as directed. A lentivirus encoding the ffluc-gene upstream of a T2A sequence and eGFP was produced in 293T cells and used to transduce Raji and JeKo-1 tumor cells. Raji, and JeKo-1 cells were expanded after iral transduction and the eGFP positive subset sort-purified.

Immunophenotyping PBMC and T-cell lines were stained with one or more of the following conjugated monoclonal antibodies: CD3, CD4, CD8, CD25, CD45RA, CD45RO, CD62L, CD69 and matched isotype controls (BD Biosciences). Staining with propidium iodide (PI, BD Biosciences) was performed for live/dead cell discrimination as directed by the manufacturer. Flow es were done on a FACSCanto, sort-purifications on a FACSAriaII (Becton Dickinson) and data ed using FlowJo software (Treestar).

Vector construction and preparation of CD19 chimeric receptor encoding irus CD19 specific chimeric receptors were constructed using: (1) the VL and VH chain segments of the CD19-specific mAb FMC63 (SEQ ID NO:3), linked by a (G4S)3 linker (SEQ ID NO:12)peptide (VL-linker-VH); (2) a spacer domain d from IgG4-Fc (Uniprot Database: P01861, (SEQ ID NO:13)) comprising either the Hinge-CH2- CH3 portion (229 AA, (SEQ ID NO:)) or Hinge only (12 AA; (SEQ ID . Both spacers contained a S ? P substitution within the Hinge domain located at position 108 of the native IgG4-Fc protein; the 27 AA transmembrane domain of human CD28 (Uniprot Database: P10747, (SEQ ID NO:14)); (4) a ing module comprising either (i) the 41 AA cytoplasmic domain of human CD28 with an LL ? GG tution located at position 186-187 of the native CD28 protein (SEQ ID NO:14) ; and/or (ii) the 42 AA cytoplasmic domain of human 4- 1BB (Uniprot Database: Q07011, (SEQ ID NO:15)); linked to (iii) the 112 AA cytoplasmic domain of isoform 3 of human CD3? (Uniprot Database: P20963, (SEQ ID NO:16)); the self cleaving T2A sequence (SEQ ID NO:8); and (6) a truncated epidermal growth factor receptor (EGFR)sequence (SEQ ID NO:9).

Codon-optimized nucleotide sequences encoding each trans gene were sized (LifeTechnologies, Carlsbad, CA) and cloned into the epHIV7 lentiviral vector using NheI and Not1 restriction sites. The epHIV7 lentiviral vector had been derived from the pHIV7 vector by replacing the cytomegalovirus er of pHIV7 with an EF-1 promoter.

CD19 chimeric receptor or tEGFR-encoding lentivirus was produced in 293T cells nsfected with the lentiviral vector and the packaging vectors pCHGP-2, pCMV-Rev2 and pCMV-G using s ection reagent (Clontech). Medium was changed 16 h after transfection, and lentivirus collected after 24, 48 and 72 h.

Generation of T -cell lines expressing the CD19 chimeric ors Sort-purified CD8+ CD45RA- CD45RO+ CD62L + central memory T -cells (TCM) of normal donors were activated with anti-CD3/ CD28 beads (Life Technologies) according to the manufacturer's instructions, and transduced with lentiviral supernatant (MOI = 3) mented with 1 µg/mL polybrene (Millipore) on day 3 after activation by centrifugation at 2,100 rpm for 45 min at 32°C. T cells were expanded in RPMI, 10% human serum, 2 mM L-glutamine and 1 % penicillinstreptomycin (CTL medium), supplemented with recombinant human (rh) lL-2 to a final concentration of 50 U/mL every 48 h. After expansion, an aliquot of each transduced T cell line was stained with biotin-conjugated anti-EGFR (epithelial growth factor receptor) antibody and streptavidin-beads (Miltenyi), and tEGFR+ T cells isolated by immunomagnetic selection.

The tEGFR+ T-cell subset was then stimulated with irradiated (8,000 rad) TM EBV-LCL at a T cell: LCL ratio of 1 :7, and expanded for 8 days in CTL medium with on of 50 U/mL rh IL-2 every 48 h.

Chromium e, cytokine secretion and CFSE proliferation assays Target cells were labeled with 51Cr (PerkinElmer) overnight, washed and incubated in triplicate at 1-2x l03 cells/well with or T cells at s effector to target (E:T) ratios. Supernatants were harvested for ? counting after a 4-hour incubation and specific lysis ated using the standard a. For analyses of cytokine secretion, target and effector cells were plated in triplicate wells at an E:T ratio of 2: 1 (Raji) or 4: 1 (K562/CDI9 and K562), and INF-?, TNF-a, IL-2, IL-4, IL-6 and IL-10 measured by multiplex cytokine immunoassay (Luminex) in supernatant d after a 24-hour incubation.

For is of proliferation, T cells were labeled with 0.2 µM carboxyfluorescein succinimidyl ester (CFSE, Invitrogen), washed and plated in triplicate wells with stimulator cells at a ratio of 2: 1 (Raji) or 4: 1 (K562/CD19 and K562) in CTL medium without exogenous cytokines. After 72 h of incubation, cells were labeled with anti-CD3 mAb and propidium iodide (PI) to exclude dead cells from analysis. Samples were analyzed by flow cytometry and cell division of live CD3+ T-cells assessed by CFSE dilution.

Experiments in NOD/SCID and NOD/SCID/?c-/- (NSG) mice All mouse ments were approved by the FRCRC Institutional Animal Chimeric receptore and Use tee. Six- to 8-week old female NOD.CBI7- Prkdcscid /J (NOD/SCID) and NOD.Cg-Prkdcscid Il2rgtmlWjl/SzJ (NSG) mice were obtained from the Jackson Laboratory or bred in-house (FRCRC. Mice were injected enously (i. v.) with 0.5 x l06 Raji-ffluc tumor cells via tail vein injection, and received injections of chimeric receptor-modified T cells, control T cells, or PBS via tail vein injection as indicated.

For bioluminescence g, mice received eritoneal (i.p.) injections of freshly prepared luciferin substrate (Caliper Life Sciences, MA) resuspended in PBS (15 µg/g body weight) and were then anesthetized with isoflurane in an induction chamber. After induction of deep anesthesia, mice were imaged using an Xenogen IVIS In Vivo Imaging System (Caliper Life Sciences, MA) at 10, 12 and 14 minutes post i.p. injection of luciferin at an acquisition time of 1 second to 1 minute in small binning mode to obtain unsaturated images. Luciferase activity was analyzed using Living Image Software (Caliper Life Sciences, MA) and the photon flux analyzed within s of interest that encompassed the entire body of each individual mouse. tical es Statistical analyses were performed using Prism Software (GraphPad, CA).

Student's t-test was performed as a two-sided test with a ence al of 95% and results considered significant with a p-value of p<0.05. tical is of survival were done by Log-rank testing and results considered significant with a pvalue of p<0.05.

Results Preparation of polyclonal CD8+ TCM-derived cell lines that express CD19 chimeric receptors with long and short extracellular spacers We constructed individual lentiviral vectors encoding a panel of codon- optimized CD 19 chimeric receptor genes to examine the influence of extracellular spacer length on the in vitro function and in vivo antitumor activity of CD19 chimeric receptor-modified T cells. Each chimeric receptor was comprised of a single chain variable fragment corresponding to the sequence of the CDl9-specific mAb FMC63 (scFv: VL-VH), a spacer d from IgG4-Fc including either the 'Hinge-CH2-CH3' domain (229 AA, long spacer) or the 'Hinge' domain only (12 AA, short spacer), and a signaling module of CD3? with membrane proximal CD28 or 4-1 BB costimulatory domains, either alone or in tandem (Figure 13A). The transgene cassette included a truncated EGFR (tEGFR) downstream from the chimeric receptor gene and separated by a cleavable T2A element, to serve as a transduction, selection and in vivo tracking marker for chimeric receptor-modified T cells.

We isolated a CD8+ CD45RO+ CD62L+ central memory T cell (TCM) cell population by cell sorting from the blood of normal donors for transduction and expansion, because of the or ability of TCM to persist in vivo after adoptive transfer. CD8+ T cells were stimulated with anti CD3/28 beads, transduced with each of the lentiviral vectors, and expanded in culture for 18 days before being used for in vitro and in vivo experiments. (Figure 13B) Similar transduction efficiencies were achieved with each of the lentiviral vectors (mean 25%) and transgene-positive T cells were enriched to uniform purity by immunomagnetic selection using a biotinylated anti-EGFR mAb and streptavidin beads. Following enrichment, each of the CD19 chimeric receptor T cell lines were expanded by a single stimulation with CD19+B-LCL, without apparent differences in in vitro growth cs between T cell lines expressing the various CD 19 chimeric receptor constructs. After expansion, the tEGFR marker was expressed at equivalent levels on >90% of the T cells uced with each of the vectors (Figure 13C).

CD19 chimeric ors with long and short extracellular spacer domain confer specific anti-tumor reactivity in vitro We compared the effector function of TCM-derived T cell lines modified to express CD19 chimeric ors with CD28 and 4-1BB ulatory signaling moieties, and either a short t/CD28';'short/4-1BB') or long ('long/CD28'; 'long/4-1BB') extracellular spacer domain tively. T cells expressing each of the 4 CD19 chimeric receptor constructs conferred specific cytolytic activity against CD19+ Raji and JeKo-l lymphoma cells, and against K562 cells that had been stably transfected with CD19, but not native CD19- K562 cells (Figure 14A). Quantitative analyses of ne tion in se to stimulation with K562/CD19 or Raji tumor cells by multiplex cytokine assay (Luminex) showed production of IFN-?, TNF-a, IL-2, IL-4, IL-6, and IL-10 by T cells expressing each of the CD19 chimeric receptors e 14B). T cells expressing CD19 chimeric receptors with a CD28 costimulatory domain produced significantly higher levels of IFN-?, TNF-a, IL-2 and IL-10 compared to the corresponding constructs with a 4-1BB costimulatory domain (Figure 14B, C). There was significantly higher IFN-y production and significantly less IL-4 production by T cells expressing the CD19 'long/CD28' chimeric receptor compared with those expressing the /CD28' chimeric receptor. Amongst the CD19 ic receptors with 4-1BB costimulatory ing module, we detected significantly higher levels of IFN-?, TNF -a, IL-2, IL-4, and IL-10 secretion in T cells expressing the construct with the short spacer domain (Figure 14B, C).

We used CFSE dye on to analyze proliferation of T cells modified with each of the CD 19 chimeric receptors after ment of CD 19+ tumor cells.

Specific and vigorous proliferation of each of the CD19 chimeric receptor T cell lines was observed 72 hours following stimulation with either K562/CD19 or Raji.

The average number of cell divisions was higher for CD19 chimeric receptor T cells with a CD28 costimulatory domain compared to those with 4-1BB, consistent with greater IL-2 production by T cells expressing a CD28 containing chimeric receptor (Figure 14B-D). We also analyzed the proportion of chimeric receptor T cells that underwent activation induced cell death after stimulation with D19 and Raji tumor cells at the end of the 72-hours by costaining the culture with CD3+ and PI.

We detected a higher frequency of CD3+ CD8+ PI+ T cells in the CD 19 chimeric receptor cell line 'long/4-1 BB', but few PI+ cells were observed with the other CD19 ic receptors. (Figure 14E).

This analysis of in vitro or functions was consistent with prior studies that have compared CD28 and 4-1BB costimulatory domains, and did not reveal differences in T cell function that would suggest that a particular CD19 chimeric receptor construct from this panel would lack anti-tumor efficacy in vivo.

T cells expressing CDI9 ic receptors with short extracellular spacer domains but not long extracellular spacer domains eradicate Raji tumors in immunodeficient mouse models We next ted the in vivo antitumor efficacy of T cells ed with each of the CD19 chimeric receptors in deficient (NOD/SCID) mice engrafted with firefly luciferase transfected Raji cells (Raji-ffluc), which enables sequential quantitative analyses of tumor burden and distribution using bioluminescence imaging. NOD/SCID mice inoculated with 0.5x106 Raji-ffluc cells via tail vein injection developed disseminated lymphoma, which if untreated led to hind limb paralysis after imately 3.5 weeks, necessitating euthanasia. Tumor bearing mice were treated with 2 doses of CD8+ TCM-derived T cells modified with each of the CD19 chimeric receptors or with a tEGFR control vector administered on day 2 and day 9 after tumor inoculation (Figure 15A).

Surprisingly, only T cells ed to express CD19 chimeric receptors with short extracellular spacer domain ('short/CD28' and 'short/4-1BB') eradicated Raji tumors in this model, whereas mice treated with T cells expressing CD19 chimeric ors with long spacer ('long/CD28' and 'long/4-1BB') developed systemic lymphoma and hind limb paralysis with nearly identical kinetics as untreated mice or mice treated with control tEGFR+ T cells (Figure 15B, C). The striking ence in antitumor activity between CD19 chimeric receptors with short and long spacer domains was highly significant and reproducible in multiple experiments with chimeric receptor T cell lines generated from 3 different normal donors.

The NOD/SCID lymphoma model may be suboptimal for predicting antitumor activity in a clinical setting because of the short al between tumor inoculation and T cell administration and the r ance to engraftment of human cells ed to more immunodeficient mouse s such as NOD/SCID/?c-/- (NSG). Thus, we evaluated antitumor ty of adoptive therapy in a more clinically relevant model in which Raji-ffluc lymphoma was established in NSG mice, and the CD19 chimeric receptor T cells were administered after 7 days when the tumor was readily detectable in the bone marrow by bioluminescence imaging (Figure 16A). We performed initial dose titration experiments to determine the minimal dose of T cells transduced with the CD19 'short/4-1BB' chimeric receptor that was required for eradication of established Raji tumors. A single dose of 2.5x106 T cells expressing CD19-chimeric receptor 'short/4-1BB' promoted complete regression of established Raji tumors and resulted in long-term tumor-free survival in 100% of mice (Figure 16B,C). At the 2.5x106 dose level, the T-cells were easily detected in the peripheral blood of NSG mice for at least 3 weeks ing adoptive transfer and tumor eradication. Thus, this model enabled comparative s both of antitumor ty and persistence of T cells modified with each of the himeric receptors in our panel (Figure 16D).

We then treated s of NSG mice that were engrafted with Raji lymphoma with PBS alone, with a single dose of 2.5x106 T cells expressing each of the CD19 ic receptors or with T cells modified with a tEGFR encoding control vector (Figure 17A). In this model of established lymphoma, T cells expressing CD19 chimeric receptors with a short extracellular spacer domain and either 4- 1BB or CD28 costimulatory s t/CD28' and /4-1BB') mediated complete tumor regression over 7-10 days and all mice survived tumor free for >56 days. By contrast, mice treated with T cells modified to express CD19 chimeric receptors with a long spacer domain ('long/CD28' and 'long/4-1BB') exhibited tumor progression and had to be sacrificed at a similar time as mice that had received control tEGFR T cells (Figure 17B, C). The lack of in vivo antitumor activity of the chimeric receptor constructs with long spacers was unexpected given the ability of T cells expressing these constructs to lyse tumor cells in vitro, and the enhanced IL-2 production and proliferation after engagement of T cells expressing the 'long/CD28' CD19 chimeric receptor compared to the 4-1BB constructs.

To provide insight into the basis for the lack of efficacy, we performed tial flow cytometry on peripheral blood samples of mice at intervals after the T cell infusion. All mice treated with T cells expressing the 'short/CD28' and 'short/4-1BB' CD19 chimeric receptors had icantly higher levels of erred T cells in the blood at all time points after adoptive transfer, compared to mice treated with T cells that expressed corresponding CD19 chimeric receptors with long extracellular spacer (p<0.01) (Figure 17D). We did not observe significant differences in T-cell persistence in the eral blood of mice that had received T cells expressing CD19 chimeric receptors with CD28 or 4-1BB co-stimulatory s and short spacer domains (Figure 17D).

The in vivo anti-tumor efficacy of CD19 chimeric receptors with long spacers is not improved by increasing T cell dose or providing an additional costimulatory domain The lack of in vivo anti-tumor efficacy and the lower level of persisting chimeric or T cells in mice treated with T cells modified with CD19 chimeric receptors with long spacer domains suggested that efficacy might be improved by increasing the chimeric receptor T cell dose or by including both CD28 and 4- IBB domains into the chimeric receptor to augment ulatory signaling. To evaluate this possibility we modified CD8+ TCM with 'long/CD28', 'short CD28', and 'long/CD28_ 4-1BB' CD19 chimeric receptor vectors and confirmed that the long/CD28_ 4-1BB' CD19 chimeric receptor conferred specific lysis and cytokine production in vitro after recognition of CD19+ target cells (Figure 18A-C).

Consistent with previous studies of CD19 chimeric receptors, the level of cytokine production and proliferation in vitro in T cells expressing the CD28_ 4-IBB' CDI9 chimeric receptor was or ed to the identical construct with CD28 alone, and superior to T cells expressing the 'long 4-IBB' CD19 chimeric receptor (Figure 18B, C).

Groups of NSG mice with established Raji tumors were then treated with a high dose of T cells (10 x106 ) T cells expressing the 'long/CD28' CD19 chimeric receptor, the 'long/CD28_ 4-IBB' CDI9 chimeric receptor, the 'short/CD28' CD19- chimeric receptor, and tEGFR alone. Tumor burden was measured by bioluminescence imaging and serial flow cytometric analyses of peripheral blood samples performed to determine the frequency of transferred T cells. Consistent with the results of our prior experiments using much lower doses of T cells, Raji tumors were tely eradicated in mice treated with T cells expressing the 'short/CD28' CD19-chimeric receptor. However, even with a 4-fold higher T cell dose, treatment with T cells expressing the CD28' CD19 chimeric receptor or the 'long/CD28_ 4-1BB' CD19 chimeric receptor did not e a discernible antitumor effect (Figure 18D,E).

Thus, increasing the chimeric receptor T cell dose and adding a 4-1BB costimulatory domain to CD19 chimeric receptors failed to me the ve impact of the longer spacer domain on antitumor activity in vivo. Thus, in this model, anti-tumor reactivity of CD19 chimeric receptors is dictated to a great extent by the length of the extracellular spacer , and not by the intracellular costimulatory signaling modules.

T cells modified with CD19 chimeric ors that possess long extracellular spacers undergo activation induced cell death in vivo We sought to determine ial mechanisms underlying the inferior in vivo antitumor activity of T cells that s CD19 chimeric ors with long spacer domains. Because lower numbers of transferred T cells modified to express CD19 chimeric receptors with long spacer domains were present in the blood, we considered the possibility that the T cells were not efficiently activated by tumor cells in vivo or conversely, that they underwent activation induced T cell death in vivo. Therefore, we labeled CD19 chimeric receptor modified and ponding control T cells with CFSE and administered these T cells to tumor bearing ji mice to examine activation, eration and survival of T cells modified with each of the CD19 chimeric receptor constructs at tumor sites in vivo (Figure 19A). At the end of their in vitro expansion and immediately prior to CFSE labeling and infusion into NSG mice bearing ished Raji tumors, T cells transduced with each of the CD19 chimeric receptors sed low levels of the tion markers CD69 and CD25 (Figure 19B).

Bone marrow was obtained from subgroups of mice 24 and 72 hours after the T cell infusion to examine the frequency, activation and proliferation of transferred T cells. At 24 hours, tumor cells (CD45+ CD3-) were present in the bone marrow in all treatment groups and a large fraction of chimeric receptor T cells, but not control T cells, had upregulated CD69 and CD25. There was no measurable dilution of CFSE in the transferred chimeric receptor T cells. (Figure 19C) Both CD69 and CD25 were expressed in a higher proportion of T cells modified with 'long spacer' CD19 chimeric receptors, suggesting these cells may have received a stronger stimulus compared to T cells with 'short spacer' CD19 chimeric receptors (Figure __C). Despite evidence of T cell activation at 24 hours there were icantly lower numbers of chimeric receptor T cells in the bone marrow of mice treated with T cells modified with the CD28 and 4-IBB 'long spacer' constructs ed to those modified with the CD28 and 4-IBB 'short spacer' constructs, or with the control tEGFR vector (Figure 19C, E).

At 72 hours after T cell transfer, T cells expressing the 'short/CD28' and 'short/4-lBB' CD19 chimeric ors had increased 3 to > 10 fold in frequency in the bone marrow and spleen, and had undergone l cell ons (Figure 19D,E). Control tEGFR+ T cells remained t in the bone marrow and spleen at 72 hours at a level similar to that observed at 24 hours, and had not divided as measured by CFSE dilution. By contrast, the numbers of T cells expressing the 'long/CD28' and 'long/4-IBB' CD19 chimeric receptors had not increased in the bone marrow and spleen. (Figure 19D, E) tent with lower cell numbers, analysis of CFSE staining in viable PI- 'long/CD28' and 'long/4-IBB' CDl9 chimeric receptor T cells demonstrated these cells had undergone a much lower number of cell ons compared with 'short/CD28' and 'short/4-IBB' CDl9 chimeric receptor T cells.

(Figure 19D)When the flow data was analyzed to include PI+ T cells, we detected a much higher frequency of PI+ CD3+ T cells in bone marrow and spleen of mice that received CD19 chimeric receptor T cells with 'long ' domains, demonstrating that a significant tion of T cells, despite being activated by tumor in vivo had undergone cell death e 19F). Consistent with the bioluminescence imaging, CD45+ CD3- Raji tumor cells were present in greater numbers in the bone marrow of mice treated with T cells expressing CD19 chimeric receptors with long spacer domains or expressing tEGFR only compared to mice d with CD19 chimeric ors with short spacer domains (Figure 19D,E, G).

Collectively, the data provides evidence that CD19 chimeric receptors with long extracellular spacer domain, despite mediating equivalent or superior effector function in vitro and izing tumor in vivo, induce a high level of activation induced cell death in vivo and fail to ate established lymphoma. sion Chimeric receptors are artificial ors that include an extracellular antigen-binding scFv, a spacer domain that provides separation of the scFv from the cell membrane and an intracellular signaling module that mediates T cell activation.

Chimeric receptors that contain a scFv derived from the CD19-specific FMC63 mAb studied here, have advanced to testing in clinical trials in patients with B-cell malignancies. Antitumor activity and T cell persistence have varied substantially in different trials. Each of these clinical trials differed in potentially critical variables, ing different gene transfer vectors, cell culture methodologies, and conditioning regimens prior to CD19 chimeric receptor T cell transfer.

We examined the possibility that the ellular spacer domain of CD19 chimeric receptors may be an important determinant of anti-tumor activity in vivo, independent of the costimulatory signaling provided by the chimeric receptor. We derived spacer domains from IgG4-Fc, which enables high levels of ic receptor cell surface expression and is less likely to provoke ition by innate immune cells compared to other IgG isotypes. We used the IgG4 ‘Hinge-CH2-CH3’ in the design of the long (229 AA) spacer constructs and the IgG4 ‘Hinge’ domain in our short (12 AA) spacer chimeric receptors. To compare the individual chimeric receptor constructs, we used purified (>90%) chimeric receptor ve CD8+ TCM– d T cells to remove differences in the cellular composition and transduction frequency as a potential source of bias in the analysis of in vitro and in vivo function. CD8+ TCM have been shown to have superior traits for adoptive immunotherapy, compared with other more prevalent T cell subsets in blood that persist poorly and are ineffective in tumor therapy. The CD19 chimeric receptor T cells were generated using a standardized culture protocol that is similar to that used to derive chimeric receptor T cells for clinical . Our data show that CD19 chimeric receptors with a short IgG4 ‘Hinge’ spacer conferred potent anti-tumor reactivity in vitro and in vivo, whereas corresponding CD19 chimeric receptors with a long spacer of IgG4 ‘Hinge-CH2-CH3’, e equivalent or or reactivity in vitro, failed to confer significant anti-tumor effects in murine lymphoma models.

Surprisingly, the length of the spacer domain proved to be a decisive element for in vivo antitumor activity, and the lack of efficacy of the ‘long spacer’ chimeric receptor could not be overcome by sing the T cell dose.

We also observed major differences in cytokine secretion and proliferation in vitro between T cells expressing CD19 chimeric receptors ning CD28 and 4- 1BB costimulatory domains, with CD28 ting secretion of IFN-?, IL-2, and TNF-a compared with 4-1BB. CD19 chimeric receptors that possessed a tandem CD28_4-1BB also ed higher levels of these cytokines compared to chimeric ors encoding 4-1BB only. However, our data shows that these differences in in vitro function were not predictive of in vivo anti-tumor efficacy, since CD19 chimeric receptors with either CD28 or 4-1BB costimulatory domain and a short spacer were similarly effective at eradicating advanced established Raji tumors in NSG mice. In contrast, CD19 chimeric receptors with suboptimal spacer length and CD28, 4-1BB, or both costimulatory domains, despite conferring similar in vitro function as the cal chimeric receptor construct with a short spacer domain, lacked significant anti-tumor activity in vivo, demonstrating the contribution of spacer length to in vivo function of ic receptor T cells.

Our studies provide insight into the ism sible for the lack of in vivo efficacy of CD19 chimeric receptors with long spacer domains. T cells expressing CD19 chimeric receptors with both long and short spacer domains could be detected in the bone marrow and spleen after adoptive transfer into NSG mice bearing established Raji lymphoma, and the majority were activated as demonstrated by upregulation of CD25 and CD69. However, T cells modified to express a CD19 chimeric receptor with a long spacer domain ted a steep decline in cell , in contrast to the marked in vivo expansion of T cells expressing CD19 chimeric receptors with a short spacer domain. The decline in T cell number was a consequence of much higher levels of cell death in the first 72 hours after adoptive transfer compared with T cells with short spacer domains, and control T cells that did not express a CD19 chimeric receptor. Collectively, these data indicate that recognition of tumor cells in vivo resulted in death of T cells expressing CD19- chimeric receptors with long spacer domains. A similar mechanism may explain the short duration and low levels of T cell persistence in the clinical trials that employed long spacer CD19-chimeric receptors (14).

The studies reported here are the first to show that the spacer domains of CD19 chimeric receptors that lack intrinsic signaling properties have dramatic effects on in vivo antitumor ty independent of costimulatory signaling, and identify the importance of analyzing the optimal composition of this region in the design of chimeric ors for clinical applications.

The term ising" as used in this specification and claims means "consisting at least in part of". When interpreting statements in this specification, and claims which include the term "comprising", it is to be understood that other features that are onal to the features prefaced by this term in each statement or claim may also be present. d terms such as "comprise" and "comprised" are to be interpreted in similar .

In this specification where reference has been made to patent specifications, other external documents, or other s of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless specifically stated ise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any iction, are prior art, or form part of the common general knowledge in the art.

In the description in this specification reference may be made to subject matter that is not within the scope of the claims of the current application. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the claims of this application.

The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be ed n. All references and documents referred to herein are hereby incorporated by reference.

Table 1 ce of anti-CD19 short spacer chimeric receptor GMCSFRss-CD19scFv-IgG4hinge-CD28tm-41BB-Zeta-T2A-EGFRt Atgctgctgctggtgaccagcctgctgctgtgcgagctgccccaccccgcctttctgctgatcccc (GMCSFRss) (SEQ ID NO:2) cagatgacccagaccacctccagcctgagcgccagcctgggcgaccgggtgaccatcagctgccggg aggacatcagcaagtacctgaactggtatcagcagaagcccgacggcaccgtcaagctgctgatctac cacaccagccggctgcacagcggcgtgcccagccggtttagcggcagcggctccggcaccgactacagcctgac catctccaacctggaacaggaagatatcgccacctacttttgccagcagggcaacacactgccctacacctttggc ggcggaacaaagctggaaatcaccggcagcacctccggcagcggcaagcctggcagcggcgagggcagcacc aagggcgaggtgaagctgcaggaaagcggccctggcctggtggcccccagccagagcctgagcgtgacctgca ccgtgagcggcgtgagcctgcccgactacggcgtgagctggatccggcagccccccaggaagggcctggaatg gctgggcgtgatctggggcagcgagaccacctactacaacagcgccctgaagagccggctgaccatcatcaag gacaacagcaagagccaggtgttcctgaagatgaacagcctgcagaccgacgacaccgccatctactactgcgc caagcactactactacggcggcagctacgccatggactactggggccagggcaccagcgtgaccgtgagcagc (CD19scFv) (SEQ ID NO:3) Gaatctaagtacggaccgccctgccccccttgccct (IgG4hinge) (SEQ ID NO:4) Atgttctgggtgctggtggtggtcggaggcgtgctggcctgctacagcctgctggtcaccgtggccttcatcatctt ttgggtg (CD28tm-)(SEQ ID NO:5) Aaacggggcagaaagaaactcctgtatatattcaaacaaccatttatgagaccagtacaaactactcaagagg aagatggctgtagctgccgatttccagaagaagaagaaggaggatgtgaactg (41BB) (SEQ ID NO:6) Cgggtgaagttcagcagaagcgccgacgcccctgcctaccagcagggccagaatcagctgtacaacgagctga acctgggcagaagggaagagtacgacgtcctggataagcggagaggccgggaccctgagatgggcggcaagc ctcggcggaagaacccccaggaaggcctgtataacgaactgcagaaagacaagatggccgaggcctacagcg agatcggcatgaagggcgagcggaggcggggcaagggccacgacggcctgtatcagggcctgtccaccgcca ccaaggatacctacgacgccctgcacatgcaggccctgcccccaagg (CD3Zeta)- (SEQ ID NO:7) Ctcgagggcggcggagagggcagaggaagtcttctaacatgcggtgacgtggaggagaatcccggccctagg (T2A) (SEQ ID NO:9) Atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatcccacgcaaagtgtg taacggaataggtattggtgaatttaaagactcactctccataaatgctacgaatattaaacacttcaaaaactgc acctccatcagtggcgatctccacatcctgccggtggcatttaggggtgactccttcacacatactcctcctctggat ccacaggaactggatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctgaaaac aggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagcaacatggtcagttttctctt gcagtcgtcagcctgaacataacatccttgggattacgctccctcaaggagataagtgatggagatgtgataattt caggaaacaaaaatttgtgctatgcaaatacaataaactggaaaaaactgtttgggacctccggtcagaaaacc aaaattataagcaacagaggtgaaaacagctgcaaggccacaggccaggtctgccatgccttgtgctcccccga gggctgctggggcccggagcccagggactgcgtctcttgccggaatgtcagccgaggcagggaatgcgtggac aagtgcaaccttctggagggtgagccaagggagtttgtggagaactctgagtgcatacagtgccacccagagtg cctgcctcaggccatgaacatcacctgcacaggacggggaccagacaactgtatccagtgtgcccactacattga cggcccccactgcgtcaagacctgcccggcaggagtcatgggagaaaacaacaccctggtctggaagtacgca ggccatgtgtgccacctgtgccatccaaactgcacctacggatgcactgggccaggtcttgaaggctgt ccaacgaatgggcctaagatcccgtccatcgccactgggatggtgggggccctcctcttgctgctggtggtggccc tggggatcggcctcttcatgtga (EGFRt) (SEQ ID NO:9) Table 2 GMCSFRss DNA: ATGCTGCTGCTGGTGACCAGCCTGCTGCTGTGCGAGCTGCCCCACCCCGCC AA: M L L L V T S L L L C E L P H P A CD19scFv DNA: TTTCTGCTGATCCCC:GACATCCAGATGACCCAGACCACCTCCAGCCTGAGC AA: F L L I P D I Q M T Q T T S S L S DNA: GCCAGCCTGGGCGACCGGGTGACCATCAGCTGCCGGGCCAGCCAGGACATC AA: A S L G D R V T I S C R A S Q D I DNA: TACCTGAACTGGTATCAGCAGAAGCCCGACGGCACCGTCAAGCTG AA: S K Y L N W Y Q Q K P D G T V K L DNA: CTGATCTACCACACCAGCCGGCTGCACAGCGGCGTGCCCAGCCGGTTTAGC AA: L I Y H T S R L H S G V P S R F S DNA: GGCAGCGGCTCCGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAG AA: G S G S G T D Y S L T I S N L E Q DNA: GAAGATATCGCCACCTACTTTTGCCAGCAGGGCAACACACTGCCCTACACC AA: E D I A T Y F C Q Q G N T L P Y T DNA: TTTGGCGGCGGAACAAAGCTGGAAATCACCGGCAGCACCTCCGGCAGCGGC AA: F G G G T K L E I T G S T S G S G DNA: AAGCCTGGCAGCGGCGAGGGCAGCACCAAGGGCGAGGTGAAGCTGCAGGAA AA: K P G S G E G S T K G E V K L Q E DNA: AGCGGCCCTGGCCTGGTGGCCCCCAGCCAGAGCCTGAGCGTGACCTGCACC AA: S G P G L V A P S Q S L S V T C T DNA: GTGAGCGGCGTGAGCCTGCCCGACTACGGCGTGAGCTGGATCCGGCAGCCC AA: V S G V S L P D Y G V S W I R Q P DNA: AAGGGCCTGGAATGGCTGGGCGTGATCTGGGGCAGCGAGACCACC AA: P R K G L E W L G V I W G S E T T 40 DNA: TACTACAACAGCGCCCTGAAGAGCCGGCTGACCATCATCAAGGACAACAGC AA: Y Y N S A L K S R L T I I K D N S DNA: AAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCC AA: K S Q V F L K M N S L Q T D D T A DNA: ATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGAC AA: I Y Y C A K H Y Y Y G G S Y A M D IgG4hinge 50 DNA: TACTGGGGCCAGGGCACCAGCGTGACCGTGAGCAGC:GAGAGCAAGTACGGA AA: Y W G Q G T S V T V S S E S K Y G CD28tm DNA: CCGCCCTGCCCCCCTTGCCCT:ATGTTCTGGGTGCTGGTGGTGGTCGGAGGC 55 AA: P P C P P C P M F W V L V V V G G DNA: GTGCTGGCCTGCTACAGCCTGCTGGTCACCGTGGCCTTCATCATCTTTTGG AA: V L A C Y S L L V T V A F I I F W 41BB DNA: GTG:AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATG AA: V K R G R K K L L Y I F K Q P F M DNA: AGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCA AA: R P V Q T T Q E E D G C S C R F P CD3Zeta DNA: GAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAG:TTCAGCAGAAGCGCC AA: E E E E G G C E L R V K F S R S A DNA: GACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAAC AA: D A P A Y Q Q G Q N Q L Y N E L N DNA: CTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGAC AA: L G R R E E Y D V L D K R R G R D DNA: ATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTAT AA: P E M G G K P R R K N P Q E G L Y DNA: AACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATG AA: N E L Q K D K M A E A Y S E I G M DNA: AAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTG AA: K G E R R R G K G H D G L Y Q G L DNA: TCCACCGCCACCAAGGATACCTACGACGCCCTGCACATGCAGGCCCTGCCC AA: S T A T K D T Y D A L H M Q A L P DNA: CCAAGG:CTCGAGGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGT AA: P R L E G G G E G R G S L L T C G EGFRt DNA: GACGTGGAGGAGAATCCCGGCCCTAGG:ATGCTTCTCCTGGTGACAAGCCTT AA: D V E E N P G P R M L L L V T S L DNA: CTGCTCTGTGAGTTACCACACCCAGCATTCCTCCTGATCCCACGCAAAGTG AA: L L C E L P H P A F L L I P R K V DNA: TGTAACGGAATAGGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCT AA: C N G I G I G E F K D S L S I N A DNA: ACGAATATTAAACACTTCAAAAACTGCACCTCCATCAGTGGCGATCTCCAC 45 AA: T N I K H F K N C T S I S G D L H DNA: ATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATACTCCTCCTCTG AA: I L P V A F R G D S F T H T P P L DNA: CAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCACAGGGTTT AA: D P Q E L D I L K T V K E I T G F DNA: TTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTTGAG AA: L L I Q A W P E N R T D L H A F E DNA: AACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTT AA: N L E I I R G R T K Q H G Q F S L DNA: GCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAG AA: A V V S L N I T S L G L R S L K E DNA: ATAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCA AA: I S D G D V I I S G N K N L C Y A DNA: AATACAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAA AA: N T I N W K K L F G T S G Q K T K DNA: ATTATAAGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGC AA: I I S N R G E N S C K A T G Q V C DNA: CATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGC AA: H A L C S P E G C W G P E P R D C DNA: GTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAAC AA: V S C R N V S R G R E C V D K C N DNA: CTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAG AA: L L E G E P R E F V E N S E C I Q DNA: TGCCACCCAGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGG AA: C H P E C L P Q A M N I T C T G R DNA: GGACCAGACAACTGTATCCAGTGTGCCCACTACATTGACGGCCCCCACTGC AA: G P D N C I Q C A H Y I D G P H C DNA: GTCAAGACCTGCCCGGCAGGAGTCATGGGAGAAAACAACACCCTGGTCTGG AA: V K T C P A G V M G E N N T L V W DNA: AAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGCCATCCAAACTGCACC AA: K Y A D A G H V C H L C H P N C T DNA: TACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGGCCTAAG 45 AA: Y G C T G P G L E G C P T N G P K DNA: ATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTG AA: I P S I A T G M V G A L L L L L V 50 DNA: GTGGCCCTGGGGATCGGCCTCTTCATGTGA (SEQ ID NO:10) AA: V A L G I G L F M * (SEQ ID NO:11) Table 3 ZXR-014 Nucleotide and amino acid ces (map of sections) GMCSFRss: -2149 CD19scFv: nt2150-2884 Igg4Hinge: nt2885-2920 CD28tm: nt2921-3004 41BB: nt3005-3130 Zeta: nt3131-3466 T2A: nt3467-3538 EGFRt: nt3539-4612 Primers for sequencing: Oligo name Sequence Region oJ02649 ATCAAAAGAATAGACCGAGATAGGGT pre-U5(SEQ ID NO:22) oJ02648 CTTTAAGACCAATGACTTAC delU3(SEQ ID NO:23) oJ02650 TTGAGAGTTTTCGCCCCG mid-Ampr(SEQ ID NO:24) oJ02651 AATAGACAGATCGCTGAGATAGGT post-Ampr(SEQ ID NO:25) oJ02652 CAGGTATCCGGTAAGCGG CoE1 ori(SEQ ID NO:26) oJ02653 CGACCAGCAACCATAGTCC SV40(SEQ ID NO:27) oJ02654 TAGCGGTTTGACTCACGG CMV(SEQ ID NO:28) oJ02655 GCAGGGAGCTAGAACGATTC psi(SEQ ID NO:29) oJ02656 TGGTATAGTGCAGCAG RRE(SEQ ID NO:30) oJ02657 TCGCAACGGGTTTGCC EF1p(SEQ ID NO:31) oJ02658 ATATCGCCACCTACT CD19Rop(SEQ ID NO:32) oJ02601 CGGGTGAAGTTCAGCAGAAG Zeta(SEQ ID NO:33) oJ02735 ACTGTGTTTGCTGACGCAAC EQ ID NO:34) oJ02715 ATGCTTCTCCTGGTGACAAG EGFRt(SEQ ID NO:35) Table 4 Uniprot P0861 IgG4-Fc(SEQ ID NO:13) 20 30 40 50 60 ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS 70 80 90 100 110 120 GLYSLSSVVT VPSSSLGTKT YTCNVDHKPS NTKVDKRVES KYGPPCPSCP APEFLGGPSV 130 140 150 160 170 180 FLFPPKPKDT LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY 190 200 210 220 230 240 RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SKAK GQPREPQVYT LPPSQEEMTK 250 260 270 280 290 300 NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG 310 320 NVFSCSVMHE ALHNHYTQKS K 1-98 CH1 99-110 Hinge 111-220 CH2 221-327 CH3 Position 108 S?P Table 5 Uniprot P10747 EQ ID NO:14) 20 30 40 50 60 MLRLLLALNL FPSIQVTGNK PMLV AYDNAVNLSC KYSYNLFSRE FRASLHKGLD 70 80 90 100 110 120 SAVEVCVVYG QVYS KTGFNCDGKL GNESVTFYLQ NLYVNQTDIY FCKIEVMYPP 130 140 150 160 170 180 PYLDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR 190 200 210 220 SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS 1-18 signal peptide 19-152 extracellular domain 153-179 transmembrane domain 180-220 intracellular domain Position 186-187 LL?GG Table 6 Uniprot Q07011 4-1BB(SEQ ID NO:15) 20 30 40 50 60 MGNSCYNIVA TLLLVLNFER PCSN CPAGTFCDNN RNQICSPCPP NSFSSAGGQR 70 80 90 100 110 120 TCDICRQCKG VFRTRKECSS DCTP GFHCLGAGCS MCEQDCKQGQ ELTKKGCKDC 130 140 150 160 170 180 CFGTFNDQKR GICRPWTNCS LDGKSVLVNG TKERDVVCGP SPADLSPGAS SVTPPAPARE 190 200 210 220 230 240 PGHSPQIISF FLALTSTALL FLLFFLTLRF SVVKRGRKKL LYIFKQPFMR PVQTTQEEDG CSCRFPEEEE GGCEL 1-23 signal peptide 24-186 extracellular domain 187-213 transmembrane domain intracellular domain Table 7 Uniprot P20963 human CD3? isoform 3 (SEQ ID NO:16) 20 30 40 50 60 MKWKALFTAA ILQAQLPITE AQSFGLLDPK LCYLLDGILF IYGVILTALF LRVKFSRSAD 70 80 90 100 110 120 APAYQQGQNQ LYNELNLGRR EEYDVLDKRR GRDPEMGGKP QRRKNPQEGL YNELQKDKMA 130 140 150 160 EAYSEIGMKG GHDG LYQGLSTATK DTYDALHMQA LPPR 1-21 signal e 22-30 extracellular 31-51 transmembrane 52-164 intracellular domain 61-89 ITAM1 100-128 ITAM2 131-159 ITAM3 Table 8 ary Hinge region Sequences Human IgG1 EPKSCDKTHTCPPCP (SEQ ID NO:17) Human IgG2 ERKCCVECPPCP (SEQ ID NO:18) Human IgG3 ELKTPLGDTHTCPRCP (EPKSCDTPPPCPRCP)3 (SEQ ID NO:19) Human IgG4 ESKYGPPCPSCP (SEQ ID NO:20) Modified Human IgG4 ESKYGPPCPPCP (SEQ ID NO:21) Modified Human IgG4 YGPPCPPCP (SEQ ID NO:51) Modified Human IgG4 KYGPPCPPCP (SEQ ID NO:52) Modified Human IgG4 EVVKYGPPCPPCP (SEQ ID NO:53) Table 9 R12 long spacer CAR: PJ_R12-CH2-CH3-41BB-Z-T2A-tEGFR (SEQ ID NO:37) GTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCT TAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATC TCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAG CTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGG GCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGA GAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGA AAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAG TATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAA CATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACA GGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTG CATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGA AGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGA CACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGCA AATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGT AGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGA AGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGACATC CCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGGCAAA GAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCC TTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTG CTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATC AAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACA GCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCT TGGATCTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTG GGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAA ACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTAC AGCAGAGATCCAGTTTGGGGATCAATTGCATGAAGAATCTGCTTAGG GTTAGGCGTTTTGCGCTGCTTCGCGAGGATCTGCGATCGCTCCGGTGCCCGTCA AGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCG GCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGAT GTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGT GCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAG CTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGA GGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCC TCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGC 40 CTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTT GCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGT TACAGATCCAAGCTGTGACCGGCGCCTACG GCTAGC CTCGAGGCC ACCATGCTGCTGCTGGTGACAAGCCTGCTGCTGTGCGAGCTGCCCCACCCCGCC 45 TTTCTGCTGATCCCCCAGGAACAGCTCGTCGAAAGCGGCGGCAGACTGGTGACA CCTGGCGGCAGCCTGACCCTGAGCTGCAAGGCCAGCGGCTTCGACTTCAGCGCC TACTACATGAGCTGGGTCCGCCAGGCCCCTGGCAAGGGACTGGAATGGATCGCC ACCATCTACCCCAGCAGCGGCAAGACCTACTACGCCACCTGGGTGAACGGACG GTTCACCATCTCCAGCGACAACGCCCAGAACACCGTGGACCTGCAGATGAACA GCCTGACAGCCGCCGACCGGGCCACCTACTTTTGCGCCAGAGACAGCTACGCCG ACGACGGCGCCCTGTTCAACATCTGGGGCCCTGGCACCCTGGTGACAATCTCTA GCGGCGGAGGCGGATCTGGTGGCGGAGGAAGTGGCGGCGGAGGATCTGAGCTG GTGCTGACCCAGAGCCCCTCTGTGTCTGCTGCCCTGGGAAGCCCTGCCAAGATC ACCCTGAGCAGCGCCCACAAGACCGACACCATCGACTGGTATCAGCA GCTGCAGGGCGAGGCCCCCAGATACCTGATGCAGGTGCAGAGCGACGGCAGCT ACACCAAGAGGCCAGGCGTGCCCGACCGGTTCAGCGGATCTAGCTCTGGCGCC GACCGCTACCTGATCATCCCCAGCGTGCAGGCCGATGACGAGGCCGATTACTAC TGTGGCGCCGACTACATCGGCGGCTACGTGTTCGGCGGAGGCACCCAGCTGACC GTGACCGGCGAGTCTAAG IgG4 spacer TA GCCCTGCCCCCCTTGCCCT GCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAG CTGATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTG AGCCAGGAAGATCCCGAGGTCCAGTTCAATTGGTACGTGGACGGCGTGGAAGT GCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGG TGGTGTCTGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACA AGTGCAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAAAAGACCATCAGC AAGGCCAAG GGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATG ACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAC CCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGT GGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACG AGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAG 4-1BB TGGGTGCTGGTGGTGGTGGGCGGGGTGCTGGCCTGCTACAGCCTGCTG GTGACAGTGGCCTTCATCATCTTTTGGGTGAAACGGGGCAGAAAGAAACTCCTG TATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGAT GGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG CD3 zeta CGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAA TCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGG ATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAAC 40 CCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTA CAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGC CTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATG CAGGCCCTGCCCCCAAGG 45 CTCGAGGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGA GGAGAATCCCGGCCCTAGG tEGFR ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCC TCCTGATCCCACGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACT CCATAAATGCTACGAATATTAAACACTTCAAAAACTGCACCTCCATCA GTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATA CTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCA CAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCT TTGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTC TTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGA TAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATA CAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATA AGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTT GTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGCGTCTCTTGCCG GAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTG AGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGC CTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGA GTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGT CCTGTGCCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGA AGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGG GGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGTGA GCGGCCGCTCTAGACCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATAATC AACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTAT GAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCT GACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGG ACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTG CCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGT AATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCT GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCT TCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTC AGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGTCGACTAG CCGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTT AAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATC TGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCT CTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGT GCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGAATTCGATATCAAGCTTAT CGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCGCCCTATAGTGAGT 40 CGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG GCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA TAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGG CGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT AAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT 45 CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT CCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA GGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAG GTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTG ACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA GCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCAC ACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGG AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAG AGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGAT CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTT CTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGT CGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAA AAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC ATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCG TTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGA TGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAG GACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAA TTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG AAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG GGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACG GGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG ATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA GCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC TGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAA AACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC ACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT 40 GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGT GGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCA GTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTT TACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATT 45 TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCA CTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCTCGAGGTCGAGA TCCGGTCGACCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTA ACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTA TGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG TTGGAGGCCTAGGCTTTTGCAAAAAGCTTCGACGGTATCGATTGGCTCA TGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAAT CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC TTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGT CAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC AATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC ATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC ATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGAATTCGGAGTGGCG AGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTG Table 10 Leader _R12- Hinge-CH2-CH3- CD28tm/41BB-Z-T2A-tEGFR (SEQ ID NO:38) Leader MLLLVTSLLLCELPHPAFLLIP R12 scFv QEQLVESGGRLVTPGGSLTLSCKASGFDFSAYYMSWVRQAPGKGLEWIATIYPSSG KTYYATWVNGRFTISSDNAQNTVDLQMNSLTAADRATYFCARDSYADDGALFNI WGPGTLVTISSGGGGSGGGGSGGGGSELVLTQSPSVSAALGSPAKITCTLSSAHKTD TIDWYQQLQGEAPRYLMQVQSDGSYTKRPGVPDRFSGSSSGADRYLIIPSVQADDE ADYYCGADYIGGYVFGGGTQLTVTG Hinge Spacer ESKYGPPCPPCP APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY HN AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSRLTVDKSRWQE GNVFSCSVMHEALHNHYTQKSLSLSLGK CD28 MFWVLVVVGGVLACYSLLVTVAFIIFWV 4-1BB KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL CD3 zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ ALPPR GRGSLLTCGDVEENPGPR tEGFR MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHI LPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRT KQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQK TKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLE GEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALL LLLVVALGIGLFM Table 11 R12 intermediate spacer CAR: PJ_R12-CH3-41BB-Z-T2A-tEGFR (SEQ ID NO:39) GTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCT TAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATC TCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAG CTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGG GCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGA GAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGA AAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAG TATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAA CATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACA GGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTG CATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGA AGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGA CACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGCA AATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGT AGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGA AGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGACATC AAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGGCAAA GAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCC TTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTG CTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATC AAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACA GCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCT TGGATCTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTG GGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAA ACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTAC AGGGACAGCAGAGATCCAGTTTGGGGATCAATTGCATGAAGAATCTGCTTAGG GTTAGGCGTTTTGCGCTGCTTCGCGAGGATCTGCGATCGCTCCGGTGCCCGTCA GTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCG GCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGAT GTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGT GTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAG CTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGA GGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCC TCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGC 40 CTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTT GCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGT TCCAAGCTGTGACCGGCGCCTACG GAATTCCTCGAGGCC R12 ScFv 45 ACCATGCTGCTGCTGGTGACAAGCCTGCTGCTGTGCGAGCTGCCCCACCCCGCC TTTCTGCTGATCCCCCAGGAACAGCTCGTCGAAAGCGGCGGCAGACTGGTGACA CCTGGCGGCAGCCTGACCCTGAGCTGCAAGGCCAGCGGCTTCGACTTCAGCGCC TACTACATGAGCTGGGTCCGCCAGGCCCCTGGCAAGGGACTGGAATGGATCGCC ACCATCTACCCCAGCAGCGGCAAGACCTACTACGCCACCTGGGTGAACGGACG GTTCACCATCTCCAGCGACAACGCCCAGAACACCGTGGACCTGCAGATGAACA GCCTGACAGCCGCCGACCGGGCCACCTACTTTTGCGCCAGAGACAGCTACGCCG ACGACGGCGCCCTGTTCAACATCTGGGGCCCTGGCACCCTGGTGACAATCTCTA GCGGCGGAGGCGGATCTGGTGGCGGAGGAAGTGGCGGCGGAGGATCTGAGCTG GTGCTGACCCAGAGCCCCTCTGTGTCTGCTGCCCTGGGAAGCCCTGCCAAGATC ACCTGTACCCTGAGCAGCGCCCACAAGACCGACACCATCGACTGGTATCAGCA GCTGCAGGGCGAGGCCCCCAGATACCTGATGCAGGTGCAGAGCGACGGCAGCT ACACCAAGAGGCCAGGCGTGCCCGACCGGTTCAGCGGATCTAGCTCTGGCGCC GACCGCTACCTGATCATCCCCAGCGTGCAGGCCGATGACGAGGCCGATTACTAC TGTGGCGCCGACTACATCGGCGGCTACGTGTTCGGCGGAGGCACCCAGCTGACC GTGACCGGCGAGTCTAAG Hinge Spacer TA CGGACCGCCCTGCCCCCCTTGCCCT GGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATG AACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC GTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAC CCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGT GGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACG AGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAG 4-1BB ATGTTCTGGGTGCTGGTGGTGGTGGGCGGGGTGCTGGCCTGCTACAGCCTGCTG GTGACAGTGGCCTTCATCATCTTTTGGGTGAAACGGGGCAGAAAGAAACTCCTG TATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGAT GGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG CD3zeta CGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAA TCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGG GGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAAC CCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTA CAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGC CTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATG CAGGCCCTGCCCCCAAGG CTCGAGGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGA GGAGAATCCCGGCCCTAGG 40 tEGFR ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCC TCCTGATCCCACGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACT CACTCTCCATAAATGCTACGAATATTAAACACTTCAAAAACTGCACCTCCATCA GTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATA 45 CTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCA CAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCT TTGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTC TTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGA TAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATA CAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATA AGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTT GTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGCGTCTCTTGCCG GAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTG AGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGC CTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGA GTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGT GTGCCACCTGTGCCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGA AGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGG GGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGTGA GCTCTAGACCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATAATC AACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTAT GAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCT GACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGG ACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTG CCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGT CGGGGAAATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCT GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCT TCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTC AGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGTCGACTAG CCGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTT AAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATC TTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCT CTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGT GCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGAATTCGATATCAAGCTTAT CGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCGCCCTATAGTGAGT CGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG GCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA TAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGG CGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT AAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT 40 CCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA GGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAG GTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTG ACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA GCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCAC 45 ACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGG AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAG AGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGAT CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTT CTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGT CGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAA AAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC ATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCG TTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGA TGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAG GACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG TGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAA TTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG AAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG GGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACG GGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG ATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA GCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC TGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAA AACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC ACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGT GAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCA GTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTT TACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATT TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCA GGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCTCGAGGTCGAGA 40 TCCGGTCGACCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTA ACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTA TGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG GCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTCGACGGTATCGATTGGCTCA TGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAAT 45 CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC TTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGT CAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC AATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC CAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC ATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGAATTCGGAGTGGCG AGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTG Table 12 Leader _R12- Hinge- CH3- CD28tm/41BB-Z-T2A-tEGFR (SEQ ID NO:40) Leader MLLLVTSLLLCELPHPAFLLIP R12 scFV QEQLVESGGRLVTPGGSLTLSCKASGFDFSAYYMSWVRQAPGKGLEWIATIYPSSG KTYYATWVNGRFTISSDNAQNTVDLQMNSLTAADRATYFCARDSYADDGALFNI WGPGTLVTISSGGGGSGGGGSGGGGSELVLTQSPSVSAALGSPAKITCTLSSAHKTD TIDWYQQLQGEAPRYLMQVQSDGSYTKRPGVPDRFSGSSSGADRYLIIPSVQADDE ADYIGGYVFGGGTQLTVTG Hinge Spacer ESKYGPPCPPCP QVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSRLTVDKSRWQE GNVFSCSVMHEALHNHYTQKSLSLSLGK CD28tm MFWVLVVVGGVLACYSLLVTVAFIIFWV 4-1BB KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL CD3 zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ ALPPR LEGGGEGRGSLLTCGDVEENPGPR tEGFR MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHI LPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRT KQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQK TKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLE GEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALL LLLVVALGIGLFM Table 13 R12 short spacer CAR: PJ_R12-Hinge-41BB-Z-T2A-tEGFR (SEQ ID NO:41) GTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCT TAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATC TCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAG CTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGG GCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGA GAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGA AAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAG TATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAA CATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACA GGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTG CATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGA AAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGA CACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGCA AATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGT AGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGA AGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGACATC AAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGGCAAA GAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCC TTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTG CTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATC AAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACA GCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCT TGGATCTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTG GGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAA ACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTAC AGGGACAGCAGAGATCCAGTTTGGGGATCAATTGCATGAAGAATCTGCTTAGG GTTAGGCGTTTTGCGCTGCTTCGCGAGGATCTGCGATCGCTCCGGTGCCCGTCA AGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCG GCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGAT TACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGT GTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAG CTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGA GGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCC TCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGC CTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTT 40 GCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGT TACAGATCCAAGCTGTGACCGGCGCCTACG GCTAGF R12 scFV ACCATGCTGCTGCTGGTGACAAGCCTGCTGCTGTGCGAGCTGCCCCACCCCGCC 45 TTTCTGCTGATCCCCCAGGAACAGCTCGTCGAAAGCGGCGGCAGACTGGTGACA CCTGGCGGCAGCCTGACCCTGAGCTGCAAGGCCAGCGGCTTCGACTTCAGCGCC ATGAGCTGGGTCCGCCAGGCCCCTGGCAAGGGACTGGAATGGATCGCC ACCATCTACCCCAGCAGCGGCAAGACCTACTACGCCACCTGGGTGAACGGACG CATCTCCAGCGACAACGCCCAGAACACCGTGGACCTGCAGATGAACA GCCTGACAGCCGCCGACCGGGCCACCTACTTTTGCGCCAGAGACAGCTACGCCG ACGACGGCGCCCTGTTCAACATCTGGGGCCCTGGCACCCTGGTGACAATCTCTA GCGGCGGAGGCGGATCTGGTGGCGGAGGAAGTGGCGGCGGAGGATCTGAGCTG GTGCTGACCCAGAGCCCCTCTGTGTCTGCTGCCCTGGGAAGCCCTGCCAAGATC ACCTGTACCCTGAGCAGCGCCCACAAGACCGACACCATCGACTGGTATCAGCA GCTGCAGGGCGAGGCCCCCAGATACCTGATGCAGGTGCAGAGCGACGGCAGCT ACACCAAGAGGCCAGGCGTGCCCGACCGGTTCAGCGGATCTAGCTCTGGCGCC GACCGCTACCTGATCATCCCCAGCGTGCAGGCCGATGACGAGGCCGATTACTAC TGTGGCGCCGACTACATCGGCGGCTACGTGTTCGGCGGAGGCACCCAGCTGACC GTGACCGGCGAGTCTAAG Hinge/Spacer TA CGGACCGCCCTGCCCCCCTTGCCCT 4-1BB ATGTTCTGGGTGCTGGTGGTGGTGGGCGGGGTGCTGGCCTGCTACAGCCTGCTG GTGACAGTGGCCTTCATCATCTTTTGGGTGAAACGGGGCAGAAAGAAACTCCTG TATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGAT GGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG CD3 zeta CGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAA TCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGG ATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAAC CCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTA CAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGC CTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATG CAGGCCCTGCCCCCAAGG CTCGAGGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGA GGAGAATCCCGGCCCTAGG tEGFR CTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCC TCCTGATCCCACGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACT CACTCTCCATAAATGCTACGAATATTAAACACTTCAAAAACTGCACCTCCATCA GTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATA CTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCA CAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCT TTGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTC 40 TTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGA TAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATA CAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATA AGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTT GTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGCGTCTCTTGCCG 45 CAGCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTG AGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGC CTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGA GTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGT GTGCCACCTGTGCCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGA AGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGG GGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGTGA GCGGCCGCTCTAGACCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATAATC AACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTAT GAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCT GACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGG ACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTG CCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGT CGGGGAAATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCT GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCT TCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTC AGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGTCGACTAG CCGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTT AAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATC TTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCT CTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGT GCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGAATTCGATATCAAGCTTAT CGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCGCCCTATAGTGAGT CGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG CCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA TAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGG CGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT GCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT CCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA GGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAG GTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTG ACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA GCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCAC ACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGG AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAG 40 AGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG TGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGAT CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTT CTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGT 45 CGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAA AAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC ATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCG TTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGA TGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAG TTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAA TTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG AAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT CTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG ACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACG GGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG ATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA GCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC TGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAA AACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC ACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGT GAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCA GTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTT TTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATT TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCA CTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCTCGAGGTCGAGA TCCGGTCGACCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTA ACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTA TGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG GCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTCGACGGTATCGATTGGCTCA TGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAAT CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC TTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGT CAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC 40 AATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC ATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC ATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA 45 TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGAATTCGGAGTGGCG AGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTG Table 14 Leader _R12 - CD28tm/41BB-Z-T2A-tEGFR(SEQ ID NO:42) Leader MLLLVTSLLLCELPHPAFLLIP scFv R12 QEQLVESGGRLVTPGGSLTLSCKASGFDFSAYYMSWVRQAPGKGLEWIATIYPSSG KTYYATWVNGRFTISSDNAQNTVDLQMNSLTAADRATYFCARDSYADDGALFNI WGPGTLVTISSGGGGSGGGGSGGGGSELVLTQSPSVSAALGSPAKITCTLSSAHKTD TIDWYQQLQGEAPRYLMQVQSDGSYTKRPGVPDRFSGSSSGADRYLIIPSVQADDE ADYYCGADYIGGYVFGGGTQLTVTG Hinge/spacer ESKYGPPCPPCP CD28tm VVGGVLACYSLLVTVAFIIFWV 4-1BB KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ ALPPR LEGGGEGRGSLLTCGDVEENPGPR tEGFR MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHI LPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRT KQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQK TKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLE GEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALL LLLVVALGIGLFM Table 15 R11 long spacer CAR: PJ_R11-CH2-CH3-41BB-Z-T2A-tEGFR (SEQ ID NO:43) GTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCT TAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATC AGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAG CGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGG GCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGA GAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGA AAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAG CAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAA CATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACA GGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTG CATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGA AGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGA CACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGCA AATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGT AGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGA AGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGACATC AAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGGCAAA GAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCC TTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTG CTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATC AAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACA GCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCT TGGATCTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTG GGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAA ACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTAC AGGGACAGCAGAGATCCAGTTTGGGGATCAATTGCATGAAGAATCTGCTTAGG GTTAGGCGTTTTGCGCTGCTTCGCGAGGATCTGCGATCGCTCCGGTGCCCGTCA AGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCG GCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGAT GTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGT GCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAG CTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGA GGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCC TCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGC 40 CTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTT GCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGT TACAGATCCAAGCTGTGACCGGCGCCTACG GCTAGC scFv R12 45 GAATTCGCCACCATGCTGCTGCTGGTGACAAGCCTGCTGCTGTGCGAGCTGCCC CACCCCGCCTTTCTGCTGATCCCCCAGAGCGTGAAAGAGTCCGAGGGCGACCTG GTCACACCAGCCGGCAACCTGACCCTGACCTGTACCGCCAGCGGCAGCGACATC TACCCCATCTCTTGGGTCCGCCAGGCTCCTGGCAAGGGACTGGAATGG ATCGGCTTCATCAACAGCGGCGGCAGCACTTGGTACGCCAGCTGGGTCAAAGGC CGGTTCACCATCAGCCGGACCAGCACCACCGTGGACCTGAAGATGACAAGCCT GACCACCGACGACACCGCCACCTACTTTTGCGCCAGAGGCTACAGCACCTACTA CGGCGACTTCAACATCTGGGGCCCTGGCACCCTGGTCACAATCTCTAGCGGCGG AGGCGGCAGCGGAGGTGGAGGAAGTGGCGGCGGAGGATCCGAGCTGGTCATGA CCCCCAGCAGCACATCTGGCGCCGTGGGCGGCACCGTGACCATCAATT GCCAGGCCAGCCAGAGCATCGACAGCAACCTGGCCTGGTTCCAGCAGAAGCCC GGCCAGCCCCCCACCCTGCTGATCTACAGAGCCTCCAACCTGGCCAGCGGCGTG CCAAGCAGATTCAGCGGCAGCAGATCTGGCACCGAGTACACCCTGACCATCTCC GGCGTGCAGAGAGAGGACGCCGCTACCTATTACTGCCTGGGCGGCGTGGGCAA CGTGTCCTACAGAACCAGCTTCGGCGGAGGTACTGAGGTGGTCGTCAAA Hinge/Spacer TA CGGACCGCCCTGCCCCCCTTGCCCT GCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAG GACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTG AGCCAGGAAGATCCCGAGGTCCAGTTCAATTGGTACGTGGACGGCGTGGAAGT GCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGG TGGTGTCTGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACA AGTGCAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAAAAGACCATCAGC AAGGCCAAG GGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATG ACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAC CCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGT GGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACG AGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAG 4-1BB ATGTTCTGGGTGCTGGTGGTGGTGGGCGGGGTGCTGGCCTGCTACAGCCTGCTG GTGGCCTTCATCATCTTTTGGGTGAAACGGGGCAGAAAGAAACTCCTG TATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGAT GGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG CD3zeta CGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAA TCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGG ATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAAC 40 CCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTA CAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGC CTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATG CAGGCCCTGCCCCCAAGG 45 CTCGAGGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGA GGAGAATCCCGGCCCTAGG tEGFR ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCC TCCTGATCCCACGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACT CACTCTCCATAAATGCTACGAATATTAAACACTTCAAAAACTGCACCTCCATCA GTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATA CTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCA CAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCT TTGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTC TTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGA TAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATA CAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATA AGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTT GTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGCGTCTCTTGCCG GAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTG AGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGC CTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGA GTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGT GTGCCACCTGTGCCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGA TCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGG GGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGTGA GCGGCCGCTCTAGACCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATAATC AACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTAT GAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCT GACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGG ACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTG CCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGT CGGGGAAATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCT GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCT TCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTC AGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGTCGACTAG CCGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTT AAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATC TGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCT CTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGT GCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGAATTCGATATCAAGCTTAT 40 CGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCGCCCTATAGTGAGT CGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG CCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA TAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGG CGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT 45 AAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT CCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA TGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAG GTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTG AAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA GCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCAC ACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGG AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT ATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAG AGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGAT CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTT CTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGT CGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAA AAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC ATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCG TTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGA TGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAG GACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAA TTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG AAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT CTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG GGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACG GGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG ATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA GCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC GAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAA AACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC 40 ACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGT GAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCA GTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTT 45 TACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATT TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCA CTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCTCGAGGTCGAGA TCCGGTCGACCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTA ACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTA TGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG GCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTCGACGGTATCGATTGGCTCA TGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAAT CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC TTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGT TGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC AATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC ATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC ATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGAATTCGGAGTGGCG AGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTG Table 16 Leader _R11- Hinge-CH2-CH3- CD28tm/41BB-Z-T2A-tEGFR (SEQ ID NO:44) Leader MLLLVTSLLLCELPHPAFLLIP R11 scFv QSVKESEGDLVTPAGNLTLTCTASGSDINDYPISWVRQAPGKGLEWIGFINSGGSTW YASWVKGRFTISRTSTTVDLKMTSLTTDDTATYFCARGYSTYYGDFNIWGPGTLVT ISSGGGGSGGGGSGGGGSELVMTQTPSSTSGAVGGTVTINCQASQSIDSNLAWFQQ KPGQPPTLLIYRASNLASGVPSRFSGSRSGTEYTLTISGVQREDAATYYCLGGVGNV SYRTSFGGGTEVVVK Hinge/Spacer ESKYGPPCPPCP APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHN AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSRLTVDKSRWQE GNVFSCSVMHEALHNHYTQKSLSLSLGK CD28tm VVGGVLACYSLLVTVAFIIFWV 4-1BB KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL CD3zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP ELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ ALPPR LEGGGEGRGSLLTCGDVEENPGPR tEGFR MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHI LPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRT KQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQK TKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLE GEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALL LLLVVALGIGLFM Table 17 R11 intermediate spacer CAR: PJ_R11-CH3-41BB-Z-T2A-tEGFR (SEQ ID NO:45) GTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCT TCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATC TCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAG CTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGG GCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGA GAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGA AAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAG TATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAA CATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACA GGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTG CATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGA AGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGA CACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGCA AATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGT AGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGA AGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGACATC AAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGGCAAA GAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCC TTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTG GCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATC AAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACA GCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCT TACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTG GGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAA ACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTAC AGGGACAGCAGAGATCCAGTTTGGGGATCAATTGCATGAAGAATCTGCTTAGG GTTAGGCGTTTTGCGCTGCTTCGCGAGGATCTGCGATCGCTCCGGTGCCCGTCA GTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCG GCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGAT GTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGT GCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAG CTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGA GGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCC TCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGC 40 CCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTT GCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGT TACAGATCCAAGCTGTGACCGGCGCCTACG GCTAGC R11 scFV 45 GAATTCGCCACCATGCTGCTGCTGGTGACAAGCCTGCTGCTGTGCGAGCTGCCC CACCCCGCCTTTCTGCTGATCCCCCAGAGCGTGAAAGAGTCCGAGGGCGACCTG GTCACACCAGCCGGCAACCTGACCCTGACCTGTACCGCCAGCGGCAGCGACATC TACCCCATCTCTTGGGTCCGCCAGGCTCCTGGCAAGGGACTGGAATGG ATCGGCTTCATCAACAGCGGCGGCAGCACTTGGTACGCCAGCTGGGTCAAAGGC CGGTTCACCATCAGCCGGACCAGCACCACCGTGGACCTGAAGATGACAAGCCT GACCACCGACGACACCGCCACCTACTTTTGCGCCAGAGGCTACAGCACCTACTA CGGCGACTTCAACATCTGGGGCCCTGGCACCCTGGTCACAATCTCTAGCGGCGG AGGCGGCAGCGGAGGTGGAGGAAGTGGCGGCGGAGGATCCGAGCTGGTCATGA CCCAGACCCCCAGCAGCACATCTGGCGCCGTGGGCGGCACCGTGACCATCAATT GCCAGGCCAGCCAGAGCATCGACAGCAACCTGGCCTGGTTCCAGCAGAAGCCC GGCCAGCCCCCCACCCTGCTGATCTACAGAGCCTCCAACCTGGCCAGCGGCGTG AGATTCAGCGGCAGCAGATCTGGCACCGAGTACACCCTGACCATCTCC CAGAGAGAGGACGCCGCTACCTATTACTGCCTGGGCGGCGTGGGCAA CGTGTCCTACAGAACCAGCTTCGGCGGAGGTACTGAGGTGGTCGTCAAA Hinge/spacer TAGGACCGCCCTGC CCCCCTTGCCCT GCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAG GACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTG AGCCAGGAAGATCCCGAGGTCCAGTTCAATTGGTACGTGGACGGCGTGGAAGT GCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGG TGGTGTCTGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACA AGTGCAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAAAAGACCATCAGC AAGGCCAAG CH3 GGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATG ACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAC CCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGT GGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACG AGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAG 4-1BB ATGTTCTGGGTGCTGGTGGTGGTGGGCGGGGTGCTGGCCTGCTACAGCCTGCTG GTGACAGTGGCCTTCATCATCTTTTGGGTGAAACGGGGCAGAAAGAAACTCCTG TATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGAT GGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG CGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAA TCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGG 40 ATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAAC CCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTA CAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGC CTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATG CAGGCCCTGCCCCCAAGG 45 T2A CTCGAGGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGA GGAGAATCCCGGCCCTAGG tEGFR ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCC TCCTGATCCCACGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACT CACTCTCCATAAATGCTACGAATATTAAACACTTCAAAAACTGCACCTCCATCA GTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATA CTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCA CAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCT TTGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTC TCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGA TAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATA CAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATA AGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTT GTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGCGTCTCTTGCCG GAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTG AGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGC CTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGA GTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGT GTGCCACCTGTGCCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGA AGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGG CCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGTGA GCGGCCGCTCTAGACCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATAATC AACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTAT GAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCT GACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGG ACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTG CCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGT CGGGGAAATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCT GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCT TCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTC AGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGTCGACTAG CCGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTT AAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATC TTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCT CTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGT GCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGAATTCGATATCAAGCTTAT 40 CGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCGCCCTATAGTGAGT CGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG GCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA TAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGG CGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT 45 AAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT CCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA GGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAG GTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTG ACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA GCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCAC ACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGG AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAG AGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGAT CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTT CTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGT CGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAA AAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC GATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCG TTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGA TGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAG GACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG TGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAA TTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG ACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT CTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG GGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACG GGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG ATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA GCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC TGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAA AACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC 40 ACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGT GAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCA GCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTT 45 TACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATT TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCA CTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCTCGAGGTCGAGA TCCGGTCGACCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTA ACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTA TGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG GCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTCGACGGTATCGATTGGCTCA TGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAAT CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC TTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGT TGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC AATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC ATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC ATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGAATTCGGAGTGGCG AGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTG Table 18 Leader _R11- Hinge-CH3- CD28tm/41BB-Z-T2A-tEGFR (SEQ ID NO:46) Leader MLLLVTSLLLCELPHPAFLLIP scFV R11 QSVKESEGDLVTPAGNLTLTCTASGSDINDYPISWVRQAPGKGLEWIGFINSGGSTW YASWVKGRFTISRTSTTVDLKMTSLTTDDTATYFCARGYSTYYGDFNIWGPGTLVT ISSGGGGSGGGGSGGGGSELVMTQTPSSTSGAVGGTVTINCQASQSIDSNLAWFQQ TLLIYRASNLASGVPSRFSGSRSGTEYTLTISGVQREDAATYYCLGGVGNV SYRTSFGGGTEVVVK Hinge/spacer ESKYGPPCPPCP QVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSRLTVDKSRWQE GNVFSCSVMHEALHNHYTQKSLSLSLGK CD28tm MFWVLVVVGGVLACYSLLVTVAFIIFWV 4-1BB KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL CD3zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ ALPPR LEGGGEGRGSLLTCGDVEENPGPRM tEGFR LLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHIL PVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTK QHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKT KIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEG EPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMG ENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLL LLVVALGIGLFM Table 19 R11 short spacer CAR: - 41BB-Z-T2A-tEGFR(SEQ ID NO:47) GTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCT TAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATC TCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAG CGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGG GCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGA GAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGA AAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAG TATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAA CATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACA GGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTG CATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGA AGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGA CACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGCA AATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGT AGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGA AGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGACATC AAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGGCAAA GAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCC TTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTG CTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATC AAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACA GCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCT TACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTG GGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAA ACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTAC AGGGACAGCAGAGATCCAGTTTGGGGATCAATTGCATGAAGAATCTGCTTAGG GTTAGGCGTTTTGCGCTGCTTCGCGAGGATCTGCGATCGCTCCGGTGCCCGTCA GTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCG GCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGAT GTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGT GCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAG CTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGA GGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCC TCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGC 40 CTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTT GCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGT TACAGATCCAAGCTGTGACCGGCGCCTACG GCTAGC scFV R11 45 GAATTCGCCACCATGCTGCTGCTGGTGACAAGCCTGCTGCTGTGCGAGCTGCCC CACCCCGCCTTTCTGCTGATCCCCCAGAGCGTGAAAGAGTCCGAGGGCGACCTG GTCACACCAGCCGGCAACCTGACCCTGACCTGTACCGCCAGCGGCAGCGACATC TACCCCATCTCTTGGGTCCGCCAGGCTCCTGGCAAGGGACTGGAATGG ATCGGCTTCATCAACAGCGGCGGCAGCACTTGGTACGCCAGCTGGGTCAAAGGC CGGTTCACCATCAGCCGGACCAGCACCACCGTGGACCTGAAGATGACAAGCCT CGACGACACCGCCACCTACTTTTGCGCCAGAGGCTACAGCACCTACTA CGGCGACTTCAACATCTGGGGCCCTGGCACCCTGGTCACAATCTCTAGCGGCGG AGGCGGCAGCGGAGGTGGAGGAAGTGGCGGCGGAGGATCCGAGCTGGTCATGA CCCAGACCCCCAGCAGCACATCTGGCGCCGTGGGCGGCACCGTGACCATCAATT GCCAGGCCAGCCAGAGCATCGACAGCAACCTGGCCTGGTTCCAGCAGAAGCCC GGCCAGCCCCCCACCCTGCTGATCTACAGAGCCTCCAACCTGGCCAGCGGCGTG CCAAGCAGATTCAGCGGCAGCAGATCTGGCACCGAGTACACCCTGACCATCTCC GGCGTGCAGAGAGAGGACGCCGCTACCTATTACTGCCTGGGCGGCGTGGGCAA CGTGTCCTACAGAACCAGCTTCGGCGGAGGTACTGAGGTGGTCGTCAAA Hinge/spacer TACGGACCGCCCTGCCCCCCTTGCCCT GGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATG ACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAC CCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGT GGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACG AGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAG 4-1BB ATGTTCTGGGTGCTGGTGGTGGTGGGCGGGGTGCTGGCCTGCTACAGCCTGCTG GTGGCCTTCATCATCTTTTGGGTGAAACGGGGCAGAAAGAAACTCCTG TATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGAT AGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG CD3zeta CGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAA TCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGG ATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAAC CCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTA CAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGC CTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATG CAGGCCCTGCCCCCAAGG CTCGAGGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGA GGAGAATCCCGGCCCTAGG tEGFR 40 ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCC TCCTGATCCCACGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACT CACTCTCCATAAATGCTACGAATATTAAACACTTCAAAAACTGCACCTCCATCA GTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATA CTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCA 45 CAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCT TTGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTC TTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGA TAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATA CAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATA AGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTT GTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGCGTCTCTTGCCG GAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTG AGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGC CTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGA GTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGT GTGCCACCTGTGCCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGA AGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGG GGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGTGA GCGGCCGCTCTAGACCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATAATC TGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTAT TTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCT GACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGG ACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTG CCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGT CGGGGAAATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCT GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCT TCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTC AGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGTCGACTAG CCGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTT AAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATC TGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCT CTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGT GCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGAATTCGATATCAAGCTTAT CGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCGCCCTATAGTGAGT CGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG GCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA TAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGG CGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT AAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT TTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA 40 GGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAG GTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTG ACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA GCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCAC ACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGG 45 AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAG AGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGAT CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTT CTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGT CGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAA AAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC ATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCG ACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGA TGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAG GACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAA TTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG AAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG TTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT CTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG GGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACG GGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG ATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA GCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC TGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAA AACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC ACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT GCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGT GAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCA GTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTT TACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATT TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCA CTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCTCGAGGTCGAGA TCCGGTCGACCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTA 40 ACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTA TGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG TTGGAGGCCTAGGCTTTTGCAAAAAGCTTCGACGGTATCGATTGGCTCA TGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAAT CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC 45 TTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGT CAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC AATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC ATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC ATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA TTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGAATTCGGAGTGGCG AGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTG Table 20 Leader _R11- Hinge- CD28tm/41BB-Z-T2A-tEGFR (SEQ ID NO:48) Leader MLLLVTSLLLCELPHPAFLLIP ScFv R11 QSVKESEGDLVTPAGNLTLTCTASGSDINDYPISWVRQAPGKGLEWIGFINSGGSTW YASWVKGRFTISRTSTTVDLKMTSLTTDDTATYFCARGYSTYYGDFNIWGPGTLVT ISSGGGGSGGGGSGGGGSELVMTQTPSSTSGAVGGTVTINCQASQSIDSNLAWFQQ KPGQPPTLLIYRASNLASGVPSRFSGSRSGTEYTLTISGVQREDAATYYCLGGVGNV GGGTEVVVK Spacer/Hinge ESKYGPPCPPCP CD28tm MFWVLVVVGGVLACYSLLVTVAFIIFWV 4-1BB KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL CD3zeta RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ ALPPR LEGGGEGRGSLLTCGDVEENPGPR tEGFR MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHI LPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRT KQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQK RGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLE GEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALL LLLVVALGIGLFM Table 21 Intermediate Spacer (SEQ ID NO:49) Hinge/spacer ESKYGPPCPPCP GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSRLTVDKSRWQE GNVFSCSVMHEALHNHYTQKSLSLSLGK Long spacer (SEQ ID NO:50) Hinge ESKYGPPCPPCP GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHN AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSRLTVDKSRWQE GNVFSCSVMHEALHNHYTQKSLSLSLGK Table 22 Her2 construct-short spacer (SEQ Id No:54 ) GMCSFss-Her2scFv-IgG4hinge-CD28tm-41BB-Zeta-T2A-EGFRt Leader Atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatccca Her2scFV gatatccagatgacccagtccccgagctccctgtccgcctctgtgggcgatagggtcaccatcacctgccgtgccagtcaggatgtg aatactgctgtagcctggtatcaacagaaaccaggaaaagctccgaaactactgatttactcggcatccttcctctactctggagtccct tctcgcttctctggttccagatctgggacggatttcactctgaccatcagcagtctgcagccggaagacttcgcaacttattactgtcag caacattatactactcctcccacgttcggacagggtaccaaggtggagatcaaaggcagtactagcggcggtggctccgggggcg gatccggtgggggcggcagcagcgaggttcagctggtggagtctggcggtggcctggtgcagccagggggctcactccgtttgtc agcttctggcttcaacattaaagacacctatatacactgggtgcgtcaggccccgggtaagggcctggaatgggttgcaag gatttatcctacgaatggttatactagatatgccgatagcgtcaagggccgtttcactataagcgcagacacatccaaaaacacagcct acctgcagatgaacagcctgcgtgctgaggacactgccgtctattattgttctagatggggaggggacggcttctatgctatggacta ctggggtcaaggaaccctggtcaccgtctcgagt Hinge spacer Gagagcaagtacggaccgccctgccccccttgccct CD28tm atgttctgggtgctggtggtggtcggaggcgtgctggcctgctacagcctgctggtcaccgtggccttcatcatcttttgggtg 4-1BB Aaacggggcagaaagaaactcctgtatatattcaaacaaccatttatgagaccagtacaaactactcaagaggaagatggctgtagc tgccgatttccagaagaagaagaaggaggatgtgaactg CD3 zeta Cgggtgaagttcagcagaagcgccgacgcccctgcctaccagcagggccagaatcagctgtacaacgagctgaacctgggcag aagggaagagtacgacgtcctggataagcggagaggccgggaccctgagatgggcggcaagcctcggcggaagaacccccag gaaggcctgtataacgaactgcagaaagacaagatggccgaggcctacagcgagatcggcatgaagggcgagcggaggcggg gcaagggccacgacggcctgtatcagggcctgtccaccgccaccaaggatacctacgacgccctgcacatgcaggccctgcccc caagg Ctcgagggcggcggagagggcagaggaagtcttctaacatgcggtgacgtggaggagaatcccggccctagg tEGFR atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatcccacgcaaagtgtgtaacggaataggt attggtgaatttaaagactcactctccataaatgctacgaatattaaacacttcaaaaactgcacctccatcagtggcgatctccacatcc tgccggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactggatattctgaaaaccgtaaaggaaatc acagggtttttgctgattcaggcttggcctgaaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggacc aagcaacatggtcagttttctcttgcagtcgtcagcctgaacataacatccttgggattacgctccctcaaggagataagtgatggaga tgtgataatttcaggaaacaaaaatttgtgctatgcaaatacaataaactggaaaaaactgtttgggacctccggtcagaaaaccaaaa ttataagcaacagaggtgaaaacagctgcaaggccacaggccaggtctgccatgccttgtgctcccccgagggctgctggggccc cagggactgcgtctcttgccggaatgtcagccgaggcagggaatgcgtggacaagtgcaaccttctggagggtgagcc 40 aagggagtttgtggagaactctgagtgcatacagtgccacccagagtgcctgcctcaggccatgaacatcacctgcacaggacgg ggaccagacaactgtatccagtgtgcccactacattgacggcccccactgcgtcaagacctgcccggcaggagtcatgggagaaa acaacaccctggtctggaagtacgcagacgccggccatgtgtgccacctgtgccatccaaactgcacctacggatgcactgggcca gaaggctgtccaacgaatgggcctaagatcccgtccatcgccactgggatggtgggggccctcctcttgctgctggtggtg gccctggggatcggcctcttcatgtga Table 23 Her2 construct-intermediate spacer (SEQ Id No:55 ) Leader Atgcttctcctggtgacaagccttctgctctgtgagttaccacaccca Her2scFv Gcattcctcctgatcccagatatccagatgacccagtccccgagctccctgtccgcctctgtgggcgatagggtcaccatcacctgc cgtgccagtcaggatgtgaatactgctgtagcctggtatcaacagaaaccaggaaaagctccgaaactactgatttactcggcatcct tcctctactctggagtcccttctcgcttctctggttccagatctgggacggatttcactctgaccatcagcagtctgcagccggaagactt cgcaacttattactgtcagcaacattatactactcctcccacgttcggacagggtaccaaggtggagatcaaaggcagtactagcggc ggtggctccgggggcggatccggtgggggcggcagcagcgaggttcagctggtggagtctggcggtggcctggtgcagccagg gggctcactccgtttgtcctgtgcagcttctggcttcaacattaaagacacctatatacactgggtgcgtcaggccccgggtaagggc ctggaatgggttgcaaggatttatcctacgaatggttatactagatatgccgatagcgtcaagggccgtttcactataagcgcagacac atccaaaaacacagcctacctgcagatgaacagcctgcgtgctgaggacactgccgtctattattgttctagatggggaggggacgg cttctatgctatggactactggggtcaaggaaccctggtcaccgtctcgagt Hinge spacer GagagcaagtacggaccgccctgccccccttgccctGgccagcctagagaaccccaggtgtacaccctgcctcccagccagga agagatgaccaagaaccaggtgtccctgacctgcctggtcaaaggcttctaccccagcgatatcgccgtggaatgggagagcaac ggccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggcagcttcttcctgtactcccggctgaccgtgg acaagagccggtggcaggaaggcaacgtcttcagctgcagcgtgatgcacgaggccctgcacaaccactacacccagaagtccc tgagcctgagcctgggcaag CD28tm Atgttctgggtgctggtggtggtcggaggcgtgctggcctgctacagcctgctggtcaccgtggccttcatcatcttttgggtg 4-1BB Aaacggggcagaaagaaactcctgtatatattcaaacaaccatttatgagaccagtacaaactactcaagaggaagatggctgtagc tgccgatttccagaagaagaagaaggaggatgtgaactg CD3 zeta Cgggtgaagttcagcagaagcgccgacgcccctgcctaccagcagggccagaatcagctgtacaacgagctgaacctgggcag aagggaagagtacgacgtcctggataagcggagaggccgggaccctgagatgggcggcaagcctcggcggaagaacccccag gaaggcctgtataacgaactgcagaaagacaagatggccgaggcctacagcgagatcggcatgaagggcgagcggaggcggg gcaagggccacgacggcctgtatcagggcctgtccaccgccaccaaggatacctacgacgccctgcacatgcaggccctgcccc caagg Ctcgagggcggcggagagggcagaggaagtcttctaacatgcggtgacgtggaggagaatcccggccctagg tEGFR atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatcccacgcaaagtgtgtaacggaataggt attggtgaatttaaagactcactctccataaatgctacgaatattaaacacttcaaaaactgcacctccatcagtggcgatctccacatcc tggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactggatattctgaaaaccgtaaaggaaatc tttttgctgattcaggcttggcctgaaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggacc catggtcagttttctcttgcagtcgtcagcctgaacataacatccttgggattacgctccctcaaggagataagtgatggaga 40 tgtgataatttcaggaaacaaaaatttgtgctatgcaaatacaataaactggaaaaaactgtttgggacctccggtcagaaaaccaaaa ttataagcaacagaggtgaaaacagctgcaaggccacaggccaggtctgccatgccttgtgctcccccgagggctgctggggccc ggagcccagggactgcgtctcttgccggaatgtcagccgaggcagggaatgcgtggacaagtgcaaccttctggagggtgagcc aagggagtttgtggagaactctgagtgcatacagtgccacccagagtgcctgcctcaggccatgaacatcacctgcacaggacgg ggaccagacaactgtatccagtgtgcccactacattgacggcccccactgcgtcaagacctgcccggcaggagtcatgggagaaa 45 acaacaccctggtctggaagtacgcagacgccggccatgtgtgccacctgtgccatccaaactgcacctacggatgcactgggcca ggtcttgaaggctgtccaacgaatgggcctaagatcccgtccatcgccactgggatggtgggggccctcctcttgctgctggtggtg gccctggggatcggcctcttcatgtga Table 24 Her2 construct-long spacer (SEQ Id No:56 ) leader Atgcttctcctggtgacaagccttctgctctgtgagttaccacaccca Her2scFV gcattcctcctgatcccagatatccagatgacccagtccccgagctccctgtccgcctctgtgggcgatagggtcaccatcacctgcc gtgccagtcaggatgtgaatactgctgtagcctggtatcaacagaaaccaggaaaagctccgaaactactgatttactcggcatcctt cctctactctggagtcccttctcgcttctctggttccagatctgggacggatttcactctgaccatcagcagtctgcagccggaagactt cgcaacttattactgtcagcaacattatactactcctcccacgttcggacagggtaccaaggtggagatcaaaggcagtactagcggc ggtggctccgggggcggatccggtgggggcggcagcagcgaggttcagctggtggagtctggcggtggcctggtgcagccagg gggctcactccgtttgtcctgtgcagcttctggcttcaacattaaagacacctatatacactgggtgcgtcaggccccgggtaagggc ctggaatgggttgcaaggatttatcctacgaatggttatactagatatgccgatagcgtcaagggccgtttcactataagcgcagacac atccaaaaacacagcctacctgcagatgaacagcctgcgtgctgaggacactgccgtctattattgttctagatggggaggggacgg cttctatgctatggactactggggtcaaggaaccctggtcaccgtctcgagt long spacer aagtacggaccgccctgccccccttgccctgcccccgagttcctgggcggacccagcgtgttcctgttcccccccaagcc caaggacaccctgatgatcagccggacccccgaggtgacctgcgtggtggtggacgtgagccaggaagatcccgaggtccagtt caattggtacgtggacggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagttcaacagcacctaccgggtggt gtctgtgctgaccgtgctgcaccaggactggctgaacggcaaagaatacaagtgcaaggtgtccaacaagggcctgcccagcagc atcgaaaagaccatcagcaaggccaagggccagcctcgcgagccccaggtgtacaccctgcctccctcccaggaagagatgacc aagaaccaggtgtccctgacctgcctggtgaagggcttctaccccagcgacatcgccgtggagtgggagagcaacggccagcct aactacaagaccacccctcccgtgctggacagcgacggcagcttcttcctgtacagccggctgaccgtggacaagagcc ggtggcaggaaggcaacgtctttagctgcagcgtgatgcacgaggccctgcacaaccactacacccagaagagcctgagcctgtc cctgggcaag CD28tm atgttctgggtgctggtggtggtgggcggggtgctggcctgctacagcctgctggtgacagtggccttcatcatcttttgggtg 4-1BB aaacggggcagaaagaaactcctgtatatattcaaacaaccatttatgagaccagtacaaactactcaagaggaagatggctgtagct gccgatttccagaagaagaagaaggaggatgtgaactg a Cgggtgaagttcagcagaagcgccgacgcccctgcctaccagcagggccagaatcagctgtacaacgagctgaacctgggcag aagggaagagtacgacgtcctggataagcggagaggccgggaccctgagatgggcggcaagcctcggcggaagaacccccag gaaggcctgtataacgaactgcagaaagacaagatggccgaggcctacagcgagatcggcatgaagggcgagcggaggcggg gcaagggccacgacggcctgtatcagggcctgtccaccgccaccaaggatacctacgacgccctgcacatgcaggccctgcccc caagg Ctcgagggcggcggagagggcagaggaagtcttctaacatgcggtgacgtggaggagaatcccggccctagg tEGFR atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatcccacgcaaagtgtgtaacggaataggt 40 attggtgaatttaaagactcactctccataaatgctacgaatattaaacacttcaaaaactgcacctccatcagtggcgatctccacatcc tgccggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactggatattctgaaaaccgtaaaggaaatc acagggtttttgctgattcaggcttggcctgaaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggacc aagcaacatggtcagttttctcttgcagtcgtcagcctgaacataacatccttgggattacgctccctcaaggagataagtgatggaga tgtgataatttcaggaaacaaaaatttgtgctatgcaaatacaataaactggaaaaaactgtttgggacctccggtcagaaaaccaaaa 45 ttataagcaacagaggtgaaaacagctgcaaggccacaggccaggtctgccatgccttgtgctcccccgagggctgctggggccc ggagcccagggactgcgtctcttgccggaatgtcagccgaggcagggaatgcgtggacaagtgcaaccttctggagggtgagcc aagggagtttgtggagaactctgagtgcatacagtgccacccagagtgcctgcctcaggccatgaacatcacctgcacaggacgg ggaccagacaactgtatccagtgtgcccactacattgacggcccccactgcgtcaagacctgcccggcaggagtcatgggagaaa acaacaccctggtctggaagtacgcagacgccggccatgtgtgccacctgtgccatccaaactgcacctacggatgcactgggcca gaaggctgtccaacgaatgggcctaagatcccgtccatcgccactgggatggtgggggccctcctcttgctgctggtggtg gccctggggatcggcctcttcatgtga

Claims (70)

THAT WHICH IS CLAIMED IS:

1. A nucleic acid ng a chimeric or, the chimeric receptor comprising: 5 (a) an antibody or antigen-binding fragment thereof that binds to a HER2, wherein the antibody or antigen-binding fragment f comprises a variable light chain (VL) domain comprising a CDRL1, a CDRL2, and a CDRL3 of the ER2 antibody zumab, and a variable heavy chain (VH) domain comprising a CDRH1, a CDRH2, and a CDRH3 of the anti-HER2 antibody 10 trastuzumab; (b) a transmembrane domain; (c) a polypeptide spacer located between the antibody or antigen-binding fragment thereof and the transmembrane domain, wherein the polypeptide spacer is an immunoglobulin hinge-CH2-CH3 region; and 15 (d) an intracellular signaling domain that comprises a CD3? signaling domain and a costimulatory domain.

2. The nucleic acid of claim 1, wherein the immunoglobulin is a human IgG1, a human IgG2, or a human IgG4.

3. The c acid of claim 1 or 2, n the polypeptide spacer 20 comprises a hinge region or modified version thereof from a human IgGl, IgG2, IgG3, or IgG4 in combination with all or a portion of a CH2 region or variant thereof and a CH3 region or variant thereof.

4. The nucleic acid of claim 3, wherein the hinge region or modified version thereof of the polypeptide spacer comprises an amino acid sequence of 25 P, wherein X1 is a cysteine, a glycine, or an arginine and X2 is a cysteine or a threonine (SEQ ID NO:1).

5. The nucleic acid of claim 3 or 4, wherein the hinge region or modified version thereof of the polypeptide spacer comprises the amino acid sequence set forth in SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID

6.NO:21, SEQ ID NO:51, SEQ ID NO:52, or SEQ ID NO:53. 5 6. The nucleic acid of any one of claims 3-5, wherein the hinge region or ed version thereof of the polypeptide spacer comprises the amino acid sequence set forth in SEQ ID NO:21.

7. The nucleic acid of any one of claims 1-6, wherein the polypeptide spacer comprises a human IgG4 hinge region or modified version f, a human 10 IgG4 CH2 domain and a human IgG4 CH3 domain.

8. The nucleic acid of any one of claims 1-7, wherein the polypeptide spacer is about 229 amino acids in length.

9. The nucleic acid of any one of claims 1-8, wherein the polypeptide spacer comprises the amino acid sequence set forth in SEQ ID NO:50. 15 10. The nucleic acid of any one of claims 1-9, wherein the antibody or antigen-binding fragment f comprises a VL domain having a least 90% sequence identity to the VL domain of the anti-HER2 antibody trastuzumab; and a

10.VH domain having at least 90% identity to the VH domain of the anti-HER2 antibody trastuzumab. 20

11. The nucleic acid of any one of claim 1-10, wherein the antibody or n-binding nt thereof comprises a VL domain of the anti-HER antibody zumab and a VH domain of the anti-HER2 antibody trastuzumab.

12. The nucleic acid of any one of claims 1-11, wherein the antibody or antigen-binding fragment thereof comprises a single chain variable fragment (scFv).

13. The nucleic acid of claim 12, wherein the scFv has a VL-linker-VH orientation.

14. The nucleic acid of any one of claims 1-13, wherein the transmembrane domain ses a transmembrane domain of a CD8 or of a CD28. 5 15. The nucleic acid of any one of claims 1-14, wherein the transmembrane domain comprises a transmembrane domain of a CD28 comprising the amino acid sequence encoded by SEQ ID NO:5 or the amino acid sequence

15.VVGGVLACYSLLVTVAFIIFWV.

16. The nucleic acid of any one of claims 1-15, wherein the 10 costimulatory domain comprises: the signaling domain of a 4-1BB or a modified version thereof; or the signaling domain of a CD28 or a modified version thereof.

17. The nucleic acid of claim 16, wherein the 4-1BB signaling domain comprises amino acids 214-255 of SEQ ID NO:15 or comprises the amino acid 15 sequence encoded by SEQ ID NO:6.

18. The nucleic acid of claim 16, n the CD28 signaling domain comprises amino acids 180-220 of SEQ ID NO:14 or comprises a ed version thereof comprising an LL ? GG substitution located at positions 186-187 of SEQ

19.ID NO:14. 20 19. The c acid of any one of claims 1-18, wherein the CD3? signaling domain comprises the amino acid sequence encoded by SEQ ID NO:7.

20. The nucleic acid of any one of claims 1-19, wherein: the antibody or n-binding fragment is an scFv comprising a VL domain of the anti-HER antibody trastuzumab and a VH domain of the anti-HER2 antibody trastuzumab; 5 the polypeptide spacer comprises the amino acid sequence of SEQ ID NO:50; the transmembrane domain comprises the amino acid sequence d by SEQ ID NO:5 and the intracellular signaling domain comprises a 4-1BB signaling domain 10 comprising the amino acid sequence d by SEQ ID NO:6 and a CD3? signaling domain comprising the amino acid sequence encoded by of SEQ ID NO:7.

21. The nucleic acid of any one of claims 12-20, wherein the scFv comprises the sequence encoded by nucleotides: CTCCTGATCCCAGATATCCAGATGACCCAGTCCCCGAGC 15 TCCCTGTCCGCCTCTGTGGGCGATAGGGTCACCATCACCTGCCGTGCCAG TCAGGATGTGAATACTGCTGTAGCCTGGTATCAACAGAAACCAGGAAAA GCTCCGAAACTACTGATTTACTCGGCATCCTTCCTCTACTCTGGAGTCCC TTCTCGCTTCTCTGGTTCCAGATCTGGGACGGATTTCACTCTGACCATCA GCAGTCTGCAGCCGGAAGACTTCGCAACTTATTACTGTCAGCAACATTAT 20 ACTACTCCTCCCACGTTCGGACAGGGTACCAAGGTGGAGATCAAAGGCA GTACTAGCGGCGGTGGCTCCGGGGGCGGATCCGGTGGGGGCGGCAGCA GCGAGGTTCAGCTGGTGGAGTCTGGCGGTGGCCTGGTGCAGCCAGGGGG CTCACTCCGTTTGTCCTGTGCAGCTTCTGGCTTCAACATTAAAGACACCT ATATACACTGGGTGCGTCAGGCCCCGGGTAAGGGCCTGGAATGGGTTGC 25 AAGGATTTATCCTACGAATGGTTATACTAGATATGCCGATAGCGTCAAG GGCCGTTTCACTATAAGCGCAGACACATCCAAAAACACAGCCTACCTGC ACAGCCTGCGTGCTGAGGACACTGCCGTCTATTATTGTTCTAGA TGGGGAGGGGACGGCTTCTATGCTATGGACTACTGGGGTCAAGGAACCC TGGTCACCGTCTCGAGT.

22. The nucleic acid of any one of claims 1-21, wherein the nucleic acid encodes a ic receptor encoded by a nucleic acid comprising the sequence of SEQ ID NO:56.

23. A chimeric receptor encoded by the nucleic acid of any one of claims 5 1-22.

24. The chimeric receptor of claim 23, wherein the chimeric receptor is encoded by a nucleic acid comprising the sequence of SEQ ID NO:56.

25. An sion vector, comprising the nucleic acid of any one of claims 1-22. 10

26. The expression vector of claim 25, further comprising a polynucleotide encoding a marker sequence, wherein the polynucleotide ng the marker sequence is operably linked in frame with the nucleic acid encoding the chimeric or.

27. The expression vector of claim 26, wherein the nucleic acid encoding 15 the chimeric receptor and the polynucleotide encoding the marker sequence are separated by a polynucleotide encoding a cleavable linker.

28. The expression vector of claim 26 or 27, wherein the marker sequence is a truncated EGFR sequence.

29. The expression vector of claim 28, wherein the truncated EGFR 20 ce is encoded by the polynucleotide of SEQ ID NO:9.

30. The expression vector of any one of claims 27-29, wherein the ble linker ses a T2A peptide.

31. The expression vector of claim 30, wherein the T2A peptide is encoded by the polynucleotide of SEQ ID NO:8.

32. The expression vector of any one of claims 25-31, wherein the sion vector comprises the nucleic acid sequence of SEQ ID NO:56. 5

33. An isolated host cell, comprising the nucleic acid of any one of claims 1-22, the chimeric or of claim 23 or 24 or the expression vector of any one of claims 25-32.

34. The host cell of claim 33, wherein the host cell is an immune cell.

35. The host cell of claim 33 or 34, wherein the host cell is a T cell. 10 36. The host cell of any one of claims 33-35, wherein the host cell is a

36.CD8+ T cell or a CD4+ T cell.

37. The host cell of any one of claims 33-36, wherein the host cell is a CD8+ T cell selected from the group consisting of a naïve CD8+ T cell, a central memory CD8+ T cell, an effector memory CD8+ T cell, and a bulk CD8+ T cell. 15

38. The host cell of claim 37, wherein the CD8+ T cell is a central memory CD8+ T cell, wherein the central memory CD8+ T cell is CD45RO+ and CD62L+.

39. The host cell of any one of claims 33-36, wherein the host cell is a

40.CD4+ T cell selected from the group consisting of a naïve CD4+ T cell, a central memory CD4+ T cell, an or memory CD4+ T cell, and a bulk CD4+ T cell. 20 40. The host cell of claim 39, n the CD4+ T cell is a naïve CD4+ T cell, wherein the naïve CD4+ T cell is CD45RA+, CD62L+, and CD45RO-.

41. A composition, comprising the host cell of any one of claims 33-40, in a pharmaceutically acceptable excipient.

42. The composition of claim 41, wherein the composition comprises a CD4+ T cell and/or a CD8+ T cell. 5

43. The composition of claim 42, n the ition comprises CD4+ T cells and CD8+ T cells, and the CD4+ T cells and the CD8+ T cells are present at about a 1:1 ratio in the composition.

44. An in vitro method for preparing a host cell, comprising: introducing the nucleic acid of any one of claims 1-22 or the expression 10 vector of any one of claims 25-32 into cells of a cyte population and culturing the cells in the presence of anti-CD3 and/or anti-CD28, and at least one homeostatic cytokine.

45. The method of claim 44, wherein the lymphocyte population 15 ses a lymphocyte that is CD45RA-, CD45RO+, and CD62L+.

46. The method of claim 44 or 45, wherein the lymphocyte population comprises a T cell. 20 47. The method of claim 46, wherein the T cell is a CD8+ T cell or a

47.CD4+ T cell.

48. The method of claim 47, wherein the CD8+ T cell is selected from 25 the group consisting of a naïve CD8+ T cell, a central memory CD8+ T cell, an effector memory CD8+ T cell, and a bulk CD8+ T cell.

49. The method of claim 48, wherein the CD8+ T cell is a central memory CD8+ T cell, wherein the central memory CD8+ T cell is CD45RO+ and

50.CD62L+. 5 50. The method of claim 47, wherein the CD4+ T cell is selected from the group consisting of a naïve CD4+ T cell, a central memory CD4+ T cell, an effector memory CD4+ T cell, and a bulk CD4+ T cell.

51. The method of claim 50, wherein the CD4+ T cell is a naïve CD4+ T 10 cell, wherein the naïve CD4+ T cell is CD45RA+, CD62L+, and CD45RO-.

52. Use of a pharmaceutical composition, comprising the nucleic acid of any one of claims 1-22, the chimeric receptor of claim 23 or 24, the expression vector of any one of claims 25-32, the isolated host cell of any one of claims 33-40, or the composition of any one of claims 41-43 in the manufacture of a medicament 15 for the treatment of a tumor expressing HER2.

53. Use of a tion of immune cells comprising the nucleic acid of any one of claims 1-22, the ic receptor of claim 23 or 24, or the expression vector of any one of claims 25-32 in the manufacture of a medicament for the treatment of a tumor expressing HER2. 20

54. The use of claim 53, wherein the tion of immune cells comprises CD8+ T cells.

55. The use of claim 54, wherein the tion of immune cells further comprises CD4+ T cells.

56. Use of a tion of CD8+ T cells comprising the nucleic acid of 25 any one of claims 1-22, the chimeric receptor of claim 23 or 24, or the expression vector of any one of claims 25-32 in the manufacture of a medicament for the treatment of a tumor expressing HER2.

57. The use of claim 56, wherein the population of CD8+ T cells is for use in combination with a population of CD4+ T cells comprising the nucleic acid of 5 any one of claims 1-22, the ic receptor of claim 23 or 24, or the expression vector of any one of claims 25-32.

58. Use of a population of CD4+ T cells comprising the nucleic acid of any one of claims 1-22, the chimeric receptor of claim 23 or 24, or the expression vector of any one of claims 25-32 in the manufacture of a medicament for the 10 treatment of a tumor expressing HER2.

59. The use of claim 58, wherein the population of CD4+ T cells is for use in combination with a population of CD8+ T cells comprising the nucleic acid of any one of claims 1-22, the chimeric or of claim 23 or 24, or the expression vector of any one of claims 25-32. 15

60. Use of a combination comprising a population of CD8+ T cells comprising the nucleic acid of any one of claims 1-22, the chimeric receptor of claim 23 or 24, or the expression vector of any one of claims 25-32 and a tion of CD4+ T cells sing the nucleic acid of any one of claims 1-22, the chimeric receptor of claim 23 or 24, or the sion vector of any one of claims 25-32 in the 20 manufacture of a medicament for the treatment of a tumor expressing HER2.

61. The use of any one of claims 57, 59, and 60, wherein the population of CD8+ T cells and the population of CD4+ T cells is for use at a ratio of about 1:1 CD8+ T cells to CD4+ T cells.

62. The use of any one of claims 57 and 59-61, wherein the population of CD8+ T cells and the population of CD4+ T cells express the same chimeric receptor.

63. The use of any one of claims 52-62, wherein the tumor is a solid 5 tumor or a hematologic malignancy.

64. The use of claim 63, wherein the solid tumor is selected from the group consisting of a breast cancer, a lung cancer, a colon cancer, a renal cancer, a pancreatic cancer, a prostate cancer, and an ovarian cancer. 10

65. A nucleic acid encoding a chimeric or as d in any one of claims 1-24 substantially as herein bed and with reference to any example

66. An expression vector as claimed in any one of claims 25-32 15 substantially as herein described and with reference to any example thereof.

67. An isolated host cell as claimed in any one of claims 33-40 substantially as herein described and with nce to any example thereof. 20

68. A composition as claimed in any one of claims 41-43 substantially as herein described and with nce to any example thereof.

69. An in vitro method as claimed in any one of claims 44-51 substantially as herein described and with reference to any example thereof.

70. A use as claimed in any one of claims 52-64 substantially as herein described and with reference to any example thereof. PCT/U